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ABSTRACT 
Providing clean drinking water is a primary challenge of this century. The ubiquitous 
occurrence of pharmaceutically active compounds (PhACs), including antibiotics, 
anticonvulsants, painkillers, estrogenic hormones, lipid regulators, beta-blockers, antihistamines, 
X-ray contrast media, etc., in drinking water sources has been reported in recent years. The 
presence of these contaminants, although at low concentrations, raises public concerns about 
potential adverse effects on aquatic ecology and human health. Another emerging concern in 
drinking water safety is the formation of toxic disinfection by-products (DBPs) when treating 
water with conventional disinfectants (i.e., free chlorine), and thus alternative disinfectants and 
disinfection processes are sought to control DBPs formation while still providing a sufficient 
barrier to pathogens. Chemical oxidation processes involving permanganate [MnO4-, Mn(VII)] 
and ferrate [FeO42-, Fe(VI)] salts are promising technologies for treatment of many PhACs. 
Permanganate is already widely used in water treatment facilities (e.g., for treatment of taste and 
odor compounds, soluble iron(II) and manganese(II)), while ferrate is an emerging water 
treatment oxidant that also has potential for use as an alternative disinfectant. This study 
investigates the oxidative transformation of PhACs using permanganate and ferrate and the use 
of ferrate for inactivation of a surrogate viral pathogen, MS2 bacteriophage. 
Survey tests show that permanganate and ferrate are both selective oxidants that target 
compounds with specific electron-rich moieties, including olefin, phenol, amine, cyclopropyl, 
thioether, and alkyne groups. Detailed kinetics studies were undertaken to characterize Mn(VII) 
oxidation of five representative PhACs that exhibit moderate to high reactivity (carbamazepine, 
CBZ; ciprofloxacin, CPR; lincomycin, LCM; trimethoprim, TMP; and 17α-ethinylestradiol, 
EE2), Fe(VI) oxidation of one representative PhAC (CBZ), and Fe(VI) inactivation of MS2 
phage (Fe(VI) reactions with other PhACs were not conducted because recent literature reports 
addressed the topic). The Mn(VII) and Fe(VI) reactions examined with PhAC and MS2 phage 
were found to follow generalized second-order rate laws, first-order in oxidant concentration and 
first-order in target contaminant concentration. The temperature dependence of reaction rate 
constants was found to follow the Arrhenius equation. Changing of solution pH had varying 
effects on reaction rates, attributed to change in electron density on the target reactive groups 
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upon protonation/deprotonation. The effects of pH on reaction rates were quantitatively 
described by kinetic models considering parallel reactions between different individual 
contaminant species and individual oxidant species. For Mn(VII) reactions, removal of PhACs in 
drinking water utility source waters was generally well predicted by kinetic models that include 
temperature, KMnO4 dosage, pH, and source water oxidant demand as input parameters. 
A large number of reaction products from Mn(VII) oxidation of CBZ, CPR, LCM, TMP, 
and EE2 and Fe(VI) oxidation of CBZ were identified by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Structures of reaction products were proposed based on MS spectral 
data along with information collected from proton nuclear magnetic resonance (1H-NMR), 
chromatographic retention time, and reported literature on Mn(VII) reactions with specific 
organic functional groups. Mn(VII) and Fe(VI) rapidly oxidize CBZ by electrophilic attack at the 
olefinic group on the central heterocyclic ring. Mn(VII) oxidation of CPR was found to occur 
primary on the tertiary aromatic amine group on the piperazine ring, with minor reactions on the 
aliphatic amine and the cyclopropyl group. LCM was oxidized by Mn(VII) through the aliphatic 
amine group on the pyrrolidine ring and thioether group attached to the pyranose ring. TMP 
oxidation by Mn(VII) was proposed to occur at the C=C bonds on the pyrimidine ring and the 
bridging methylene group. EE2 oxidation by Mn(VII) resulted in several types of products, 
including dehydrogenated EE2, hydroxylated EE2, phenolic ring cleavage products, and 
products with structural modifications on the ethynyl group. 
Although little mineralization of PhAC solutions was observed after Mn(VII) treatment, 
results from bioassay tests of three antibiotics show that the antibacterial activity was effectively 
removed upon reaction with Mn(VII), demonstrating that incomplete oxidation of PhACs during 
Mn(VII) treatment will likely be sufficient to eliminate the pharmaceutical activity of impacted 
source waters. 
Overall, results show that reactions with Mn(VII) likely contribute to the fate of many 
PhACs in water treatment plants that currently use Mn(VII), and the kinetic model developed in 
this study can be used to predict the extent of PhAC removal by Mn(VII) treatment. For water 
contaminated with highly Mn(VII)-reactive PhACs (e.g., carbamazepine, estradiol), specific 
application of Mn(VII) may be warranted. Results suggest Fe(VI) may be a useful disinfecting 
agent, but more work is needed to characterize its activity and mode of inactivating with other 
pathogens of concern. 
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CHAPTER 1  
INTRODUCTION 
1.1  Motivation 
Worldwide occurrence of pharmaceutically active compounds (PhACs) in drinking water 
sources (e.g., surface waters and groundwater) has been well documented in recent years [1-11]. A 
series of national reconnaissances conducted by the U.S. Geological Survey found many organic 
wastewater contaminants in streams, groundwater and finished drinking water throughout the U.S. 
[1, 12-14]. Detected compounds include antibiotics, anticonvulsants, painkillers, cytostatic drugs, 
estrogenic hormones, lipid regulators, beta-blockers, antihistamines, X-ray contrast media, and 
emerging classes of nitrogenous disinfection byproducts. Pharmaceuticals end up in aquatic 
environments as a result of incomplete metabolism in humans and animals, improper disposal of 
unused medication, and ineffective removal in municipal sewage treatment plants (STPs) [15]. 
Table  1.1 summarizes the results of some recent surveys of the occurrence of selected 
pharmaceutical compounds in U.S. surface water, groundwater, and finished drinking water.  
Although concentrations of PhACs detected in drinking water sources are typically at 
levels of ng/L to µg/L [12, 16, 17] as shown in Table  1.1, there remains serious public concerns about 
potential accumulative health effects of long-term exposure to even low levels of these 
biologically active compounds, especially considering unknown interactive effects of complex 
pharmaceutical mixtures (e.g., synergistic or antagonistic toxicity). In one recent study, it was 
reported that the growth of human embryonic cells was inhibited by a mixture of 13 therapeutic 
drugs at environmental levels [18]. The presence of PhACs in surface waters is also of concern 
because of their potential toxicity to aquatic organisms. Richards and co-workers reported adverse 
effects of pharmaceutical mixtures on aquatic microcosms [19]. There also remains considerable 
ongoing debate about the potential for development of increased antibiotic resistance in 
pathogenic microorganisms due to continuous exposure to sub-therapeutic concentrations of 
antibiotic compounds discharged to the environment [20-22]. One study reported an increase of the 
selection rates of an antibiotic resistance gene upon exposure to 20 µg/L of oxytetracycline [23]. 
The presence of trace antibiotics in groundwater is newly reported to affect the nitrate levels in 
the water by altering the composition of the nitrate-reducing microcosms and inhibiting their 
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nitrate reduction capabilities [24]. Furthermore, endocrine disrupting chemicals (e.g., synthetic 
steroid hormones) often exhibit non-monotonic dose-response relationships wherein ultra-low 
concentrations (i.e. ng/L) can elicit biological effects [25].  
Waterborne viral pathogens have been found in drinking water sources for decades [26-28], 
and disinfection processes using free chlorine as the primary disinfectant have been applied in 
drinking water facilities for over a century [29]. In 2006, the U.S. Environmental Protection 
Agency (USEPA) released the Long Term 2 Enhanced Surface Water Treatment Rule 
(LT2ESWTR) and Stage 2 Disinfectants and DBPs Rule (Stage 2 DBPR) in response to the control 
of Cryptosporidium parvum oocysts and disinfection by-products (DBPs) formation [30]. As a 
result, many U.S. drinking water utilities have begun to switch the primary disinfectant from free 
chlorine to other alternative processes, most often UV disinfection or treatment with combined 
chlorine. This practice raises emerging concerns related to viral pathogens, especially enteric 
viruses, because viruses are much more resistant to inactivation by UV light and combined 
chlorine than to free chlorine [29, 30].    
Because of issues described above, there is growing interest in the water treatment 
community in the fate and degradation of emerging chemical micropollutants and viral pathogens 
in both natural aquatic environments and during conventional treatment processes, and the 
development of new technologies to more effectively protect drinking water quality from these 
threats. These are the issues that motivate the work described in this thesis. 
1.2  Pharmaceutical Reactions with Drinking Water Oxidants 
Many PhACs contain electron-rich functional groups that are susceptible to oxidation 
during drinking water treatment, including phenol, amine, olefin, and thioether groups. Previous 
studies have investigated the oxidative treatment of PhACs by common drinking water oxidants 
and disinfectants, including ozone, free and combined chlorine, and chlorine dioxide [31-34]. The 
homogeneous aqueous oxidation of PhACs can typically be modeled with second-order rate laws: 
 ]Oxidant][PhAC[[PhAC] 2kdt
d −=   ( 1.1) 
where k2 is the apparent second-order rate constant (M-1 s-1), which can vary widely with solution 
conditions. Table  1.2 summarizes the results of several recent studies on the reactivity of three 
drinking water oxidants with commonly detected PhACs. Overall, ozone reacts the fastest with 
most PhACs, exhibiting k2 values ranging from <1 M-1 s-1 to 7×109 M-1 s-1 at pH 7 [31, 35-41]. 
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Chlorine dioxide and free chlorine exhibit lower reactivity with the PhACs examined [32-34, 42-48]. 
Studies also report high reactivity of PhACs with hydroxyl radicals generated through advanced 
oxidation processes, including ozonation, with k2 values approaching diffusion-controlled 
limitations (109-1010 M-1 s-1 at 25 oC) [31, 49]. Although extremely reactive, their poor selectivity 
might result in ineffective treatment, particularly in organic-rich matrices and waters with high 
alkalinity that act to scavenge hydroxyl radicals. 
Various effects were observed on the pharmaceutical activity of PhAC solutions after 
treatment with water oxidants. Lee and coworkers [50] demonstrated that reactions between several 
oxidants and the steroidal hormone 17α-ethinylestradiol eliminate the estrogenic activity of 
solutions and attributed the reductions in activity to formation of initial reaction products that elicit 
substantially reduced estrogenic responses in the in vitro bioassays. Dodd and coworkers [51] found 
that reactions of O3 and ⋅OH with most classes of antibiotics lead to stoichiometric deactivation, 
indicating that reaction products exhibit significantly reduced potencies. In contrast, reports show 
that chlorination can sometimes produce byproducts that are more toxic than the parent 
compounds [52]. Also, O3 and ⋅OH reactions with the β-lactams penicillin G and cephalexin was 
reported to yield some products that retain significant antibacterial potency, identified as the 
stereoisomeric (R)-sulfoxides of the parent antibiotics [53]. 
1.3 Permanganate and Ferrate Chemistry 
Chemical oxidation processes involving salts of permanganate [MnO4-; Mn(VII)] and 
ferrate [FeO42-; Fe(VI)] ions may be promising technologies for treatment of many PhACs and 
pathogens due to their unique chemical and physical properties. Potassium permanganate (KMnO4) 
is already widely used in water treatment processes to control taste and odor, remove color, control 
biological growth, and remove dissolved iron and manganese [29]. It has also been used extensively 
for in-situ chemical oxidation (ISCO) processes in subsurface remediation applications [54, 55]. 
When compared to other common drinking water oxidants, Mn(VII) is still a relatively strong 
oxidant with a standard reduction potential (E0) of 1.68 V (versus a standard hydrogen electrode) 
under acidic conditions, higher than that of dissolved oxygen (1.23 V), chlorine dioxide (0.95 V), 
and hypochlorite (1.48 V) as shown in Table  1.3 [56]. Mn(VII) has been reported to oxidize a wide 
range of persistent organic chemicals, including phenols, chlorinated ethenes, and polycyclic 
aromatic hydrocarbons, etc. [54] Mn(VII) can be used as an alternative chemical to pre-chlorination 
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and has been reported to greatly reduce formation of halogenated disinfection byproducts (DBPs) 
during drinking water treatment by oxidizing chlorine DBP precursors [57]. 
Potassium ferrate (K2FeO4) is also gaining increasing attention as an environmentally 
friendly oxidant for use in water treatment. While naturally occurring iron is usually present in the 
+2 (ferrous) and +3 (ferric) oxidation states, iron in ferrate exists at the +6 oxidation state (there 
are also less stable Fe(V) and Fe(IV) ferrate redox states), which gives rise to its strong oxidation 
potential. Fe(VI) has an even higher E0 (2.20 V) than ozone (2.08 V) under acidic conditions [56], 
and Fe(VI) exhibits elevated reactivity with a wide range of organic and inorganic compounds [58]. 
Permanganate and ferrate also share a number of properties that make them advantageous 
alternative oxidants for water and wastewater treatment applications. Both oxidants produce 
innocuous reduction products (e.g., MnO2(s) and Fe(OH)3(s)), which can function as efficient 
coagulants and adsorbents for removing other contaminants from water (e.g., DBP precursors) [58, 
59]; MnO2(s) has also been shown to act as an oxidant for PhACs [60-64].  
Whereas Mn(VII) exists predominantly as the deprotonated MnO4- species throughout the 
pH range of natural waters (pKa for HMnO4 = -2.25 [65]), Fe(VI) has a more complex acid-base 
chemistry that needs to be considered when assessing aqueous redox reactions. The fully 
protonated acid form of ferrate (H2FeO4) is a much weaker acid than HMnO4 as shown in Equation 
( 1.2) and ( 1.3), and this results in variable Fe(VI) speciation throughout the pH range of natural 
waters (Figure  1.1) [58]. 
 H2FeO4 H+ + HFeO4-   pKa1 = 3.5  ( 1.2) 
 HFeO4- H+ + FeO42-    pKa2 = 7.3  ( 1.3) 
As a result, Fe(VI) redox reactions are often reported to be highly dependent on solution pH [58]. In 
addition, Fe(VI) auto-decomposes in water according to the stoichiometry shown in Equation ( 1.4) 
[58].  
 4 FeO4 2- + 10 H2O → 4 Fe(OH)3(s) + 3O2↑ + 8 OH-  ( 1.4) 
Rates of auto-decomposition increase dramatically with decreasing pH, and Fe(VI) does not 
persist for long at pH ≤ 7. Whereas Fe(VI) auto-decomposition complicates practical applications 
of Fe(VI) treatment processes, it also eliminates concerns about overdosing of Fe(VI) during 
treatment applications since the resulting decomposition product, Fe(OH)3(s), is harmless and will 
be removed by downstream sedimentation and filtration processes. 
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1.4 Research Objectives and Thesis Outline 
Although Mn(VII) and Fe(VI) are potential drinking water oxidants, little is currently 
known about their effectiveness for PhAC and/or viral treatment, and the work described in this 
thesis aims to fill this knowledge gap in the field of water treatment chemistry. The primary 
objectives of this research were to: (a) characterize the kinetics and mechanisms of reactions 
between representative PhACs and Mn(VII)/Fe(VI); (b) assess the potential use of these reactions 
to remove problematic PhACs and associated pharmaceutical activity during drinking water 
treatment operations; and (c) examine the inactivation kinetics of bacteriophage MS2, a surrogate 
viral pathogen, by treatment with Fe(VI).  
Initially, a large group of PhACs were tested for their reactivity with Mn(VII) and Fe(VI). 
Figure  1.2 and Figure  1.3 summarizes the survey results for Mn(VII) and Fe(VI) oxidation, 
respectively. For Mn(VII), ten compounds out of eighteen PhACs tested showed moderate to high 
reactivity with Mn(VII), with >50% degradation being observed within 1 h. Six PhACs 
(acetaminophen, bisphenol A, carbamazepine, chlortetracycline, 17α-ethinylestradiol, and 
triclosan) showed very high reactivity, with complete degradation occurring in less than 10 min, 
whereas four compounds (ciprofloxacin, diclofenac, lincomycin, and trimethoprim) exhibited 
moderate reactivity with Mn(VII). For Fe(VI), eight out of twelve tested PhACs (acetaminophen, 
atenolol, carbamazepine, diclofenac, ciprofloxacin, 17α-ethinylestradiol, sulfamethoxazole and 
triclosan) showed moderate to high reactivity with Fe(VI). Surprisingly, Fe(VI) did not show a 
major enhanced reactivity with PhACs when compared to Mn(VII) despite of its higher oxidation 
potential. Therefore, detailed kinetics and mechanisms studies in this research were more focused 
on PhAC reactions with Mn(VII) because Mn(VII) is already commonly used in water treatment 
and is more stable and readily available to utilities than Fe(VI) and recent studies have already 
reported on Fe(VI) reactions with several of the surveyed PhACs [66-68].  
Chapter 2 focuses on the oxidation kinetics and mechanism of an anticonvulsant drug, 
carbamazepine (CBZ), by Mn(VII) and Fe(VI). Chapter 3 discusses the kinetics of Mn(VII) 
oxidation of three common antibiotics: ciprofloxacin (CPR), lincomycin (LCM), and 
trimethoprim (TMP). Chapter 4 details the identification of reaction products and pathways for 
the three antibiotics, along with results from experiments assessing the effects of Mn(VII) 
treatment on the antibacterial potency of solutions. Chapter 5 presents the kinetics and products 
of Mn(VII) reactions with the synthetic hormone, 17α-ethinylestradiol (EE2). Chapter 6 
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describes the inactivation kinetics of a non-pathogenic surrogate for enteric viruses, MS2 phage, 
by Fe(VI). Chapter 7 summarizes key findings from the thesis research, describes implications of 
the study to water and wastewater treatment, and outlines future research needs.  
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Figure  1.1 Change of ferrate speciation with pH. 
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Figure  1.2 Survey results of PhAC reactivity with Mn(VII). Individual bars represent the 
percent of each PhAC remaining after treatment with Mn(VII) for 1 min, 10 min and 1 h. 
Reaction conditions: [Mn(VII)]0 = 500 µM, [PhAC]0 = 10 µM, 25 oC, pH 8.0 (10 mM 
bicarbonate buffer). 
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Figure  1.3 Survey results of PhAC reactivity with Fe(VI). Individual bars represent the 
percent of each PhAC remaining in solution after treatment with Fe(VI) for 1 min, 10 min 
and 1 h. Reaction conditions: [Fe(VI)]0 = 100 µM, [PhAC]0 = 10 µM, 25 oC, pH = 9.0 (50 
mM phosphate + 5 mM borate buffer). 
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Table  1.1 Occurrence of PhACs surveyed in this study in U.S. streams, groundwater and 
finished drinking water 
Surface watera Groundwaterb 
Finished 
drinking 
Waterc 
Target  
PhACs  
(abbreviation) max.  
(µg/L) 
med. 
(µg/L) 
Detection 
frequency 
max. 
(µg/L) 
Detection  
frequency 
max. 
(µg/L) 
acetaminophen (ACT) 10 0.11 23.8% 0.38 6.4%  
atenolol (ATN)      0.018[69] 
bisphenol A (BPA) 12 0.14 41.2% 2.55 29.8% 0.42 
caffeine (CFF) 6 0.081 61.9% 0.13 12.8% 0.12 
carbamazepine (CBZ) 0.19 [12]  21.6%   0.26 
chlortetracycline (CTC) 0.69 0.42 2.4%    
ciprofloxacin (CPR) 0.03 0.02 2.6%    
17α-ethinylestradiol (EE2) 0.83 0.073 15.7%    
ibuprofen (IBP) 1 0.2 9.5% 3.11 2.15% 0.93 [70] 
lincomycin (LCM) 0.73 0.06 19.2% 0.32 5.4%  
sulfamethizole (SMZ) 0.13 0.13 1%    
sulfamethoxazole (SMX) 1.9 0.15 19% 1.11 23.4% 0.003 [70] 
triclosan (TRC) 2.3 0.14 57.6%   0.73 [69] 
trimethoprim (TMP) 0.71 0.15 12.5%    
a Data from Kolpin et al. [1] unless otherwise noted. The number of samples analyzed is from 84 to 104 for different PhACs. 
b Data from Barnes et al. [13] The number of samples analyzed is from 37 to 47 for different PhACs. 
c Data from Stackelberg et al. [14] unless otherwise noted. 
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Table  1.2 Reactivity of selected PhACs with common drinking water oxidantsa 
Ozone  
O3 
Free chlorine 
HOCl/OCl- 
Chlorine dioxide  
ClO2 Target PhACs 
k2 (M-1 s-1) k2 (M-1 s-1) k2 (M-1 s-1) 
acetaminophen 3.1×106 [35] 1.1×102 [43]  
atenolol 2×103 [36] 1.3×10-2 [32]  
bezafibrate 5.9×102 [31]  <0.01 [33] 
bisphenol A 1×106 [37] 20 [46]  
caffeine 0.7 [40] 1.6×102 [47]  
carbamazepine 3×105 [31]  <0.015 [33] 
ciprofloxacin 1.9×104 [38] 7.6×105 [34]  
diclofenac 1×106 [31]  1×104 [33] 
17α-ethinylestradiol 7×109 [31] 1.1×102 [43] 105 [33] 
ibuprofen 9.6 [31] negligible [32] <0.01 [33] 
iopromide <1 [31]  <0.01 [33] 
lincomycin 6.6×105 [71]   
sulfamethizole  5.6×102 [42]  
sulfamethoxazole 2.5×106 [31] 1.8×103 [44] 1×103 [33] 
triclosan 3.8×107 [41] 4.7×102 [48]  
trimethoprim 2.7×105 [38] 56 [45]  
a k2: values presented are apparent second-order rate constants at pH 7 and ambient temperature (20-25 ºC). Reaction between free 
chlorine and caffeine was determined to be second-order with respect to [HOCl] and first order with respect to [caffeine], and the 
unit of rate constant is M-2 s-1. 
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Table  1.3 Standard reduction potential of Mn(VII) and Fe(VI) compared to other oxidantsa 
Oxidant Reaction E0 (V) 
permanganate, Mn(VII) MnO4- + 4H+ + 3e- MnO2(s) + 2H2O 1.68 
 MnO4- + 2H2O + 3e- MnO2(s) + 4OH- 0.59 
ferrate, Fe(VI) FeO42- + 8H+ + 3e- Fe3+ + 4H2O 2.20 
 FeO42- + 4H2O + 3e- Fe(OH)3(s) + 5OH- 0.70 
ozone O3 + 2H+ + 2e- O2 + H2O 2.08 
 O3 + 2H2O + 2e- O2 + 2OH- 1.24 
hypochlorite HOCl + H+ + 2e- Cl- + H2O 1.48 
 OCl- + H2O + 2e- Cl- + 2OH- 0.84 
hydrogen peroxide H2O2 + 2H+ + 2e- 2H2O 1.78 
 H2O2 + 2e- 2OH- 0.88 
chlorine dioxide ClO2 + e- ClO2- 0.95 
dissolved oxygen O2 + 4H+ + 4e- 2H2O 1.23 
 O2 + 2H2O + 2e- 4OH- 0.40 
a Adapted from Sharma (2004) 
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CHAPTER 2  
OXIDATION OF CARBAMAZEPINE BY POTASSIUM PERMANGANATE 
AND FERRATE: REACTION KINETICS AND MECHANISM1 
2.1 Abstract 
Experimental studies were conducted to examine the oxidation of carbamazepine, an 
anticonvulsant drug widely detected in surface waters and sewage treatment effluent, by potassium 
salts of permanganate [KMnO4; Mn(VII)] and ferrate [K2FeO4; Fe(VI)]. Results show that both 
Mn(VII) and Fe(VI) rapidly oxidize carbamazepine by electrophilic attack at an olefinic group in 
the central heterocyclic ring, leading to ring-opening and a series of organic oxidation products. 
Reaction kinetics follow a generalized second-order rate law, with apparent rate constants at pH 
7.0 and 25 °C of 3.0(±0.3)×102 M-1 s-1 for Mn(VII) and 70(±3) M-1 s-1 for Fe(VI). Mn(VII) reaction 
rates exhibit no pH dependence, whereas Fe(VI) reaction rates increase dramatically with 
decreasing pH, due to changing acid-base speciation of Fe(VI). Further studies with Mn(VII) show 
that most common non-target water constituents, including natural organic matter, have no 
significant effect on rates of carbamazepine oxidation; reduced metals and (bi)sulfide exert a 
stoichiometric Mn(VII) demand that can be incorporated into the kinetic model. The removal of 
carbamazepine in two utility source waters treated with KMnO4 agrees closely with predictions 
from the kinetic model that was parameterized using experiments conducted in deionized water at 
much higher reagent concentrations. 
2.2 Introduction 
Recent studies report widespread occurrence of pharmaceutical compounds in aquatic 
environments [1-3]. Although most pharmaceuticals are detected at trace levels (ng/L−µg/L), 
concerns about the effects of long-term exposure on public health and aquatic ecology remain, 
especially considering unknown synergistic effects of pharmaceutical mixtures [4, 5]. Pomati and 
co-workers recently reported that growth of human embryonic cells was inhibited by a mixture of 
                                                     
1  A modified version of Chapter 2 was published in Environmental Science & Technology, 2009, 
43, 509-515. (L. Hu lead author with co-authors H. M. Martin, O. Arce-Bulted, M. N. Sugihara, 
K. A. Keating, and T. J. Strathmann). 
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pharmaceuticals present in water at environmentally relevant concentrations [5], and others report 
adverse effects of pharmaceutical mixtures on aquatic microcosms [6]. As a result, there are 
growing public concerns about the treatment and fate of pharmaceuticals. 
Chemical oxidation processes involving permanganate [MnO4-; Mn(VII)] and ferrate 
[FeO42-; Fe(VI)] salts are promising technologies for treatment of some pharmaceuticals. Both 
oxidants exhibit large reduction potentials (E0KMnO4 = +1.68 V, E0K2FeO4 = +2.20 V at acidic 
conditions) [7], but are considered selective oxidizing agents because their kinetic reactivity with 
different classes of organic chemicals spans several orders of magnitude [7, 8]. Mn(VII) is already 
widely used by utilities for control of dissolved manganese, taste/odor/color, and biological 
growth [9]. Mn(VII) has also been reported to oxidize a wide range of persistent organic 
contaminants [8]. Fe(VI) is attracting growing attention for several water treatment applications 
because of the reagent’s selective oxidizing properties [7, 10-14]. The instability of Fe(VI) salts has 
limited their use in field treatment applications, but recent efforts are focused on developing 
technologies for on-site Fe(VI) generation [15]. Mn(VII) and Fe(VI) are also attractive oxidizing 
agents because they are nonhalogenating and generate insoluble and environmentally benign 
reduction products (e.g.,MnO2(s) and Fe(OH)3(s)) that can be readily removed through 
sedimentation/filtration. Furthermore, the MnO2(s) and Fe(OH)3(s) products can act as coagulants 
and adsorbents to promote physical removal of pharmaceuticals and other constituents of concern 
(e.g., disinfection byproduct precursors) [7, 11]. 
Carbamazepine (CBZ) is a widely prescribed anticonvulsant and mood-stabilizing drug 
that has been detected frequently in treated wastewater effluent and drinking water sources at 
concentrations up to 6.3 µg/L [2, 4, 16-18]. High effluent concentrations of CBZ result from low 
removal efficiencies during conventional wastewater treatment; some studies report removal 
efficiencies for CBZ of only ~7% [2, 16]. It has also been suggested that the CBZ-glucuronide 
conjugate, a common human metabolite, can also be dissociated back to the parent drug during 
biological treatment processes [17]. 
 
N
O NH2  
carbamazepine (CBZ) 
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Earlier contributions have examined oxidative treatment of CBZ with chlorine and 
chlorine dioxide (both are ineffective) [19], ozone [20], and advanced oxidation processes [21], but 
information on treatment with Mn(VII) and Fe(VI) is lacking. This contribution describes for the 
first time the oxidation of CBZ by potassium permanganate and ferrate salts, with a focus on 
characterizing the pathways and kinetic parameters for CBZ-Mn(VII) and CBZ-Fe(VI) reactions. 
Because Mn(VII) is widely used by utilities, additional experiments were also conducted with the 
oxidant to assess the effects of important non-target water constituents (e.g., natural organic matter, 
dissolved ions), and to compare kinetic model predictions with measurements of CBZ removal 
during treatment of utility source waters. 
2.3 Materials and Methods 
2.3.1 Reagents 
All solutions were prepared in reagent-grade deionized water (18 MΩ·cm; Barnstead 
Nanopure system). Unless otherwise indicated, all chemicals were of high purity and were used as 
received from Sigma-Aldrich-Fluka. Suwannee River natural organic matter (NOM) from a 
reverse osmosis isolate was obtained from the International Humic Substances Society. Deuterated 
methanol was obtained from Cambridge Isotope Laboratories. K2FeO4 was prepared according to 
Delaude et al. [22], yielding a material with an iron content that was 98% Fe(VI). Fe(VI) stock 
solutions were prepared in a 5 mM phosphate/1 mM borate buffer (pH ~9.1) mixture that is 
reported to stabilize Fe(VI) and slow autodecomposition [23]; stock solutions were used within 30 
min of preparation to minimize artifacts from Fe(VI) autodecomposition. 
2.3.2 Identification of Reaction Products 
To identify reaction products, a series of phosphate-buffered CBZ solutions (100 µM CBZ; 
pH 7.0) were treated with varying doses of Mn(VII) or Fe(VI) (50−300 µM) for >2 h (tests 
demonstrated that reactions come to completion within this time). The resulting solutions were 
then filtered (0.2 µm PTFE) to remove Mn(IV) or Fe(III) (hydr)oxide products, and filtrates were 
analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with positive-mode 
electrospray ionization (ESI+). The major final product of CBZ-Mn(VII) reactions was further 
characterized by proton nuclear magnetic resonance (1H NMR) spectroscopy after concentrating 
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from a 1 L reaction using a solid phase extraction procedure described below for utility water 
experiments. Details of analytical procedures are provided in the Section  2.5. 
2.3.3 Kinetic Experiments 
Batch kinetic experiments were conducted in 0.1 L water-jacketed glass beakers connected 
to a constant-temperature water bath. Reactions were initiated by spiking excess Mn(VII) or Fe(VI) 
into pre-equilibrated solutions containing 5 µM CBZ, 25 mM phosphate buffer, and non-target 
water constituents of interest. Aliquots were then periodically collected and quenched with 
hydroxylamine (quenching with thiosulfate yielded the same results) before analyzing with 
high-performance liquid chromatography with photodiode array detection (HPLC-PDA). For 
kinetic experiments examining the influence of reduced non-target water constituents (Fe2+, Mn2+, 
HS-), MOPS buffer was used in place of phosphate because tests showed that metal coordination 
by phosphate affected reaction rates. It should be noted that MOPS reacts with Mn(VII), but the 
reaction occurs much more slowly than the CBZ reaction being monitored. 
A procedure similar to that described by Lee and coworkers [23] was used to monitor 
CBZ-Fe(VI) reactions to account for Fe(VI) autodecomposition during individual batch 
experiments. Fe(VI) concentration was monitored simultaneously with CBZ concentrations by 
colorimetric analysis [24], and the Fe(VI) exposure (∫0t [Fe(VI)]·dt) corresponding to each CBZ 
measurement was calculated (procedure details provided with the results). 
2.3.4 Experiments in Utility Source Waters 
Experiments were conducted to test the accuracy of the CBZ-Mn(VII) kinetic model in two 
utility source waters at conditions more relevant to water treatment operations (1−4 mg/L KMnO4, 
10 µg/L CBZ). The 10 µg/L initial CBZ concentration was chosen to be closer to ambient 
concentrations (ng/L to µg/L), but high enough to permit analysis with HPLC-PDA. KMnO4 was 
dosed into a series of 0.5 L CBZ-amended utility source water samples and allowed to react under 
constant mixing for a desired time period (1−30 min) before quenching with hydroxylamine. 
Samples were then filtered (0.45 µm glass fiber) to remove suspended solids and concentrated by 
solid phase extraction (SPE) with a method adapted from Ternes et al. [25]. Solutions were passed 
through Oasis HLB SPE cartridges (Waters, 500 mg, LP) at a flow rate of 10 mL/min using a 
Visiprep vacuum manifold (Sigma-Aldrich). SPE cartridges were sequentially preconditioned 
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with 3×2 mL hexane, 3×2 mL methanol, 1 mL water, 2 mL of 1 g/L tetramethylammonium 
hydroxide, and then 5×2 mL water. After extraction, SPE cartridges were dried under a gentle 
stream of air for one hour. CBZ concentrates were then eluted with 4×1 mL methanol and 
evaporated to dryness before reconstituting in 1 mL of a 20 mM phosphate buffer (pH 6.0) for 
analysis. Sulfamethoxazole, which tests showed to be unreactive with Mn(VII), was used as a 
surrogate standard to account for varying extraction efficiency.  
2.4 Results and Discussion 
2.4.1 Reaction Products 
Experiments demonstrate that CBZ is rapidly oxidized in water by both Mn(VII) and 
Fe(VI), and reactions yield a number of products detected by LC-MS/MS (Table  2.1). For 
CBZ-Mn(VII) reactions, 12 products were detected, whereas only six were detected for 
CBZ-Fe(VI) reactions. Most of the analytes have greater molecular weights than CBZ, and are 
suggestive of oxygen insertion into the structure. In addition, four of the products are shared by 
Mn(VII) and Fe(VI) reactions, suggesting similar reaction mechanisms. The fact that CBZ 
oxidation by Fe(VI) yields fewer products might be attributed to higher reactivity of Fe(VI) with 
some of the products formed initially (e.g., alcohols [7]), which prevents buildup and detection of 
these analytes in solution. Structures are proposed for each intermediate/product based upon the 
molecular ion masses and MS/MS fragmentation patterns (MS/MS fragmentation patterns 
provided in Table  2.1; proposed fragmentation pathways provided in Table  2.2; mass spectra 
provided in Table A.1. in Appendix A). Comparison of the structures indicates transformation of 
the olefinic double bond in the central heterocyclic ring to alcohol, aldehyde, ketone, and carboxyl 
groups, whereas the two outside aromatic rings remain intact. The formation of different products 
under different Mn(VII) and Fe(VI) dosing is shown in Table  2.3. 
For four products (II, III, VII, IX) where the proposed structures would result from 
cyclization reactions [26, 27], e.g., 
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N
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O
O OH  ( 2.1) 
alternative structures consistent with fragmentation patterns can and have been proposed 
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elsewhere [20, 28]. To confirm the validity of the proposed cyclization products, 1H NMR 
spectroscopy was used to analyze the structure of III, one of the major final stable products of the 
CBZ-Mn(VII) reaction. Spectra obtained for the isolated reaction product (Figure  2.1) agree 
closely with spectra collected for an authentic standard of 4-carboxy-9-acridanone, which 
corresponds to the proposed structure for III. 
2.4.2 Proposed CBZ Oxidation Pathways 
Reaction pathways for CBZ oxidation by Mn(VII) and Fe(VI) are proposed in Figure  2.2 
and Figure  2.3 (identified structures indicated with Roman numerals). The proposed pathways for 
reactions with both oxidants are similar in that reactions are initiated by electrophilic attack at the 
olefinic double bond on the central heterocyclic ring by Mn(VII) or Fe(VI). There are two possible 
initiation steps: (a) formation of a cyclic ester through a 3+2 electrocyclic addition of the oxidant 
to the olefinic bond; or (b) formation of a four-centered organometallic complex from a 2+2 
addition to the olefinic bond. Both mechanisms have been reported for alkene oxidation by 
Mn(VII) [29, 30]. Although, to our knowledge, there are no previous reports addressing the 
mechanisms of alkene oxidation by Fe(VI), reactions with alcohols have been proposed to be 
initiated by a 2+2 addition of an Fe=O bond to the α−C−H group [31]. Electron transfer from CBZ 
to the oxidant then leads to decomposition and hydrolysis to a range of products, including 
alcohols, aldehydes, and other compounds derived from oxidation of the olefinic carbon atoms. 
Reaction steps labeled with dashed arrows involve intramolecular cyclization via electrophilic 
aromatic substitution as illustrated in Equation ( 2.1) [26, 27]. Intramolecular cyclization of VI to III 
was previously reported [26, 27]. Several steps also involve hydrolysis of the urea group 
(−NHCONH2) on the central heterocyclic ring, which is enhanced following oxidation of the 
olefin group to more electron-withdrawing carbonyl moieties. Acid hydrolysis of phenylurea, 
having a similar structure with CBZ, has been reported previously [32]. According to the reaction 
schemes, Mn(VII) and Fe(VI) mediate incomplete oxidation of CBZ to organic byproducts rather 
than mineralization to inorganic products. This was confirmed by observing no significant 
decreases in dissolved organic carbon in Mn(VII)- and Fe(VI)-treated CBZ solutions (Figure  2.4). 
The lone nitrogen atom in CBZ also remains intact in all the products identified, indicating no 
nitrogen mineralization either. Thus, further studies will be needed to assess the effects of CBZ 
oxidation on pharmaceutical potency and/or toxicity since the parent compound is not mineralized. 
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2.4.3 Kinetic Parameters for CBZ-Mn(VII) Reactions 
Results from experiments designed to measure kinetic parameters of CBZ-Mn(VII) 
reactions are summarized in Figure  2.5. Batch experimental results (e.g., see Figure  2.5A) show 
that CBZ is rapidly oxidized by Mn(VII). For example, ~90 % of CBZ is oxidized by 75 µM 
Mn(VII) in <2 min. Figure  2.5A also shows that CBZ oxidation follows a pseudo-first-order rate 
law when Mn(VII) concentration is in excess. Measured pseudo-first-order rate constants (kobs, s-1) 
for all batch experiments are summarized Table  2.4. Figure  2.5B−D show the effects of Mn(VII) 
concentration, pH, and temperature on reaction kinetics. 
Results in Figure  2.5B show that kobs varies linearly with Mn(VII) concentration, 
demonstrating a first-order dependence on Mn(VII) concentration. Thus, CBZ-Mn(VII) reaction 
kinetics follow a generalized second order rate law, 
 ]CBZ][VII)(Mn[]CBZ[]CBZ[ 2obs kkdt
d ==−   ( 2.2) 
where k2 represents the apparent second-order rate constant, which is determined to be equal to 
3.0(±0.3)×102 M-1 s-1 at pH 7.0 and 25 °C (uncertainties ± 1σ). Compared with other water 
treatment oxidants, Mn(VII) is fairly effective in treating CBZ. Huber and co-workers [19] reported 
that ClO2 (k2 < 0.015 M-1 s-1 at pH 7, 20 °C) and Cl2 (k2 < 1.5 M-1 s-1; estimated from a reported 
half-life minimum) both react very slowly with CBZ. At the other end of the spectrum, O3 (k2 ≈ 
3×105 M-1 s-1) and ·OH (k2 = 8.8×109 M-1 s-1) oxidize CBZ much more rapidly than Mn(VII) [33]. 
However, the higher reactivity of these oxidants is balanced by their shorter lifetimes in natural 
waters; half-lives for O3 and ·OH in water with typical amounts of dissolved organic matter are 
estimated to be a few minutes and a few microseconds, respectively [34]. 
Figure  2.5C shows that varying pH has no significant effect on CBZ-Mn(VII) reaction 
kinetics. The lack of pH dependence is not surprising because neither Mn(VII) nor CBZ possess 
pKa values near the pH range examined. This result also demonstrates that minor species of either 
reactant (e.g., HMnO4, pKa = −2.25 [35]) are not significant contributors to the observed reaction 
rates. 
The temperature dependence shown in Figure  2.5D follows Arrhenius behavior, exhibiting 
a linear relationship between measured rate constants and the reciprocal of absolute temperature 
(T): 
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where Ea is the apparent activation energy, R is the universal gas constant, and A is the Arrhenius 
pre-exponential constant. Fitting Equation ( 2.3) to experimental data yields Ea = 22(±2) kJ/mol. 
The fit-derived value of Ea falls at the lower end of the range expected for reactions under chemical 
control, and indicates a rather small temperature dependence [36]. The enthalpic (∆H ++) and 
entropic (∆S ++) contributions to the activation energy were determined to be 19(±1) kJ/mol and 
-140(±5) J/K/mol, respectively, by fitting the temperature-dependent kinetic data with the Eyring 
equation [37]: 
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where kB is Boltzmann’s constant, h is Planck’s constant. Activation parameters for the Mn(VII) 
reaction with trichloroethene (TCE), a compound containing an olefin group as the reaction site, 
similar to CBZ, were reported to be Ea = 41.46 kJ/mol, ∆H++ = 39 kJ/mol, and ∆S ++= −115 J/K/mol 
(note: value of ∆S ++ has been corrected from original reference to correct a calculation error) [30]. 
The Ea and ∆H++ values (variables are directly related) for the CBZ-Mn(VII) reaction are much 
lower than those reported for the TCE-Mn(VII) reaction, indicating a smaller energy difference 
between the transition state and the reactants for the former. The large difference in Ea and ∆H++ 
values is also consistent with the large difference in rate constants measured for the two 
compounds that are believed to react by similar mechanisms (3.0×102 M-1 s-1 for CBZ vs 6.7×10-1 
M-1 s-1 for TCE). ∆S ++ provides information about the level of order in the transition state complex, 
so the similarity in values for CBZ and TCE reactions is consistent with formation of similar 
activated complexes with Mn(VII) in the transition state. 
2.4.4 Kinetic Parameters for CBZ-Fe(VI) Reactions 
In general, CBZ reacts more slowly with Fe(VI) than with an equivalent concentration of 
Mn(VII). Figure  2.6A shows the degradation of both CBZ and Fe(VI) during a typical batch 
reaction. Although initially present in significant stoichiometric excess, Fe(VI) autodecomposes 
rapidly at circumneutral pH and cannot be assumed to remain constant during reactions with CBZ 
[7]. Therefore, a pseudo-first-order rate law is not appropriate for modeling CBZ degradation, and 
so a different procedure was used to obtain kinetic parameters for CBZ-Fe(VI) reactions. A 
 27 
second-order rate law Equation ( 2.5) is assumed for individual batch reactions, as reported 
previously for Fe(VI) reactions with phenolic hormones [23]: 
 [ ] ]][[ CBZFe(VI)CBZ 2kdtd =−   ( 2.5) 
An approach described by Lee and co-workers is then used to determine values of k2 [23]. 
First, Equation ( 2.5) is rearranged and d[CBZ]/[CBZ] is integrated to yield the following 
expression: 
 [ ][ ] ∫−=
tt k
 
0 2
0
 [Fe(VI)]dt
CBZ
CBZln )(   ( 2.6) 
The term ∫0t [Fe(VI)]·dt is defined as “Fe(VI) exposure”, similar to “C·t” values commonly used to 
model disinfection processes where decay of the disinfectant is accounted for during pathogen 
inactivation studies [23]. Since the variation of Fe(VI) concentration over time is measured, the 
Fe(VI) exposure corresponding to each measurement of CBZ concentration can be calculated by 
numerical integration using a trapezoidal method as illustrated in the shadowed area of Figure 
 2.6A. Then, according to Equation ( 2.6), a plot of ln([CBZ]t/[CBZ]0) versus the corresponding 
Fe(VI) exposure data should yield a linear correlation with a slope representing k2 for the batch 
reaction (Figure  2.6A inset). Measured k2 values for all batch experiments are summarized in 
Table  2.5. The batch reaction shown in Figure  2.6A yields k2 = 70 (±3) M-1 s-1. This is roughly 
25% of the k2 value for the CBZ-Mn(VII) reaction at the same pH and temperature. The slower 
kinetics for CBZ-Fe(VI) reactions are somewhat unexpected but are likely due to the elevated 
reactivity of Mn(VII) with olefin groups [8, 30]. In general, Fe(VI) is considered a stronger oxidant 
than Mn(VII) and more reactive with organic compounds at room temperature and circumneutral 
pH. For example, Fe(VI) oxidizes substituted phenols 2−10 times faster than Mn(VII) at pH7 [8, 23]. 
Unlike Mn(VII), Fe(VI) reactivity is, in general, highly pH dependent due to the metal’s 
varying acid-base speciation (Figure  2.6B) [7]. H2FeO4 is a diprotic acid with pKa1 of 3.5 and pKa2 
of 7.3 [7]. The effect of pH on measured k2 values for CBZ-Fe(VI) reactions is shown in Figure 
 2.6C. Rate constants increase nearly 300-fold when pH decreases from 11 to 6. Since CBZ does 
not possess a relevant pKa, the pH dependency can be quantitatively modeled by assuming that 
individual Fe(VI) species react with CBZ via parallel reactions with independent second-order rate 
constants: 
 CBZ + H2FeO4 ⎯→⎯ 1αk Products  ( 2.7) 
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 CBZ + HFeO4- ⎯→⎯ 2αk Products  ( 2.8) 
 CBZ + FeO42- ⎯→⎯ 3αk Products  ( 2.9) 
If equilibrium between Fe(VI) species is maintained (i.e., acid-base reactions are much faster than 
redox reactions), measured k2 values are equal to the weighted sum contributions of individual 
pathways: 
 3322112 αkαkαkk ααα ++=   ( 2.10) 
The Fe(VI) speciation fractions α1, α2, and α3 can be calculated as a function of pH, and the 
variation of k2 can be fit with Equation ( 2.10) to obtain estimates of the individual second-order 
rate constants. The solid line in Figure  2.6C represents the best fit results, where kα2 = 
1.4(±0.5)×102 M-1 s-1, and kα3 = 3.8(±1.9) × 10-1 M-1 s-1 (the first term in Equation ( 2.10) was found 
to be insignificant, presumably because α1 is so small over the pH range examined; reactions at pH 
< 6 cannot be monitored because Fe(VI) rapidly autodecomposes). Dashed lines in Figure  2.6C 
represent the predicted contributions of the individual reaction pathways to the net reactivity of 
Fe(VI) with CBZ. The fitting result indicates that HFeO4− is much more reactive than FeO42−, in 
agreement with a number of previous reports of Fe(VI) reactivity [14, 23, 38]. The protonation of 
FeO42− reduces the electron-donating capacity of the coordinated oxygen ligands, thereby making 
the metal center more electron deficient and a stronger oxidant [38]. 
2.4.5 Effect of Non-target Water Constituents on CBZ-Mn(VII) Reactions 
Because of its greater reactivity with CBZ and current widespread use by utilities, Mn(VII) 
reactivity with CBZ was examined further to evaluate the influence of important non-target water 
constituents and to test the accuracy of a kinetic model for predicting CBZ removal in utility 
source waters. Batch kinetic studies indicate that high concentrations of most water constituents, 
including 10 mM Ca2+, Mg2+, HCO3−, NH4+, and NO3−, 20 mg/L FeOOH(s) and SiO2(s), and 10−20 
mg/L of NOM, have no significant effect on CBZ-Mn(VII) reaction rates (Table  2.4). The results 
are also consistent with the observation of very little or no demand for Mn(VII) of these substances 
over 60 min measured in separate tests. Although the tested NOM source (Suwannee River) shows 
no apparent effect, a wider diversity of NOM sources will need to be evaluated to conclude 
whether or not NOM influences rates of CBZ reactions with Mn(VII) during water treatment. 
In contrast to the substances described above, the presence of three reduced species (RS) 
with known Mn(VII) reactivity, Fe2+, Mn2+, and HS−, decreases the apparent rate of CBZ oxidation 
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substantially. Figure  2.7 show that values of kobs decrease linearly with increasing concentrations 
of the RS. Furthermore, no differences in kobs measurements are noted when the RS are added 
simultaneously with CBZ compared to when the RS are added 1 min before adding CBZ. This 
indicates that Mn(VII) reacts much faster with these substances than with CBZ, and that their net 
effect on rates of CBZ oxidation can be quantified by assuming an effective concentration of 
Mn(VII) in the kinetic model, where 
 [ ] [ ] [ ]demanddosedeff Mn(VII)Mn(VII)Mn(VII) −=   ( 2.11) 
and [Mn(VII)]demand can be estimated using the net stoichiometry of Mn(VII) reacting with 
individual RS. At pH 7, experiments show that the apparent net stoichiometric demands for 
Mn(VII) with RS are ≈ 1/3[Fe2+], ≈ 2/3[Mn2+], and ≈ 2.7/3[HS−]. Additional details on the 
determination of stoichiometric demands are described in the Section  2.5. 
2.4.6 Predictive Model for Water Treatment of CBZ 
Based on the kinetic parameters obtained for CBZ-Mn(VII) reactions in laboratory 
solutions, in both the presence and absence of non-target water constituents, the following 
predictive model was developed to describe CBZ oxidation in natural water: 
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where k2 (298K) = 3.0×102 M-1 s-1, Ea = 22 kJ/mol, and [Mn(VII)]eff is determined according to 
Equation ( 2.11). However, [Mn(VII)]eff ≈ [Mn(VII)]dosed for surface water sources where RS are 
typically present at only very low concentrations. Equation ( 2.12) assumes that [Mn(VII)]eff is in 
large excess of CBZ, which is typical of utilities where permanganate is used. The model can be 
used to estimate CBZ removal in existing water treatment utilities or Mn(VII) dosing required to 
meet a specific treatment objective. 
The accuracy of Equation ( 2.12) was tested for treatment of two drinking water utility 
source waters amended with 10 µg/L CBZ. The two utilities use surface water reservoirs as sources 
with similar water quality characteristics (Table  2.6). Results presented in Figure  2.8 show 
generally good agreements between model predictions and measurements of CBZ removal during 
treatment with 1−4 mg/L KMnO4. Both measurements and model prediction show >95% CBZ 
treatment is achieved within 30 min when the source waters are treated with 2 mg/L KMnO4 
(Figure  2.8A).The degree of CBZ treatment achieved for a reaction time of 10 min increases with 
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increasing KMnO4 dose (Figure  2.8B), and model predictions fall within one standard deviation 
of the measured values. Thus, these results indicate that Equation ( 2.12), which was developed 
from “clean system” laboratory experiments using high reagent concentrations, can be used to 
estimate CBZ removal during permanganate treatment processes at water utilities. 
2.5 Supporting Information 
2.5.1 Details of Analytical Procedures 
CBZ concentrations during kinetic studies were determined by high-performance liquid 
chromatography-photodiode array (HPLC-PDA) detection (Shimadzu AVP system). A Novapak 
C18 column (3.9×150 mm, 4 µm particle size) was used as the stationary phase, and a mobile 
phase with 25% acetonitrile/75% aqueous buffer (10 mM hydroxylamine, pH 6) was used with an 
isocratic flow rate of 1 mL/min. Dissolved organic carbon (DOC) measurements of Mn(VII)- and 
Fe(VI)-treated CBZ solutions was carried out using a Phoenix 8000 TOC analyzer 
(Tekmar-Dohrmann, Cincinnati, OH). 
Mn(VII) and Fe(VI) concentrations were determined spectrophotometrically using a 
double-beam spectrophotometer (Shimadzu UV-2401PC). The concentration of Mn(VII) stock 
solutions was verified by direct absorbance measurement at λ = 525 nm (ε = 2460 M-1 cm-1) [8]. 
Fe(VI) concentration was determined colorimetrically by measuring the absorbance of 
Fe(VI)-oxidized 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonate) (ABTS) at λ = 415 nm (ε = 
34000 M-1 cm-1), according to a procedure described by Lee et al. [24]. 
Reaction products were identified by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) analysis performed on a Thermo Finnigan LCQ DecaXP system outfitted with a 
Thermo Surveyor HPLC. Separation was accomplished using an Agilent C-18 column (Zorbax, 
Eclipse XDB-C18, 2.1×150 mm, 3.5 µm particle size). A gradient method with a flow rate of 0.2 
mL/min was used with two mobile phases (A: 95% H2O/5% acetonitrile/0.1% formic acid; B: 5% 
water/95% acetonitrile/0.1% formic acid). Phase A was maintained at 100% for the first 3 min, 
then the percentage of phase B was linearly increased to 25% during the next 12 min, then to 50% 
during the following 40 min. MS analyses were conducted in positive mode electrospray 
ionization (ESI+) over a mass-to-charge (m/z) range from 50–800, and a quadruple ion trap MS 
was used to separate ions with varying m/z values. Further fragmentation of selected ions was 
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achieved through collision-induced dissociation (CID), with an oscillating radiofrequency 
alternating current voltage of 31 V. No quantification of individual products was completed at this 
time because reference standards are not available for most of the identified compounds. 
A proton nuclear magnetic resonance (1H-NMR) spectrum for the major final product of 
CBZ-Mn(VII) reactions (product III in Table  2.1) was acquired with a Varian Unity 400 MHz 
instrument, in a 5 mm Nalorac QUAD probe, after dissolving in deuterated methanol. Chemical 
shifts (δ) are reported in ppm and referenced to residual protonated methanol at δ = 3.34 ppm. 
General parameters for the one-pulse experiments at ambient temperature were a 4300 Hz spectral 
width, 64 scans, a 90o pulse width, and 18K data points. Data processing was performed with 
NUTS software (Acorn NMR) with line broadening of no more than 0.3 Hz and zero filling to 32K 
points. The spectrum of the final product was compared against the spectrum of a reference 
standard of 4-carboxy-9-acridaone. 
Water quality characteristics for source waters obtained from surface reservoirs used by 
two central Illinois drinking water utilities were determined using standard methods of analysis. 
Source water pH was measured using an Orion 3-star plus benchtop pH meter following a 3 point 
calibration (pH 4, 7, and 10). Alkalinity was determined by titrating source water samples to pH 
4.5 using a standardized 0.01 N nitric acid solution. The permanganate demand of the source 
waters was determined after adjusting solutions to pH 7 and dosing with 4 mg/L of KMnO4, then 
measuring the residual Mn(VII) concentrations spectrophotometrically as a function of exposure 
time. Total dissolved solids (TDS) was determined gravimetrically after evaporating 1 L of filtered 
water (0.7 µm, Millipore glass fiber, 90 mm diameter) and drying the resulting residue at 105 ºC 
for >1 h and cooling in a desiccator. Total suspended solids (TSS) was determined by weighing the 
filters after drying overnight at 103-105 ºC and cooling in a desiccator. Total organic carbon (TOC) 
analysis was conducted using a Phoenix 8000 TOC analyzer (Tekmar-Dohrmann, Cincinnati, OH). 
Standardized potassium biphthalate solutions (Aqua solutions, Deer Park, TX) were used to 
prepare reference TOC standards. Ammonium concentrations were determined using the 
colorimetric nesslerization method (HACH Method 8038). Briefly, samples were derivatized 
using Nessler reagents and absorbance was measured at λ = 254 nm. Concentrations of inorganic 
anions (nitrate, chloride, and sulfate) were determined by ion chromatography using a Dionex 
ICS-2000 system equipped with a conductivity detector. An IonPac AS18 anion-exchange column 
(4×250 mm with 7.5 µm particle size) was used with a mobile phase containing 36 mM KOH 
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operated at a flow rate of 1.0 mL/min. 
2.5.2 Effects of Reduced Species on Reaction Kinetics 
The presence in solution of reduced inorganic species, Fe2+, Mn2+, and HS−, decreases the 
apparent rate of CBZ oxidation substantially. Figure  2.7 shows that measured values of kobs for 
CBZ reacting with a 75 µM dose of Mn(VII) decrease linearly with increasing concentrations of 
each reduced species (RS). Tests also show no differences in kobs when the RS are added to the 
Mn(VII) solution either simultaneously with CBZ or 1 minute prior to introducing CBZ, indicating 
that the RS react much faster than CBZ. As a result, the net effect of RS on rates of CBZ oxidation 
can be quantified by assuming an effective concentration, rather than dosed concentration, of 
Mn(VII) when making kinetic model predictions, where: 
 [ ] [ ] [ ]demanddosedeff Mn(VII)Mn(VII)Mn(VII) −=   ( 2.13) 
[Mn(VII)]demand can be estimated for waters for which concentrations of individual RS are known 
using the net stoichiometric demand ratios for individual RS reacting with Mn(VII) at the 
conditions under consideration. The net stoichiometric demand ratios can be calculated by 
comparing the second-order rate constant for CBZ-Mn(VII) reactions (300 M-1 s-1) with the slopes 
obtained from the plots of kobs versus concentration of individual RS (Figure  2.7). The ratio 
between these two numbers is indicative of the stoichiometric coefficient between Mn(VII) and 
the RS because the first-order rate constant for CBZ-Mn(VII) reactions is linearly dependent on 
Mn(VII) concentration remaining after reaction with RS and thus is negatively related to Mn(VII) 
concentration consumed by RS. Using this approach, the estimated net stoichiometric demand 
ratios for Mn(VII) reacting with Fe2+ is (94/300 ≈ 1/3) and for Mn(VII) reacting with Mn2+ is 
(175/300 ≈ 2/3) from data in Figure  2.7, consistent with the following reaction stoichiometries: 
 2 MnO4- + 3 Mn2+ + 2 H2O → 5 MnO2(s) + 4 H+  ( 2.14) 
 MnO4- + 3 Fe2+ + 7 H2O → MnO2(s) + 3 Fe(OH)3(s) + 5 H+  ( 2.15) 
The effect of HS- is more complex since the stoichiometric ratio between HS− and Mn(VII) 
is known to vary from 2:3 to 8:3 depending on solution conditions (e.g., pH, exposure to oxygen). 
A combination of the following reactions can occur [39]: 
 2 MnO4- + 3 HS- + 5 H+ → 2 MnO2(s) + 3 S0(s) + 4 H2O (dominant at pH<7.5)  ( 2.16) 
 8 MnO4- + 3 HS- → 8 MnO2(s) + 3 SO42- + 5 OH- (dominant at pH>7.5)  ( 2.17) 
The observed slope in Figure  2.7 for HS− indicates a net stoichiometric demand ratio of 2.7/3 
 33 
(267/300) for Mn(VII) reacting with HS−, indicating the occurrence of both Equation ( 2.16) and 
( 2.17), but a likely predominance of Equation ( 2.16) under conditions examined (pH 7.0), in 
agreement with expectations from the reported pH criteria. 
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2.7 Figures and Tables 
 
Figure  2.1. Aromatic region of 1H-NMR spectra of (A) isolated final product from 
CBZ-Mn(VII) reaction, and (B) 4-carboxy-9-acridanone reference standard. The spectra 
agree closely, with the exception of a few additional small peaks in the sample isolated from 
the reaction mixture, which are presumed to be due to impurities in the solid phase extract. 
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Figure  2.2. Reaction pathways for CBZ oxidation by Mn(VII). 
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Figure  2.3. Reaction pathways for CBZ oxidation by Fe(VI). 
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Figure  2.4. Dissolved organic carbon remaining in CBZ solutions following treatment with 
Mn(VII) and Fe(VI). Reaction condition: [CBZ]0 = 80 µM, varying [Mn(VII)] and [Fe(VI)], 
pH 7.0 (25 mM phosphate buffer), 25 ºC. Reactions were allowed to run for >10 h to reach 
completion before filtering (0.2 µm PTFE) and analyzing. 
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Figure  2.5. Kinetics of CBZ oxidation by Mn(VII). (A) Results from a typical batch 
reaction, (B) effect of Mn(VII) concentration, (C) effect of pH, and (D) effect of 
temperature.  
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Figure  2.6. Kinetics of CBZ-Fe(VI) reactions. (A) CBZ and Fe(VI) degradation in a batch 
reaction ([CBZ]0 = 5 µM, [Fe(VI)]0 = 100 µM, pH 7, 25 mM phosphate buffer, 25 °C). Inset 
shows fit of batch kinetic data from panel A using Equation ( 2.6), (B) calculated Fe(VI) 
speciation versus pH, (C) effect of pH on rate constants for CBZ-Fe(VI) reactions and 
associated model fit (pH 6−11, [CBZ]0 = 5 µM, [Fe(VI)]0 = 100 µM, 25 mM phosphate 
buffer (+5 mM borate buffer for pH 9−11 at 25 °C). The solid line in panel C depicts the 
model fit results, and dashed lines show predicted contributions of reactions with HFeO4− 
and FeO42− to the overall k2 values measured at different pH conditions. 
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Figure  2.7. Effect of reduced species (RS) on the rate of CBZ oxidation by Mn(VII). 
Reaction Conditions: [CBZ]0 = 5 µM, [Mn(VII)]dosed = 75 µM, pH 7.0 (1 mM MOPS buffer), 
25 ºC. 
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Figure  2.8. Comparison of kinetic model predictions and measured removal of CBZ during 
treatment of utility source waters with KMnO4: (A) Removal of CBZ as a function of time 
in source waters treated with 2 mg/L KMnO4; (B) Removal of CBZ after 10 min in source 
waters dosed with different concentrations of KMnO4. CBZ concentrations reported 
relative to Mn(VII)-free control samples, where negligible CBZ degradation is observed. 
Uncertainties indicated by 1 SD provided when replicate samples measured.  
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Table  2.1. Reaction products detected by LC-MS/MS during CBZ-Mn(VII) and CBZ-Fe(VI) 
reactions 
Product  
ID 
ESI(+) MS  
m/z a 
ESI (+) MS2  
m/z 
Proposed  
Structure 
Product of  
Mn(VII)b 
Product of  
Fe(VI)b 
CBZ 237 
237, 220, 
 194c 
N
O NH2  
  
I 196 n.d.d 
N
H
O
 
√  
II 224 196c 
N
H
O
O H 
√  
IIIe 240 240, 222c 
N
H
O
O OH 
√  
IV 251 
251c, 223, 
 208, 180 N+
O
NH2O  
√ √ 
V 255 
237c, 219, 
 195, 167 N
HO
O NH2
 
√  
VI 258 
240c, 222, 
 196 N
H
O O
OH
HO
H  
√  
VII 267 
250, 239, 
 224c, 196 N
O
O HO NH2  
√ √ 
VIII 271 253c, 210 
N
HO OH
O NH2  
√  
IX 283 
265c, 240,  
222, 196 N
O
O OHO NH2  
√ √ 
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Table  2.1. (cont.) 
Product  
ID 
ESI(+) MS  
m/z a 
ESI (+) MS2  
m/z 
Proposed  
Structure 
Product of  
Mn(VII)b 
Product of  
Fe(VI)b 
X 285 
267c, 239, 
 224, 196 N
O O
O NH2
OH
H
 
√ √ 
XI 301 
283, 258c, 
 240 N
O O
O NH2
OH
HO
 
√  
XII 303 285c, 267 
N
HO O
O NH2
OH
HO
 
√  
XIII 226 
208c, 198, 
 180 N
H
O OH
 
 √ 
XIV 267 249c, 221 
N
NO
O
OH
 
 √ 
a m/z values shown are for protonated molecular ions (M+H)+.  
b Table  2.3 lists the [Mn(VII)]/[CBZ] and [Fe(VI)]/[CBZ] ratios where individual products were detected.  
c indicates the most abundant fragment ion.  
d no MS/MS spectrum for this compound is obtained because this is a minor product and is not selected by the instrument to 
proceed to further fragmentation.  
e proposed structure confirmed by 1H-NMR. 
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Table  2.2. ESI(+) MS/MS spectra and structural interpretation of reaction products 
Product Fragmentation Pathways 
CBZ 
CBZ m/z:237
m/z:220
m/z:194
-NH3(17)
-HCNO(43)
-CO(28)
+H2(2)
N
O NH3+
N
C
O
N
H2+
 
II 
N
H2+
O
N
H2+
O
-CO(28)
Product II m/z:224 m/z:196
O H
 
III N
H2+ O OH
O
-H2O(18)
N
H O
O
Product III m/z:240 m/z:222  
IV 
N
H+
Product IV m/z:251
m/z:208
m/z:180
N+
NH2
O
m/z:223
-CO(28)
-CONH(43)
-CO(28)
-CONH(43)
N+
O
NH2O
N
H+
O
 
V Product V m/z:255 m/z:237
N
CH
NH2+
m/z:219
m/z:195
N
H
m/z:167
N
+H2O
O NH2
N
O NH2
N
C
N
-H2O(18)
-CNH2(28)
-C2H2(26)
-H2O(18)
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Table  2.2. (cont.) 
Product Fragmentation Pathways 
VI 
Product VI m/z:258
N
H2+
O
m/z:196
-H2O(18)
-CO2(44)
N
H O OH2+
O
N
H O
O
m/z:240
m/z:222
-CO(28)
N
H2+
O O
OH
HO
-H2O(28)
 
VII 
Product VII m/z:267
N
O
O NH3+
m/z:239
N
H2+
O
N
H2+
O
m/z:224
-CONH(43) -NH3(17)
-CO(28)
-CO(28)
-CONH(43)
m/z:196
N
O
O HO NH3+
N
O
O HOO H
m/z:250
 
VIII 
Product VIII m/z:271 m/z:253
-H2O(18) -CONH(43)
m/z:210
NH+
HO OH
O NH2
NH+
O
O NH2
N
H2+
O
IX 
-H2O(18)
m/z:265Product IX m/z:283
N
O
O NH2
m/z:240 m/z:222
N
H2+
O
m/z:196
-CO2(44)
-CONH -CONH(43)
-H2O(18)
O OH2+
N
O
O NH2
O
N
H
O
O OH2
+ NH
O
O
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Table  2.2. (cont.) 
Product Fragmentation Pathways 
X 
N
O NH2
O O
N
O NH3+
O
N
H2+
O
Product X m/z:285 m/z:267
m/z:239 m/z:196
-H2O(18)
-CO(28)
-CONH(43)
-CO(28)
N
O NH2
O O
H
+H2O H
N
H
O O
m/z:224
H-CONH(43)
 
XI 
m/z:283
-H2O(18)
m/z:240
COOH
HOOC
N
H2+
m/z:258
-CONH(43)
NH+
O NH2
O OOH
HO
N
O
OH
O
NH2
N
H
OO
OH
O
-CONH(43)
Product XI m/z:301
-H2O(18)
 
XII 
CH
N
O NH2
OOH
+H2O
HO
N
O NH2
OO
+H2O-H2O(18)
N
O NH2
OO
H
-H2O(18)
H
Product XII m/z:303 m/z:285 m/z:267  
XIII 
-CO(28)
Product XIII m/z:226 m/z:208 m/z:180
N
H
O OH2+
N
H
O
N
H
-H2O(18)
 
XIV 
Product XIV m/z:267 m/z:249
N
NO
O
OH2+
N
NO
O
N
NO
m/z:221
-CO(28)-H2O(18)
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Table  2.3. Formation of CBZ products under different Mn(VII) and Fe(VI) dosing 
[Mn(VII)]/[CBZ] [Fe(VI)]/[CBZ] 
Product ID 
0.5:1 1:1 2:1 3:1 
 
0.5:1 1:1 2:1 3:1 
I    √      
II   √ √      
III   √ √      
IV √ √ √   √ √ √ √ 
V  √ √       
VI   √ √      
VII √ √ √    √ √ √ 
VIII √ √ √ √      
IX   √ √    √ √ 
X √ √       √ 
XI   √ √      
XII √ √        
XIII      √ √ √  
XIV       √ √ √ 
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Table  2.4. Measured pseudo-first-order rate constants for CBZ oxidation by Mn(VII) 
pH T (ºC) 
[Mn(VII)]0 
(µM) 
[CBZ]0 
(µM) 
Non-Target Water  
Constituents 
[Buffer] 
(mM) 
kobsa 
(10-2 s-1) 
5 25 75 3.9 N/A 25b 2.0(±0.1) 
6 25 75 3.9 N/A 25b 1.9(±0.2) 
7 25 75 3.8 N/A 25b 2.2(±0.04) 
8 25 75 4.4 N/A 25b 2.0(±0.1) 
9 25 75 3.9 N/A 25b 2.1(±0.04) 
7 5 75 3.6 N/A 25b 1.2(±0.03) 
7 10 75 3.6 N/A 25b 1.5(±0.04) 
7 15 75 3.8 N/A 25b 1.6(±0.04) 
7 30 75 3.8 N/A 25b 2.6(±0.08) 
7 25 50 4.0 N/A 25b 1.3(±0.02) 
7 25 75 4.1 N/A 25b 2.2(±0.1) 
7 25 100 4.1 N/A 25b 2.2(±0.1) 
7 25 125 4.1 N/A 25b 4.0(±0.1) 
7 25 150 4.1 N/A 25b 4.4(±0.1) 
7 25 75 4.4 10 mg/L NOM 25b 2.2(±0.1) 
5 25 75 5.2 20 mg/LNOM 25b 2.1(±0.1) 
6 25 75 5.1 20 mg/L NOM 25b 2.4(±0.1) 
7 25 75 5.2 20 mg/L NOM 25b 2.1(±0.1) 
7 25 75 4.0 10 mM MgCl2 25b 2.0(±0.1) 
7 25 75 3.9 10 mM CaCl2 25b 2.2(±0.03) 
7 25 75 3.9 10 mM NH4Cl 25b 1.8(±0.04) 
7 25 75 3.9 10 mM NaHCO3 25b 1.9(±0.03) 
7 25 75 3.8 10 mM NaNO3 25b 2.1(±0.04) 
7 25 75 5.3 20 mg/L FeOOH 25b 2.5(±0.1) 
7 25 75 5.1 20 mg/L SiO2 25b 2.1(±0.04) 
7 25 75 5.2 75 µM Fe2+ 1c 1.4(±0.01) 
7 25 75 4.9 150 µM Fe2+ 1c 0.75(±0.01) 
7 25 75 5.1 225 µM Fe2+ 1c 0.071(±0.008)
7 25 75 4.9 37.5 µM Mn2+ 1c 1.5(±0.01) 
7 25 75 4.9 75 µM Mn2+ 1c 0.86(±0.01) 
7 25 75 6.1 112.5 µM Mn2+ 1c 0.23(±0.01) 
7 25 75 5.2 18.75 µM HS- 1c 1.8(±0.03) 
7 25 75 5.2 37.5 µM HS- 1c 1.2(±0.04) 
7 25 75 5.1 75 µM HS- 1c 0.76(±0.01) 
a Uncertainties represent 1 σ derived from linear regression.  
b Phosphate buffer. 
c MOPS buffer 
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Table  2.5. Measured second order rate constants for CBZ-Fe(VI) batch reactions 
pHa T (ºC) [Fe(VI)]0 (µM) [CBZ]0 (µM) k2 (M-1 s-1)b 
6 25 68c 5 76(±4) 
7 25 91 5 70(±3) 
8 25 94 5 36(±4) 
9 25 108 5 2.7(±0.1) 
10 25 102 5 0.97(±0.02) 
11 25 93 5 0.29(±0.02) 
a 25 mM phosphate buffer (+5 mM borate buffer for pH 9−11). 
b Uncertainties represent 1 σ derived from linear regression. 
c The lower Fe(VI) initial concentration at pH 6 is due to the faster Fe(VI) self-decomposition during pre-mixing. 
 
 
 
Table  2.6. Composition of central Illinois drinking water utility source waters 
 Utility 1 Utility 2 
Source reservoir reservoir 
pH 8.02 7.99 
Alkalinity (mg L-1 as CaCO3) 106 136 
60 min KMnO4 demand (mg L-1) 0.7 0.6 
TDS (mg L-1) 225 245 
TSS (mg L-1) 7 6 
TOC (mg L-1) 4 4 
Ammonia (mg L-1 as N) non-detectable non-detectable 
Nitrate (mg L-1 as N) 3 10 
Chloride (mg L-1) 52 29 
Sulfate (mg L-1 as S) 67 75 
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CHAPTER 3  
OXIDATION KINETICS OF ANTIBIOTICS DURING WATER 
TREATMENT WITH POTASSIUM PERMANGANATE1 
3.1 Abstract 
The ubiquitous occurrence of antibiotics in aquatic environments raises concerns about 
potential adverse effects on aquatic ecology and human health, including the promotion of 
increased antibiotic resistance. This study examined the oxidation of three widely detected 
antibiotics (ciprofloxacin, lincomycin, and trimethoprim) by potassium permanganate [KMnO4; 
Mn(VII)]. Reaction kinetics were described by second-order rate laws, with apparent second-order 
rate constants (k2) at pH 7 and 25 °C in the order of 0.61(±0.02) M-1 s-1 (ciprofloxacin) < 1.6(±0.1) 
M-1 s-1 (trimethoprim) < 3.6(±0.1) M-1 s-1 (lincomycin). Arrhenius temperature dependence was 
observed with apparent activation energies (Ea) ranging from 49 kJ mol-1 (trimethoprim) to 68 kJ 
mol-1 (lincomycin). Rates of lincomycin and trimethoprim oxidation exhibited marked pH 
dependences, whereas pH had only a small effect on rates of ciprofloxacin oxidation. The effects 
of pH were quantitatively described by considering parallel reactions between KMnO4 and 
individual acid-base species of the target antibiotics. Predictions from a kinetic model that 
included temperature, KMnO4 dosage, pH, and source water oxidant demand as input parameters 
agreed reasonably well with measurements of trimethoprim and lincomycin oxidation in six 
drinking water utility sources. Although Mn(VII) reactivity with the antibiotics was lower than 
that reported for ozone and free chlorine, its high selectivity and stability suggests a promising 
oxidant for treating sensitive micropollutants in organic-rich matrices (e.g., wastewater). 
3.2 Introduction 
Antibiotics are therapeutic agents used to treat bacterial infections in humans and animals, 
and they are also widely used as livestock growth promoters [1]. Many commonly prescribed 
antibiotics are now ubiquitous in aquatic environments, especially those that receive effluent from 
wastewater treatment facilities [2-8]. Fluoroquinolones, lincosamides, trimethoprim, and 
                                                     
1  A modified version of Chapter 3 was published in Environmental Science & Technology, 2010, 
44, 6416-6422. (L. Hu lead author with co-authors H. M. Martin, and T. J. Strathmann). 
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sulfonamides have been among the most frequently detected antibiotics [5, 6, 9]. For example, a 
national survey detected ciprofloxacin, lincomycin, trimethoprim, and sulfamethoxazole in 2.6, 
19.2, 12.5, and 12.5%, respectively, of streams sampled throughout the U.S. [5]. Despite the low 
concentrations at which these chemicals have been detected (ng/L−µg/L), serious concerns exist 
about the adverse effects of antibiotics on aquatic ecology and human health, especially when 
considering potential synergistic effects of mixtures of antibiotics and other pharmaceutically 
active compounds. Pomati and co-workers [10] reported that growth of human embryonic cells was 
inhibited by a mixture of 13 pharmaceuticals (including four antibiotics) at environmental 
concentrations. Other researchers have also reported that long-term exposure to low levels of 
antibiotics promoted increased antibiotic resistance among microbial populations in 
effluent-impacted environments [11-14]. As a result, there has been growing interest in the 
environmental fate and drinking water treatment of antibiotics and related micropollutants. 
Current water and wastewater treatment practices were not specifically designed to treat 
antibiotic micropollutants. Antibiotics have been detected in effluents from wastewater treatment 
facilities [8, 15, 16], and one recent study reported detection of a large number of pharmaceuticals in 
drinking water sources as well as finished drinking water [2]. Therefore, better understanding of the 
fate of antibiotics during individual water and wastewater treatment processes is needed to 
optimize operations to treat micropollutants of concern and eliminate the pharmaceutical activity 
of treated waters. Permanganate [MnO4-; Mn(VII)], widely used by water utilities (e.g., for 
treatment of taste and odor compounds, soluble iron(II) and manganese(II) [17]), is a promising 
technology for oxidative treatment of antibiotics and related micropollutants. Mn(VII) is a strong 
oxidant that reacts selectively with organic chemicals that contain electron-rich moieties, 
including phenolic, olefin, amino, thiol, ether, aldehyde, and ketone groups [18-20]. In addition, 
unlike chlorine-based oxidants, reactions with Mn(VII) do not produce halogenated byproducts, 
and the insoluble reduction product, MnO2(s), can enhance coagulation processes [17]. However, to 
date little information is available on Mn(VII) reactions with important classes of antibiotics. 
This study examined for the first time aqueous reactions between Mn(VII) and three commonly 
detected antibiotics (Table  3.1: ciprofloxacin, CPR; lincomycin, LCM; and trimethoprim, TMP) 
under natural water conditions. Detailed kinetics experiments were conducted to characterize 
reactions, including examining the effects of Mn(VII) concentration, temperature, and pH. The 
effects of pH were quantitatively interpreted by considering changes in acid-base speciation of the 
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target antibiotics. Results from experiments conducted in well-characterized laboratory solutions 
were used to develop a predictive kinetic model for antibiotic treatment in drinking water sources 
of variable composition, and the model was validated using tests conducted in source waters 
obtained from six drinking water utilities. 
3.3 Materials and Methods 
3.3.1 Reagents and Materials 
All chemicals were of high purity and were used as received from Sigma-Aldrich-Fluka (St. 
Louis, MO). Solutions were prepared in reagent-grade deionized water (>17.8 MΩ·cm). 
Glassware was washed by soaking in a 1 M HCl for >24 h and repeatedly rinsing with deionized 
water. 
3.3.2 Reaction Kinetics 
Batch experiments were conducted to characterize the oxidation kinetics of CPR, LCM, 
and TMP using procedures similar to those previously reported [21]. Typically, batch reactions were 
conducted in 100 mL water-jacketed beakers connected to a circulating water bath for temperature 
control. Reactions were initiated by spiking excess concentration of Mn(VII) into pre-equilibrated 
and pH-adjusted solutions containing 10−20 µM target antibiotic and 25 mM phosphate buffer. 
Although a recent study reported that phosphate buffer enhanced Mn(VII) oxidation of triclosan 
[22], tests showed no enhancement of phosphate buffer on Mn(VII)-antibiotic reaction rates (a 
slight inhibition was observed for CPR, attributed to the prevention of autocatalytic reactions 
when MnO2(s) was formed). After initiating reactions, aliquots were periodically collected and 
quenched with excess hydroxylamine, which rapidly reduced residual Mn(VII) and MnO2(s) to 
Mn2+. Residual antibiotic concentrations in the collected aliquots were then measured by high 
performance liquid chromatography with photodiode array detection (HPLC-PDA) to track the 
reaction progress. 
3.3.3 Utility Source Water Experiments 
LCM and TMP were also examined as representative antibiotics in a larger study on 
Mn(VII) reactivity with pharmaceutically active compounds in surface waters obtained from six 
drinking water utilities. For these experiments, a much lower initial antibiotic concentration (10 
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µg/L) was used to better mimic environmental levels (ng/L−µg/L), while still being high enough to 
permit accurate measurement by HPLC-PDA following solid phase extraction (SPE). In these 
experiments, reactions were initiated by spiking varying amounts of Mn(VII) into a series of 500 
mL unfiltered source water samples maintained at room temperature (measured for each reaction) 
and amended with the target antibiotics. After the desired reaction time, excess hydroxylamine 
was added to each reactor to quench any further reaction. Water samples were then filtered (0.45 
µm glass fiber) and concentrated using SPE before analyzing with HPLC-PDA. 
3.3.4 Analytical 
Antibiotic concentrations were determined using high performance liquid chromatography 
equipped with UV-Vis photodiode array detection (HPLC-PDA; Shimadzu AVP System; 
Columbia, MD). The stationary phase was a Novapak C-18 column (3.9×150 mm, 4 µm particle 
size; Waters Corporation, Milford, MA) and the mobile phase (1 mL/min) was an isocratic mixture 
of acetonitrile and an aqueous buffer. For CPR, the aqueous buffer was 2.5 mM 
sodium-1-heptanesulfonate adjusted to pH 2.2. For LCM and TMP, the buffer was 10 mM 
hydroxylamine adjusted to pH 6. The percentages (v/v) of acetonitrile used for CPR, LCM, and 
TMP were 15%, 12%, and 15%, respectively. 
Prior to HPLC-PDA analysis, residual antibiotics present in solutions from experiments 
conducted in utility source waters were pre-concentrated using a solid phase extraction (SPE) 
method adapted from Hao et. al [23]. SPE cartridges (Oasis HLB, 500 mg, LP; Waters) were 
preconditioned sequentially with 5 mL methanol and 5 mL deionized water followed by washing 
with 5 mL of 5% methanol in water. 10 µg/L sulfamethoxazole (SMX) was added as a non-reactive 
internal standard to quenched reactor samples to account for varying extraction efficiency, and a 
Visiprep vacuum manifold (Sigma-Aldrich, St. Louis, MO) was then used to introduce the 500 mL 
samples at 10 mL/min. After extraction, SPE cartridges were dried under a gentle stream of air for 
1 h before eluting with 5 mL methanol. The eluates were then evaporated to dryness and 
reconstituted in 1 mL deionized water before analyzing with HPLC-PDA. SPE recoveries for 
LCM, TMP and SMX were 49.3±10.4%, 70.6±12.7%, and 61.7±9.5%, respectively. 
Quantification was accomplished by calibration against external reference standards after 
correcting for SPE recoveries using the internal standard. 
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Utility source water characteristics were determined using procedures described 
previously [21]. To independently quantify the matrix oxidant demand during utility source water 
experiments, Mn(VII) decay in each source water was determined spectrophotometrically (λ = 525 
nm) in 5 cm-optical-path cuvettes using a double-beam spectrophotometer (Shimadzu 
UV-2401PC). Solutions were filtered (0.2 µm PTFE) prior to analysis to eliminate spectral 
interference from MnO2 precipitates. 
3.4 Results and Discussion 
3.4.1 Reaction Kinetics 
Initial tests showed that three antibiotics (CPR, LCM, and TMP) exhibited marked 
reactivity with Mn(VII), whereas two other commonly detected sulfonamide antibiotics 
(sulfamethoxazole and sulfamethizole) were unreactive with Mn(VII) on time scales relevant to 
water treatment processes (≤ 1 h). The kinetics of CPR, LCM, and TMP oxidation in batch 
reactions followed a pseudo-first order rate law when the Mn(VII) concentration was in large 
excess of the initial antibiotic concentration (Figure  3.1), indicating that reactions were first-order 
with respect to antibiotic concentration. Pseudo-first-order rate constants (kobs, s-1) determined for 
all batch reactions are listed in Table  3.2. Figure  3.2A shows that measured kobs values increased 
linearly with increasing Mn(VII) concentration, demonstrating that reactions were also first-order 
with respect to Mn(VII) concentration. Thus, reaction kinetics for the target antibiotics followed a 
generalized second-order rate law: 
 tottot2tot [ATB][Mn(VII)]dt
d[ATB] k−=   ( 3.1) 
where [Mn(VII)]tot and [ATB]tot represent the total Mn(VII) and antibiotic concentrations, 
respectively, and k2 is the apparent second order rate constant (k2, M-1 s-1). At pH 7 and 25 °C, k2 
values for the reactions were 0.61 ± 0.02 M-1 s-1 (CPR), 3.6 ± 0.1 M-1 s-1 (LCM), and 1.6 ± 0.1 M-1 
s-1 (TMP) (uncertainties = 1 σ) (Figure  3.2A). Waldemer and coworkers [19] reported the reaction 
rate constants between Mn(VII) and a wide range of organic compounds at circumneutral pH and 
room temperature conditions, including chlorinated alkanes and alkenes, aromatic hydrocarbons, 
ethers, nitro explosives, and substituted phenols, with k2 values that ranged from 7×10-6 to 2×102 
M-1 s-1. In comparison with this range of reactivities, the three antibiotics were within the more 
reactive end of the spectrum, only being less reactive than compounds that possess highly 
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Mn(VII)-reactive olefin and phenolic functional groups [24, 25]. At similar conditions, we found that 
the anticonvulsant drug carbamazepine, which contains an olefin group, was more reactive with 
Mn(VII) (k2 = 3.0×102 M-1 s-1 [21]) than the antibiotics examined here. 
Previous studies showed antibiotic oxidation by several drinking water oxidants, including 
ozone and free chlorine [26-29]. Oxidation rate constants for the three antibiotics with Mn(VII) were 
lower than those reported for reactions with ozone (1.9×104 M-1 s-1 for CPR, 6.6×105 M-1 s-1 for 
LCM, and 2.7×105 M-1 s-1 for TMP) and free chlorine (7.6×105 M-1 s-1 for CPR and 56 M-1 s-1 for 
TMP) under comparable conditions. The relative reactivity of the three oxidants with these 
antibiotics qualitatively followed the trend in calculated standard reduction potentials at pH 7 
(EH,7): Mn(VII) (1.13 V vs NHE) < free chlorine (1.27 V) < ozone (1.67 V). Although Mn(VII) 
was less reactive with the antibiotics than free chlorine and ozone, its high selectivity may result in 
greater stability in organic-rich aquatic matrices (e.g., wastewater), and a larger fraction of the 
applied Mn(VII) dosage may be available to react with the target antibiotics in these systems. 
However, further research is needed to directly compare the treatment effectiveness of equivalent 
dosages of different oxidants in diverse aquatic matrices. 
The proposed Mn(VII)-reactive functional groups in the structures of the three antibiotics 
are summarized in Table  3.1 (dashed circles). The piperazine ring in the CPR structure contains 
secondary aliphatic and tertiary aromatic amine groups that are potential sites of Mn(VII) reaction. 
These groups have previously been identified as sites of fluoroquinolone oxidation by ozone, 
chlorine, and MnO2 [26, 28, 30]. Mn(VII) reaction at the piperazine ring was supported by the very 
low reactivity observed with flumequine, a structurally related fluoroquinolone that lacks the 
piperazine ring moiety (Figure  3.3). 
LCM contains a tertiary aliphatic amine on the pyrrolidine ring and a thioether group on the 
pyranose ring that are potential target sites for Mn(VII) oxidation. These groups have been 
proposed as sites for ozone reaction [26], and the reactivity of Mn(VII) with aliphatic amines and 
thioether compounds has been documented [31-33]. 
Dodd and co-workers [26, 27] postulated that ozone and chlorine react with TMP either 
through the trimethoxybenzene or pyrimidine rings. Kinetics experiments using substructural 
analogues of these moieties (3,4,5-trimethoxytoluene and 1,4-diaminopyrimidine) showed that 
Mn(VII) was much more reactive with 1,4-diaminopyrimidine (Figure  3.4), indicating that this 
was the likely site for TMP oxidation. Mn(VII) oxidation of the 5,6 double bond in pyrimidine 
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rings (structural ring positions indicated in) within nucleic acids has been well documented [34]. In 
addition, Freeman et al. [35] reported a rate constant for Mn(VII) reaction with the pyrimidine 
compound uracil (k2 = 1.9 M-1 s-1 at pH 7 and 25 °C) similar to the value measured for TMP in this 
study, and the 5,6 double bond was proposed as the reaction site. However, additional 
measurements of reaction products are necessary to unambiguously determine the sites of Mn(VII) 
reactions with the three target antibiotics (see Chapter 4). 
Rate constants for Mn(VII) reactions with the antibiotics exhibited temperature 
dependence consistent with the Arrhenius equation (Figure  3.2B), with apparent activation 
energies (Ea) of 54 ± 3 kJ/mol for CPR, 68 ± 4 kJ/mol for LCM, and 49 ± 5 kJ/mol for TMP. This 
corresponded to a doubling of reaction rates for every 9, 8, and 10 °C increase, respectively, in 
temperature. A previous study on Mn(VII) oxidation of CPR in highly alkaline solution reported 
much weaker temperature dependence [36], suggesting that a different reaction mechanism operates 
under natural water conditions. 
Figure  3.5 shows that solution pH had varying effects on Mn(VII) reactions with the target 
antibiotics. Mn(VII) reactions with CPR exhibited a relatively weak pH dependence, where k2 only 
varied from 0.6 to 1.0 M-1 s-1 from pH 5 to 9 (Figure  3.5A). Although the effect of pH was 
relatively small, replicate experiments confirmed that the difference was significant at the 95% 
confidence level. The weak pH dependence was somewhat surprising because the acid-base 
speciation of CPR changed over this pH range, and CPR reactions with ozone and free chlorine 
were strongly pH dependent [26, 28], with the proposed secondary aliphatic amine target moiety 
being two orders-of-magnitude more reactive when deprotonated. The small pH dependence 
observed suggested that Mn(VII) was mainly targeting the tertiary aromatic amine (N1 site; 
structural positions indicated in Table  3.1) on the piperazine ring instead of the aliphatic amine 
(N4), similar to the mechanism proposed for fluoroquinolone reactions with MnO2 [30]. Whereas 
the N4 amine undergoes deprotonation over the pH range examined, speciation of the N1 nitrogen 
remains unchanged. This conclusion was further supported by the fact that modification of the N4 
site had very little effect on Mn(VII) reactivity (ciprofloxacin versus enrofloxacin in Figure  3.3). 
The small change in k2 observed with changing pH may have been due to limited contributions of 
the N4 amine to overall CPR reactivity or to the effects of N4 protonation/deprotonation on 
electron density at the N1 amine site. 
LCM reactivity increased significantly with increasing pH, with two orders-of-magnitude 
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increase in k2 when pH increased from 5 to 9 (Figure  3.5B). Ozone reaction with LCM showed a 
similar pH dependence [26], consistent with the dominant reactive site being the tertiary amine 
group on the pyrrolidine ring, which underwent a change in acid-base speciation over the pH range 
examined. Deprotonation increases electron density on the amine nitrogen, increasing reactivity 
with oxidants. 
TMP exhibited an opposite pH dependence trend to that observed for LCM, where k2 
decreased by more than one order-of-magnitude when pH increased from 5 to 9 (Figure  3.5C). 
The pH dependence also contrasted with the trend reported for TMP reactions with free chlorine [27] 
and ozone [26]. Although the proposed Mn(VII)-reactive site (5,6 olefinic double bond) did not 
change acid-base speciation, the neighboring N1 site (Table  3.1) was protonated at pH < pKa2, 
which in turn could have affected reactivity with Mn(VII). Olefins react with Mn(VII) by 
formation of a 3 + 2 cyclic diester intermediate [21, 25, 37, 38]. The olefin carbon atoms act as 
electrophiles during diester formation, so the presence of electron-withdrawing groups on 
neighboring atoms increases reaction rates by enhancing electrophilicity of the reacting carbon 
atoms [37, 38]. Thus, Mn(VII) reactivity with TMP increased with decreasing pH because 
protonation of the N1 atom increased the electron withdrawing character of this group adjacent to 
the reaction site. 
3.4.2 Correlating Kinetics with Antibiotic Speciation 
The effects of pH on reaction kinetics were quantitatively related to changes in acid-base 
speciation of the target antibiotics. Although permanganate exhibits acid-base chemistry, the pKa 
of HMnO4 is very low (−2.25 [39]), and the conjugate base, MnO4−, was the dominant species over 
the pH range examined. The three target antibiotics have various acid-base groups with 
characteristic pKa values [26, 29, 40] that were used to calculate the distribution of species present at 
different pH conditions. The pH dependency of reaction rates then resulted from individual 
antibiotic species reacting with MnO4− via parallel reactions that could be described by 
independent second-order rate constants: 
 MnO4- + ATBi → Products, k2i; i = 1,2,3…  ( 3.2) 
where ATBi represents individual species of the target antibiotic and i refers to the species 
protonation level (e.g., 1 = fully protonated, 2 = first conjugate base, etc.). For example, LCM1 
represents the monoprotonated lincomycin species, whereas LCM2 is the neutral molecule. Thus, 
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k21 is the species-specific second-order rate constant for deprotonated MnO4− reaction with the 
monoprotonated LCM1. If equilibrium between antibiotic species was maintained during redox 
reactions with Mn(VII) [41], the effect of pH on the apparent oxidation rate constant could be 
quantitatively described by Equation ( 3.3): 
 ∑==−
i
tottoti2itottot2
tot [ATB][Mn(VII)][ATB][Mn(VII)]
dt
d[ATB] αkk   ( 3.3) 
and it follows that 
 ∑=
i
iikk α22   ( 3.4) 
where αi represents the fraction of antibiotic species i, which can be calculated as a function of pH 
using the reported pKa values. Figure  3.5 shows the results of least-squares fitting of the kinetic 
data for each antibiotic with Equation ( 3.4) and the predicted contribution of individual species to 
the overall rate constants (i.e., k2iαi). The model fits agreed closely with experimental data and the 
fit-derived species-specific rate constants are summarized in Table  3.1. For CPR, the small 
difference between kij values was attributed to the fact that Mn(VII) was reacting predominantly 
with the aromatic N1 site which did not change speciation. Deprotonation of the neighboring N4 
can have a small effect on electron density at the reactive N1 site through inductive effects, 
possibly explaining the small difference between k22 and k23. For LCM, k22 was nearly two 
orders-of-magnitude greater than k21, attributed to increased electron density of the deprotonated 
amine group on the pyrrolidine ring. For TMP, k22 was much larger than k23, which was attributed 
to enhanced Mn(VII) reactivity with the 5,6-double bond when the neighboring heterocyclic 
nitrogen atom was in the more electron-withdrawing protonated state [37, 38]. 
The correlation observed between Mn(VII) reaction rates and acid-base speciation of the 
antibiotics contrasted with recent reports of Mn(VII) reactivity with phenolic micropollutants [22, 
42]. The reason for the difference was unclear, but may be due to the effects of ligands and 
autocatalytic mechanisms that complicate modeling of Mn(VII) reactions with phenolic moieties 
[42]. 
3.4.3 Mn(VII) Treatment of Antibiotics in Utility Source Waters 
The oxidative treatment of LCM and TMP by Mn(VII) was also analyzed in six utility 
source waters, whose properties are summarized in Table  3.3 and Table  3.4. Figure  3.6A and B 
summarizes the measured removal of LCM and TMP in utility source waters with three different 
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doses of KMnO4 (2, 6, and 18 mg/L). Results showed a general trend of increasing antibiotic 
removal with increasing KMnO4 doses. For LCM, an average of 60% removal was observed for a 
6 mg/L KMnO4 dose and 30 min reaction time, whereas only about 20% of TMP was oxidized by 
the same KMnO4 dosage and a longer reaction time (120 min). In comparison, the anticonvulsant 
drug carbamazepine, which contains a Mn(VII)-reactive olefin group, was removed to a much 
greater degree in some of the same source waters [21], with 80% removal being observed after 
treatment with 2 mg/L KMnO4 for 10 min. Figure  3.6A and B also shows that the extent of LCM 
and TMP removal varied among the six source waters, which was attributed to differences in key 
water quality characteristics, including pH and the matrix KMnO4 demand (Table  3.3 and Table 
 3.4). The strong influence of pH is shown in Figure  3.5. KMnO4 demand of the source water 
matrix reduces the effective Mn(VII) concentration available to react with target antibiotics. 
It should be noted that the KMnO4 dosages used here were greater than those typically used 
in drinking water treatment facilities (e.g., for Mn removal, taste-and-odor control, etc.), and little 
removal of the tested antibiotics would be expected at most facilities currently using KMnO4. To 
specifically target antibiotic removal, higher KMnO4 dosages and/or longer reactor residence 
times will be needed. Use of KMnO4 to specifically target antibiotic removal might be more 
applicable in wastewater treatment facilities with longer retention times, higher organic loadings 
to consume residual KMnO4, and built-in solids removal capabilities to handle the associated 
residual solids. Further research is needed to measure antibiotic removal at actual wastewater and 
drinking water treatment facilities during the application of KMnO4. 
3.4.4 Predictive Kinetic Model for Water Treatment 
Antibiotic oxidation by Mn(VII) during water treatment can be predicted using Equation 
( 3.5) along with kinetic parameters described for individual target antibiotics in previous sections: 
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where [ATB]0 and [ATB] are the antibiotic concentration initially present before treatment and the 
concentration remaining after Mn(VII) treatment, respectively. Term 1 calculates the apparent 
second-order rate constants at 25 °C and the pH of interest by accounting for the effects of 
antibiotic acid-base speciation on reactivity with Mn(VII) (Table  3.1). Term 2 corrects the 
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apparent rate constant to the temperature of interest using Ea values determined above (Figure 
 3.2B). R and T represent the universal gas constant and absolute temperature, respectively. In term 
3, CtMn(VII) is the integrated Mn(VII) exposure during treatment (∫0t [Mn(VII)·dt), which accounts 
for the applied Mn(VII) dosage, treatment time, and oxidant demand of the source water matrix; 
this is equivalent to the widely used Ct concept for modeling disinfection processes. Figure  3.7 
illustrates how CtMn(VII) is determined by measuring Mn(VII) decay as a function of time in the 
matrix of interest. The CtMn(VII) corresponding to each source water was determined by measuring 
Mn(VII) consumption in the absence of antibiotics in separate experiments (Table  3.4). 
Equation ( 3.5) can be used to either estimate the expected antibiotic removal percentage 
for an existing Mn(VII) dose and reaction time used at a treatment facility or to determine the 
Mn(VII) dose and/or reaction time required to achieve a desired treatment goal. The accuracy of 
Equation ( 3.5) was tested by comparing model predictions with the measurements in the utility 
source waters. Results of the comparison are summarized in Figure  3.6C and D. It can be seen that 
the majority of model predictions agreed with measurements at the 95% confidence level. While 
most model predictions agreed closely with measured values in the six utility source waters, all 
model predictions for TMP and LCM agreed within a factor of 2.8 and 3.2, respectively, of 
measured values. The close agreement between measurements and model predictions was 
especially notable given that experiments in the utility source waters were conducted at conditions 
that differ significantly from those used to parametrize Equation ( 3.5) (e.g., much lower initial 
antibiotic and Mn(VII) concentrations, poorly characterized source waters, suspended solids 
present). Reactions of both antibiotics with Mn(VII) were highly pH dependent, so discrepancies 
may have been due, in part, to errors in pH measurements. Underpredictions of the model may also 
resulted from autocatalytic processes involving the MnO2(s) product [43, 44] and the effects of 
unknown ligands (e.g., NOM) that were present in the sourcewaters [42], factors that were not 
considered in the model, but which might have accelerated oxidation of the antibiotics. Although 
Equation ( 3.5) could be modified to include autocatalytic processes and ligand effects, it will be 
difficult to predict these processes a priori in natural water matrices of varying composition. 
Instead, we recommend that Equation ( 3.5) be used to provide a conservative baseline prediction 
of antibiotic treatment, and then consider that any autocatalytic processes and ligand effects may 
act to provide an additional level of treatment (i.e., a safety factor) above model predictions. Since 
reactions with Mn(VII) under water treatment conditions are not expected to mineralize the 
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antibiotics [21], additional studies are needed to identify the products of these reactions and assess 
the effects of treatment on the antibiotic activity of solutions. 
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3.6 Figures and Tables 
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Figure  3.1. Oxidation of antibiotics by Mn(VII) during batch reactions and 
pseudo-first-order model fits. Experimental conditions: [CPR]0 = 10 µM, [LCM]0 = 20 µM, 
[TMP]0 = 10 µM, [Mn(VII)]0 = 500 µM, 25 ºC, pH 7, 25 mM phosphate buffer. 
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Figure  3.2. Effect of (A) Mn (VII) concentration and (B) temperature on measured rate 
constants for oxidation of antibiotics. Reaction conditions. [CPR]0 = 10 µM, [LCM]0 = 20 
µM, [TMP]0 = 10 µM, 25 mM phosphate buffer, pH 7, 25 °C for (A); [CPR]0 = 10 µM, 
[LCM]0 = 20 µM, [TMP]0 = 10 µM, [Mn(VII)]0 = 500 µM, 25 mM phosphate, pH 7 for (B). 
Lines represent linear regressions of measured data. Uncertainties represent 1 σ. 
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Figure  3.3. Reactivity of ciprofloxacin and structurally related fluoroquinolones with 
Mn(VII) at pH 5 and pH 9. Conditions: [fluoroquinolone]0 = 10 µM, [Mn(VII)]0 = 500 µM, 
25 mM phosphate buffer, 25 oC. 
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Figure  3.4. Mn(VII) oxidation of trimethoprim (TMP) in comparison to two analogues that 
represent sub-structural moieties within the TMP structure. Experimental conditions: C0 = 
10 µM, [Mn(VII)]0 = 500 µM, 25 ºC, pH 7, 25 mM phosphate buffer. 
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Figure  3.5. Effect of pH on measured and model-predicted rate constants for Mn(VII) 
reactions with (A) ciprofloxacin, (B) lincomycin, and (C) trimethoprim. Reaction conditions: 
[CPR]0 = 10 µM, [LCM]0 = 20 µM, [TMP]0 = 10 µM, [Mn(VII)]0 = 500 µM, 25 mM 
phosphate, 25 °C. Symbols represent measurements and lines indicate overall model 
predictions with Equation ( 3.4) (solid) and contributions of individual antibiotic species to 
the apparent rate constants (dashed, dotted). Fit-derived kinetic parameters for each 
antibiotic are listed in Table  3.1. 
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Figure  3.6. Measured oxidation of (A) LCM and (B) TMP during Mn(VII) treatment in six 
utility source waters at varying applied KMnO4 dosages. Comparison of measurements and 
model predictions with Equation ( 3.5) for (C) LCM and (D) TMP. Conditions: [ATB]0 = 10 
µg/L, pH unadjusted (see Table  3.3), room temperature, trxn = 30 min (LCM) and 120 min 
(TMP). Uncertainties for measured values are triplicate-averaged 95% confidence levels, 
and uncertainties for predicted values are obtained by assuming ± 0.2 pH and ± 1 °C 
uncertainties. Different symbols in panels C and D refer to experiments conducted in 
different source waters. 
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Figure  3.7. Representative degradation of KMnO4 in utility source water and illustration of 
Mn(VII) exposure (CtMn(VII)) calculations. [KMnO4]0 = 6 mg/L, unfiltered source water. 
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Table  3.1. Summary of pKa values and species-specific rate constants for Mn(VII)-antibiotic 
reactions 
Antibiotic Structurea pKa,1 pKa,2
k21b 
(M-1 s-1) 
k22b 
(M-1 s-1) 
k23b 
(M-1 s-1) 
CPR 5.9[45] 8.2[45] 0.52(±0.05) 0.34(±0.08) 1.2(±0.1) 
LCM 7.8[46] --- 0.5(±0.1) 43(±6) --- 
TMP 3.2[26] 7.1[26] --- 2.6(±0.3) 0.17(±0.05)
a Structures shown for neutral species. Arrows showing sites of protonation for antibiotics and numbers indicate order of 
deprotonation. Proposed reactive groups are highlighted with dashed circles. Numbers on TMP structure indicate pyrimidine ring 
positions referred to in the discussion.  
b Rate constants at 25 oC. Uncertainties represent 1 σ from model fitting.  
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Table  3.2. Measured pseudo-first-order rate constants for antibiotic oxidation by Mn(VII) 
 pH 
T 
(ºC) 
[Mn(VII)]0 
(µM) 
[ATB]0 
(µM) 
[Phosphate] 
(mM) 
kobsa 
(10-3 s-1) 
CPR 7 25 200 10 25 0.12(±0.01) 
 7 25 300 10 25 0.15(±0.01) 
 7 25 400 10 25 0.24(±0.01) 
 7 25 500 10 25 0.32(±0.01) 
 7 25 600 10 25 0.37(±0.01) 
 5 25 500 10 25 0.30(±0.01) 
 5 25 500 10 25 0.22(±0.01) 
 5 25 500 10 25 0.24(±0.01) 
 6 25 500 10 25 0.31(±0.01) 
 7 25 500 10 25 0.35(±0.01) 
 7 25 500 10 25 0.26(±0.01) 
 8 25 500 10 25 0.39(±0.01) 
 9 25 500 10 25 0.58(±0.02) 
 9 25 500 10 25 0.44(±0.02) 
 9 25 500 10 25 0.47(±0.02) 
 7 9 500 10 25 0.097(±0.006) 
 7 20 500 10 25 0.26(±0.01) 
 7 30 500 10 25 0.52(±0.01) 
 7 35 500 10 25 0.68(±0.02) 
 7 25 500 10 5 0.37(±0.02) 
 5 25 500 10 25 0.32(±0.01) 
ENR 5 25 500 10 25 0.32(±0.01) 
 9 25 500 10 25 0.43(±0.01) 
FLU 5 25 500 10 25 0.008(±0.01) 
 9 25 500 10 25 0.01(±0.002) 
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Table  3.2. (cont.) 
 pH 
T 
(ºC) 
[Mn(VII)]0 
(µM) 
[ATB]0 
(µM) 
[Phosphate] 
(mM) 
kobsa 
(10-3 s-1) 
LCM 7 25 300 20 25 1.0(±0.1) 
 7 25 500 20 25 2.0(±0.1) 
 7 25 800 20 25 2.7(±0.1) 
 7 25 1000 20 25 3.7(±0.2) 
 5 25 500 20 25 0.31(±0.02) 
 6 25 500 20 25 0.55(±0.05) 
 7 25 500 20 25 2.3(±0.1) 
 8 25 500 20 25 13(±1) 
 9 25 500 20 25 24(±1) 
 7 7 500 20 25 0.53(±0.01) 
 7 17 500 20 25 1.3(±0.1) 
 7 30 500 20 25 5.1(±0.1) 
 7 35 500 20 25 7.2(±0.2) 
TMP 7 25 300 10 25 0.46(±0.01) 
 7 25 500 10 25 0.75(±0.01) 
 7 25 700 10 25 1.16(±0.02) 
 7 25 900 10 25 1.50(±0.01) 
 7 25 1000 10 25 1.58(±0.01) 
 5 25 500 10 25 1.52(±0.01) 
 6 25 500 10 25 1.35(±0.01) 
 7 25 500 10 25 0.70(±0.01) 
 8 25 500 10 25 0.24(±0.01) 
 9 25 500 10 25 0.12(±0.01) 
 5 25 500 10 25 1.55(±0.01) 
 6 25 500 10 25 1.21(±0.01) 
 7 9 500 10 25 0.19(±0.01) 
 7 17 500 10 25 0.34(±0.02) 
 7 30 500 10 25 0.97(±0.01) 
 7 35 500 10 25 1.11(±0.05) 
TMT 7 25 500 10 25 0.002(±0.001) 
DAP 7 25 500 10 25 0.26(±0.03) 
a Uncertainties represent 1 σ derived from linear regression. 
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Table  3.3. Utility source water characteristics 
Utility 1 2 3 4 5 6 
Source Water Type Reservoir Reservoir River River River Reservoir
pH 8.34 8.05 8.01 7.13 7.44 7.83 
Ammonia (mg/L as N) 0.3 0.3 0.7 0.4 0.6 0.2 
Alkalinity (mg/L as CaCO3) 198 144 166 92 70 100 
TOC (mg/L) 4 4.3 N/Da N/Da 1.3 N/Da 
TSS (mg/L) 29 5.3 17 1.2 20 < 1 
TDS (mg/L) 533 174 663 556 177 617 
Chloride (mg/L) 18.5 36 28.3 295 17.2 88.1 
Nitrate (mg/L) 21.3 12 12.8 14.2 6.2 8.0 
Sulfate (mg/L) 19.4 13 90.5 24.6 46.3 238 
a Below detection limit. 
 
 
Table  3.4. Permanganate decay in utility source waters 
Utility 1 t (min) 1 10 30 60 91 120 
 [KMnO4] (mg/L) 5.3 4.8 4.7 4.1 3.9 3.8 
Utility 2 t (min) 1 22 44 60 90 120 
 [KMnO4] (mg/L) 5.6 4.8 4.2 3.9 3.7 3.5 
Utility 3 t (min) 1 12 30 63 91 120 
 [KMnO4] (mg/L) 5.6 5.1 4.6 4.6 4.2 4.1 
Utility 4 t (min) 1 11 27 61 93 120 
 [KMnO4] (mg/L) 5.7 5.2 4.7 4.3 4.3 4.3 
Utility 5 t (min) 1.3 15.5 31 60 90.5 120 
 [KMnO4] (mg/L) 6 5.3 4.9 4.6 4.3 3.9 
Utility 6a t (min) 1 14 29 59 89 120 
 [KMnO4] (mg/L) 6.2 5.8 5.7 5.6 5.6 5.4 
a Source water samples for Utility 6 collected following application of chlorine at intake pumps, which reduced KMnO4 demand. 
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CHAPTER 4  
OXIDATION OF ANTIBIOTICS DURING WATER TREATMENT WITH 
POTASSIUM PERMANGANATE: REACTION PATHWAYS AND 
DEACTIVATION1 
4.1 Abstract 
Recent work demonstrates that three widely administered antibiotics (ciprofloxacin, 
lincomycin, and trimethoprim) are oxidized by potassium permanganate [KMnO4; Mn(VII)] under 
conditions relevant to water treatment operations. However, tests show that little to no 
mineralization occurs during reactions with Mn(VII), so studies were undertaken to characterize 
the reaction products and pathways and to assess the effects of Mn(VII)-mediated transformations 
on the antibacterial activity of solutions. Several oxidation products were identified for each 
antibiotic by liquid chromatography-tandem mass spectrometry (LC-MS/MS). For ciprofloxacin, 
twelve products were identified, consistent with oxidation of the tertiary aromatic and secondary 
aliphatic amine groups on the piperazine ring and the cyclopropyl group. For lincomycin, seven 
products were identified that indicate structural changes to the pyrrolidine ring and thioether group. 
For trimethoprim, seven products were identified, consistent with Mn(VII) reaction at C=C double 
bonds on the pyrimidine ring and the bridging methylene group. Oxidation pathways are proposed 
based on the identified products. Bacterial growth inhibition bioassays (E. coli DH5α) show that 
the mixture of products resulting from Mn(VII) reactions with the antibiotics collectively retain 
negligible antibacterial potency in comparison to the parent antibiotics. These results suggest that 
permanganate can be an effective reagent for eliminating the pharmaceutical activity of selected 
micropollutants during drinking water treatment. 
4.2 Introduction 
The ubiquitous occurrence of antibiotics in aquatic environments [1-4] has raised numerous 
concerns, including possible adverse effects on aquatic ecology [5, 6] and human health [7], but the 
                                                     
1  A modified version of Chapter 4 was published in Environmental Science & Technology, 2011, 
45, 3635-3642. (L. Hu lead author with co-authors A. M. Stemig, K. H. Wammer, and T. J. 
Strathmann).  
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greatest concern is the potential for increased antibiotic resistance among microbial populations 
continuously exposed to low levels of antibiotics [8, 9]. A growing body of research indicates that 
conventional water and wastewater treatment practices are inadequate for removing some 
antibiotic micropollutants and their associated antibacterial activity [10-12]. Thus, extensive efforts 
are underway to characterize the fate of antibiotics during water treatment processes [10, 13, 14] and 
to develop new treatment processes to more effectively treat contaminated water sources [15-18]. 
Past studies report on oxidative treatment of antibiotics, including reactions with chlorine 
[19-22], chlorine dioxide [16, 18], ozone [23-25], ferrate [26], and UV-TiO2 photocatalysis [27-30]. However, 
there is limited knowledge on the treatment of antibiotics with permanganate, [MnO4-; Mn(VII)], 
an oxidizing agent commonly used to oxidatively precipitate and promote adsorption of reduced 
metals (Mn, As, and Fe), control biofouling, and address taste and odor problems [31]. Mn(VII) 
oxidizes a wide range of organic pollutants [32-34], and a recent contribution [35] by the authors 
shows that three widely administered antibiotics (ciprofloxacin, lincomycin, and trimethoprim) are 
oxidized by Mn(VII) under conditions relevant to water treatment operations. Reaction kinetics 
can be described by considering parallel reactions between MnO4- and different acid-base species 
of the target antibiotics, and treatment efficiency in utility source waters can be predicted by 
considering the pH and temperature dependence of reaction kinetics plus the matrix oxidant 
demand [35]. 
Mn(VII) is a selective oxidant that targets electron-rich functional groups [32, 36], and 
Mn(VII) reactions with organic compounds typically generate a series of incomplete oxidation 
products and yield little mineralization [33]. Thus, characterizing the reaction products and 
elucidating the controlling reaction mechanisms is important for identifying the Mn(VII)-reactive 
moieties in the target contaminants and predicting Mn(VII) reactivity with related compounds that 
possess the same functional groups. In addition, identifying the structures of reaction products 
generated from pharmaceutically active compounds can be useful for assessing whether or not 
Mn(VII) reactions transform structural features critical to the pharmaceutical modes of action [15, 37, 
38]. Analysis of reaction products can be coupled with bioassays to link chemical treatment 
endpoints with biological effects [38-40]. Lee and coworkers [38] demonstrated that reactions 
between several oxidants and the steroidal hormone 17α-ethinylestradiol eliminate the estrogenic 
activity of solutions and attributed the reductions in estrogenicity to formation of initial reaction 
products that elicit substantially reduced estrogenic responses in the in vitro bioassays. Dodd and 
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coworkers [15] found that reactions of O3 and ⋅OH with most classes of antibiotics lead to 
stoichiometric deactivation (i.e., one mole-equivalent of potency is eliminated for each mole of 
parent antibiotic degraded), indicating that reaction products exhibit significantly reduced 
potencies. In contrast, O3 and ⋅OH reactions with the β-lactams penicillin G and cephalexin yield 
some products that retain significant antibacterial potency, identified as the stereoisomeric 
(R)-sulfoxides of the parent antibiotics [41]. 
This contribution examines the products, pathways, and deactivation of three antibiotics 
(ciprofloxacin, lincomycin, and trimethoprim) during reactions with Mn(VII); this follows a 
previous report describing the kinetics of these reactions [35]. For each antibiotic, several reaction 
products are identified based on information collected with liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). This information is then used to elucidate the pathways for reactions 
with Mn(VII). Finally, bacterial growth inhibition bioassays are employed to quantify the effects 
of Mn(VII) treatment on the antibacterial potency of solutions. The target antibiotics are among 
the most frequently detected in wastewater effluents [10-12]. Ciprofloxacin (CPR) is a 
fluoroquinolone antibiotic that is active against both gram-positive and gram-negative bacteria. 
CPR acts by inhibiting microbial DNA replication and repair by targeting two enzymes, DNA 
topoisomerase II (DNA gyrase) and DNA topoisomerase IV [42]. Lincomycin (LCM) is a 
lincosamide antibiotic that acts by blocking protein synthesis when binding to the 23S rRNA 
portion of the 50S subunit of bacterial ribosomes and causing premature dissociation of the 
peptidyl-tRNA from the ribosome [43]. Trimethoprim (TMP) is a dihydrofolate reductase (DHFR) 
inhibitor that prevents DNA replication by competing with dihydrofolate for binding to DHFR [37]. 
4.3 Materials and Methods 
4.3.1 Reagents and Analytical 
Unless otherwise indicated, all chemicals were of high purity and were used as received 
from Sigma-Aldrich-Fluka. Tryptone, yeast extract, and agar were purchased from Becton, 
Dickenson, and Company (Sparks, MD). Iso-Sensitest bacterial growth medium was purchased 
from Oxoid (Basingstoke, Hampshire, England). Details of analytical methods for measuring 
parent antibiotic concentrations, mass spectra of reaction products, dissolved organic carbon 
(DOC), and optical density of bacterial incubations are provided in Section  4.5.1.1. 
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4.3.2 Reaction Products 
To identify reaction products resulting from Mn(VII) reactions with each target antibiotic, 
a series of 20 mL ammonium acetate-buffered (pH 7) antibiotic solutions were treated with 
varying doses of Mn(VII). Ammonium acetate was used instead of phosphate buffer, used in 
earlier kinetics experiments [35], to aid ionization and eliminate the matrix effect of phosphate in 
the mass spectrometer. Elevated initial antibiotic concentrations (160 µM for CPR, 400 µM for 
LCM, and 200 µM for TMP) and Mn(VII) concentrations (100−800 µM) were also used to 
facilitate detection. Sufficient time was allowed for oxidation reactions to reach completion. Tests 
demonstrated negligible adsorption of the parent antibiotics to MnO2(s), the reduction product of 
Mn(VII). Samples were then filtered before analyzing by liquid chromatography-electrospray 
ionization-tandem mass spectrometry (LC-ESI-MS/MS; details provided in Section  4.5.1.1). A 
similar series of Mn(VII)-reacted antibiotic samples were also prepared and analyzed for residual 
DOC. 
4.3.3 Antibacterial Activity Bioassays 
Quantitative bioassays were adapted from procedures described previously [39] to compare 
the bacterial growth inhibition potential of solutions containing the parent antibiotics with 
Mn(VII)-reacted solutions. For each target antibiotic, a series of solutions (pH 7) were dosed with 
varying concentrations of Mn(VII) and allowed sufficient time for reactions to reach completion. 
Growth of Escherichia coli reference strain DH5α was then measured in untreated and 
Mn(VII)-treated antibiotic solutions and compared against antibiotic-free blanks to quantify the 
relative potency of solutions. Bacterial growth after 6 hours was quantified by measuring the 
change in optical density at λ = 600 nm (∆OD600). Details of the sample preparation and bioassay 
procedures are provided in Section  4.5.1.2. 
4.4 Results and Discussion 
An earlier contribution by the authors established that CPR, LCM, and TMP are readily 
degraded upon reaction with Mn(VII) [35]. Although oxidation of the antibiotics is presumed, DOC 
measurements after treatment with different dosages of Mn(VII) show that little or no 
mineralization of the organic compounds occurs during the reactions (Figure  4.1). Instead, 
reactions lead to incomplete oxidation, and LC-MS/MS analysis reveals a variety of organic 
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products for each antibiotic (Table  4.1−Table  4.3 and detailed discussion on procedures for 
product identification provided in Section  4.5.2). The following sections summarize the products 
identified and the proposed Mn(VII) reaction pathways for CPR, LCM and TMP. 
4.4.1 Mn(VII)-Ciprofloxacin Reactions 
Twelve products from Mn(VII)-CPR reactions were identified and their proposed 
structures are shown in Table  4.1 (products numbered sequentially based on molecular weight). 
The proposed structures are consistent with the expected importance of two principal Mn(VII) 
reaction sites, the tertiary aromatic amine and the secondary aliphatic amine groups on the 
piperazine ring substituent [35]. In addition, there are two products (III and VI) reflecting structural 
changes to the cyclopropyl group. However, the core fluoroquinolone structure remains intact in 
all the products identified, which is consistent with kinetics data for flumequine (a structurally 
related fluoroquinolone lacking the piperazine ring and cyclopropyl group substituents) showing 
little reactivity with Mn(VII) [35]. Structural changes to the piperazine ring include dealkylation (I 
and IV) and formation of alcohols (XI and XII) and amides (II, V, VII, VIII, IX, and X). Oxidation 
of the cyclopropyl group leads to ring cleavage and formation of acetyl (III) and allyl aldehyde (VI) 
moieties. Several of the observed products (I, II, IV, V, VII, and X) have also been reported for 
CPR reactions with other oxidants, including O3 (I and IV) [25], ClO2 (I, IV, and X) [18], HOCl (I and 
IV) [22], MnO2(s) (I, IV, V, and X) [44], alkaline permanganate (pH>12) (I and IV) [45], photolysis (I, 
IV, and VII) [46] and photocatalysis (I, II, IV, and X) [47]. 
CPR reaction with Mn(VII) is proposed to proceed by several pathways illustrated in 
Figure  4.2, based upon both the identified products and literature reports of Mn(VII) reactions 
with amines and olefin groups. Structures identified by LC-MS/MS are indicated by Roman 
numerals and unidentified intermediates are indicated by italicized letters. The proposed reaction 
mechanisms are consistent with conclusions drawn from kinetics experiments that the tertiary 
aromatic amine in the piperazine ring is the primary reactive site [35]. According to Rawalay et al. 
[48], tertiary amines are oxidized by neutral permanganate to enamines (RCH=CRNR2) and/or to 
Schiff bases (RCH=NR). Both enamines and Schiff bases can then undergo further hydrolysis to 
form aldehydes and degraded amines, which are subject to further oxidation. C-C bonds in 
cyclopropyl groups have been reported to possess partial characteristics of highly 
Mn(VII)-reactive olefin bonds [33, 49], including π character and sp2 hybridization, and thus are 
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expected to be susceptible to Mn(VII) oxidation [50]. 
The initiation step of Mn(VII)-CPR reactions is proposed to be the oxidative formation of 
an enamine (intermediate A: Int. A) from the aromatic amine group, as reported by Rawalay and 
coworkers [48]. The enamine intermediate can then be transformed by multiple parallel reactions to 
produce a series of products through either hydrolysis or further Mn(VII) oxidation of the newly 
formed C=C double bonds [33, 49]. The partially dealkylated product IV is formed when Int. A 
undergoes two consecutive hydrolysis steps. The ring-opened amide product X is produced by 
oxidation of the enamine C=C double bond in Int. A. The enamine can also be hydrolyzed to 
mono-hydroxylated intermediates (Int. B and Int. C), further oxidation of which yields the 
carbonyl products VIII and VII, respectively. Hydrolysis of Int. B yields a ring-opened geminal 
diol intermediate (structure not shown), which quickly converts to Int. E. Hydrolysis of the 
aromatic amide group in X forms product V. Similar to the initiation step with CPR, the amine 
groups in Ints. B, C, and E and product V can be oxidized to their respective enamines (Ints. D, F, 
G, and H), and subsequent oxidation of the associated olefin groups yield XIIa/XI, XIIb, Int. I, and 
II, respectively. Product IX is formed by further oxidation of the hydroxyl group in XI to a ketone 
group. The cyclopropyl group in Int. I is oxidized to yield aldehyde (III) and carboxylic acid (VI) 
products; the same products can also be obtained through cyclopropyl group oxidation followed by 
Mn(VII) reaction at the piperazine ring. Hydrolysis of Int. H produces I with the piperazine ring 
fully dealkylated. Collectively, the identified reaction products indicate that Mn(VII) reactions 
alter the piperazine and cyclopropyl substituents, but leave the core fluoroquinolone group intact, 
so it is unclear how oxidation by Mn(VII) will affect the antibacterial activity of CPR solutions. 
4.4.2 Mn(VII)-Lincomycin Reactions 
Seven products were detected for Mn(VII)-LCM reactions, and their proposed structures 
are summarized in Table  4.2. Reactions with Mn(VII) transform the aliphatic amine group on the 
pyrrolidine ring and the methyl thioether (-SCH3) moiety, which are the same reactive sites 
proposed for O3 [51]. Oxidation of the pyrrolidine ring amine group leads to dealkylation (I) and 
formation of iminiums (IIa and IIb), alcohols (Va and Vb), amides (IV and VII), and cyclic ester 
(III) products. Oxidation of the thioether group yields the corresponding sulfone (R1R2SO2, VI and 
VII) products. Pospisil and coworkers [52] reported the formation of sulfone product VI upon 
oxidation of LCM with H2O2 and biotransformation of LCM using cell free extracts of two 
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Streptomyces bacteria. 
It is interesting to note that the pyranose ring remains intact in the LCM-Mn(VII) oxidation 
products, in contrast to a recent study which reports cleavage of the ring in clindamycin (a 
structurally related lincosamide of LCM) by MnO2(s) [17]. The difference in observations may be 
due to different mechanisms by which the Mn-based oxidants react with organic compounds or to 
the fact that the pyranose ring might be destabilized by surface complex formation on MnO2(s) 
prior to oxidation. Alternatively, the LC-MS/MS procedure used in this study may have poor 
sensitivity for detecting any ring-cleavage products of LCM that might have formed during 
reactions with Mn(VII). 
Figure  4.3 shows the proposed pathways for LCM oxidation by Mn(VII). Mn(VII) 
reaction with the pyrrolidine ring amine group is initiated by formation of iminiums (Int. A, 
products IIa and IIb). Hydrolysis of the iminiums, Int. A, products IIa and IIb, yields demethylation 
product I, hydroxylated products Va and Vb, respectively. Va is then oxidized by Mn(VII) to form 
the amide product IV. Hydrolysis of I yields a ring-cleavage intermediate B, which is further 
oxidized to form an imine intermediate C. Oxidation of Int. C yields Int. D, with a carboxylic acid 
and a hydroxyl groups formed at each end of the opened pyrrolidine ring. Intramolecular 
esterification of Int. D then yields a stable five-member cyclic ester III. Sulfone products, VI and 
VII, form as a result of direct oxidation of the thioether group on LCM and IV [53], respectively. 
Although sulfoxide products of LCM were not observed here, they are likely intermediate 
precursors for oxidation of thioether to sulfone products [54]. Like CPR, LCM-Mn(VII) reactions 
yield products with structures similar to the parent compound, so the effects on antibacterial 
activity are also unclear. 
4.4.3 Mn(VII)-Trimethoprim Reactions 
For TMP-Mn(VII) reactions, seven products were detected by LC-MS/MS (Table  4.3). 
The products show that Mn(VII) reacts with the pyrimidine ring and the methylene group that 
bridges to the trimethoxybenzene ring. Reaction at the pyrimidine group is consistent with results 
of kinetics studies conducted with analogues of the two ring systems in the TMP structure [35], 
where Mn(VII) oxidation of 1,4-diaminopyrimidine is much faster than oxidation of 
3,4,5-trimethoxytoluene. Oxidation of the C=C double bonds (C4=C5, or C5=C6) on the 
pyrimidine ring yields alcohol, aldehyde, ketone and carboxylic acid products (I, II, V, VI and VII), 
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consistent with previous reports of olefin group oxidation [33, 49]. Mn(VII) reaction with the 
bridging methylene group produces a hydroxylated TMP (IV) and a ketone (III). This bridging 
methylene group is also reported as the active site for TMP photolysis [55]. 
Figure  4.4 shows the proposed mechanisms for Mn(VII)-TMP reactions. Reaction is 
initiated by 3+2 cyclic addition of Mn(VII) to the C4=C5 or C5=C6 double bond on the pyrimidine 
ring. Freeman and co-workers [56] report a similar mechanism for Mn(VII) oxidation of uracil 
(2,4-dihydroxylpyrimidine), which is structurally similar to the 2,4-diaminopyrimidine moiety in 
TMP. This mechanism is also consistent with well documented Mn(VII) reactions with olefin 
groups [33, 49], indicating that the C=C bonds in the diaminopyrimidine ring have olefinic 
characteristics. Oxidation of the C=C double bonds yields hydroxyl, aldehyde, ketone, and 
carboxylic acid products. For example, oxidation at the C5=C6 bond first produces dihydroxylated 
TMP (VII), with further oxidation cleaving the pyrimidine ring and yielding Vb. Vb then 
undergoes hydrolysis to yield II. Oxidation on the C4=C5 bond yields Va, and further hydrolysis of 
the amide group in Va yields the carboxylic products VI or I. Alternatively, reactions can be 
initiated by a hydride abstraction from the bridging methylene group to form a carbocation 
intermediate, which yields IV upon hydroxylation. Further oxidation of IV yields a ketone product 
III. Mn(VII) reaction at the bridging methylene group is attributed to activation by the two 
attached rings. Hydride abstraction by Mn(VII) is documented [57] and carbocation intermediates 
of pyrimidines have been previously reported [58]. 
For TMP, the integrity of the pyrimidine ring is reported to be essential for antibacterial 
activity [37]. Thus, since several of the observed products include modifications to the pyrimidine 
ring, including ring opening, at least partial deactivation of TMP can be anticipated during Mn(VII) 
treatment. 
4.4.4 Antibacterial Activity 
A variety of organic products are identified for Mn(VII)-antibiotic reactions, but the 
potency of these reaction products relative to the parent antibiotics remains unclear. Quantitative 
bioassays were conducted to address the effects of Mn(VII) treatment on the potency of antibiotic 
solutions. Figure  4.5 shows the measured antibacterial concentration-growth inhibition curves for 
untreated and Mn(VII)-treated antibiotic solutions. Bacterial growth in untreated samples is 
plotted as a function of antibiotic concentration over a serial dilution series, whereas growth in 
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Mn(VII)-treated samples is plotted as a function of the residual undegraded antibiotic 
concentration measured following treatment with different Mn(VII) dosages. Growth of E. coli 
strain DH5α in solutions exposed to antibiotics and reaction products is indicated by ∆OD600, the 
change in optical density of the solution at 600 nm after a 6-h incubation. Large ∆OD600 values 
correspond to strong growth and minimal growth inhibition from analytes in solution. Comparing 
the measured growth of E. coli DH5α in the presence of untreated antibiotics (closed triangles) 
versus in the presence of Mn(VII)-treated antibiotics (open triangles), few differences can be 
found in terms of bacterial growth inhibition, indicating that antibacterial potency in 
Mn(VII)-treated samples can be attributed mostly to the residual parent compound remaining after 
Mn(VII) treatment. If products had exhibited significant potency, ∆OD600 curve would have 
shifted to the left and downward. Change of bacterial growth inhibition with antibiotic 
concentration can be quantified by fitting measured data with a Boltzmann curve [39], 
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where x is the log of antibiotic concentration, y is the 6-h ∆OD600, A1 is the value of y 
corresponding to no growth inhibition, A2 is the value of y corresponding to maximum growth 
inhibition, dx is the slope, and x0 is the midpoint of the curve, corresponding to the log of the 
median effective antibiotic concentration (EC50). Model fits for both untreated and 
Mn(VII)-treated antibiotic solutions are shown in Figure  4.5. Fit-derived log(EC50) values for 
Mn(VII)-treated and untreated solutions are not significantly different at the 95% confidence level, 
confirming that bacterial growth inhibition in the Mn(VII)-reacted samples can be attributed 
mainly to the residual parent compound concentration remaining after Mn(VII) treatment, and the 
Mn(VII) reaction product mixture collectively contributes negligible antibacterial activity to the 
samples in comparison to the parent antibiotic. This does not preclude some minor oxidation 
products from possessing similar or even greater activities than their parent antibiotics, but their 
concentrations are too low to detect their effects in the bioassay. These findings are notable 
because they demonstrate that incomplete oxidation of antibiotics during Mn(VII) water treatment 
processes will likely be sufficient to eliminate the antibacterial activity of impacted source waters. 
Reductions in antibiotic potency upon Mn(VII) treatment can be interpreted in light of the 
identified reaction products. For CPR, although the core fluoroquinolone structure remains intact 
following reaction with Mn(VII), oxidation of the piperazine and cyclopropyl substituents can also 
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be expected to reduce potency [40, 59]. Quinolones having small or linear substituents at the C-7 
position (see Figure  4.2) have been reported to exhibit lower potency than analogues substituted 
with heterocyclic rings containing peripheral basic nitrogens like CPR [59]. In addition, 
cyclopropyl group substitution at the N-1 position is reported to be optimal for fluoroquinolone 
antibacterial activity [59]. Thus, oxidation of the piperazine and cyclopropyl rings forms a series of 
products that are expected to exhibit reduced potency. 
None of the functional groups in LCM believed to be responsible for binding to 23S rRNA 
of bacteria (carbonyl and ring-bound hydroxyl groups) are oxidized by Mn(VII). However, 
oxidation of the thioether group leads to LCM-sulfone [23, 60], which possess significantly lower 
antibacterial potency than the parent structure [60], possibly due to interruption of intermolecular 
hydrogen bonding patterns at adjacent hydroxyl and methyl groups. 
TMP is a dihydrofolate reductase inhibitor, and the diaminopyrimidine moiety, which 
resembles part of the structure of 7,8-dihydrofolic acid, is critical to the compound’s antibacterial 
activity [37]. Thus, elimination of antibacterial potency during Mn(VII) treatment is consistent with 
the observed cleavage of the pyrimidine ring during Mn(VII)-TMP reactions. 
4.5 Supporting Information 
4.5.1 Analytical and Bioassay Procedures 
4.5.1.1 Analytical 
Concentrations of the parent antibiotics were determined using a Shimadzu high 
performance liquid chromatograph (HPLC; VP series) equipped with photodiode array detection 
(PDA). The detailed HPLC methods are the same as those reported in [35]. Dissolved organic 
carbon (DOC) of Mn(VII)-reacted solutions was analyzed using a Shimadzu TOC analyzer 
(TOC-VCPN, Kyoto, Japan). 
Organic reaction products were identified by liquid chromatography coupled with tandem 
mass spectrometry (LC-MS/MS). Analysis was performed on an Agilent 1200 LC/MSD Trap 
XCT Ultra instrument with a Zorbax Eclipse XDB-C18 column (2.1×50 mm, 3.5 µM particle size). 
Different gradient methods were used for separation of products for the three target antibiotics. 
The mobile phases and gradient methods (0.2 mL/min) are summarized in Table  4.4. For MS 
analyses, ionization was achieved through positive-mode electrospray (ESI+) over a 
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mass-to-charge (m/z) range of 50–500. An ion trap was used to isolate and fragment target ions, 
and the auto-MS(2) mode was used with a fragmentation voltage of 1.0 V. A conversion 
dynode/electron multiplier system was used to detect and record the MS1 and MS2 spectra. For 
ciprofloxacin, product analysis was also performed on a Micromass Q-TOF ultima to obtain more 
fragments in MS2 spectra and aid product identification. The same column and mobile phase 
gradient were used as described above. The collision induced dissociation (CID) energy applied 
was 35 V. 
4.5.1.2 Antibacterial Activity Bioassays 
Quantitative bioassays were used to determine the effects of Mn(VII) treatment on the 
bacterial growth inhibition potential of antibiotic solutions. For CPR and TMP, Mn(VII)-reacted 
solutions were prepared by dosing a series of 20-mL phosphate-buffered solutions (pH 7) with 
varying concentrations of Mn(VII) and allowing sufficient time for the reactions to reach 
completion. After reaction, excess hydroxylamine was added to reactors to reduce residual Mn(VII) 
and MnO2(s) to soluble Mn2+. The quenched solutions were then subjected to solid phase extraction 
(SPE) to remove inorganic salts (e.g., Mn2+, phosphate, hydroxylamine) before using in bioassays. 
For LCM, reaction samples were prepared using a different procedure because the antibacterial 
activity bioassay working concentration range was too high to permit use of SPE without 
overloading the resin cartridges. Instead, Mn(VII)-reacted LCM samples were prepared by dosing 
varying concentrations of Mn(VII) into LCM solutions and directly collecting filtered supernatant 
after allowing reactions to reach completion. To minimize potential artifacts from inorganic 
solution constituents on LCM bioassay results, reactions were conducted in unbuffered solutions 
and varying amounts of KCl were added to samples to obtain a constant K+ concentration (to 
match the varying K+ associated with different doses of KMnO4). After reaction completion, 
suspensions were centrifuged and the supernatant was filtered and pH adjusted to 7 for use in 
bioassays (pH drifted from 7 to 9-10 during reactions). 
For Mn(VII)-reacted CPR and TMP samples, SPE was performed using Oasis HLB 
cartridges (Waters, 500 mg, LP). First, SPE cartridges were sequentially conditioned with 5 mL 
methanol and 5 mL H2O. Antibiotic solutions were then directly loaded to the preconditioned 
cartridges mounted on a Visiprep vacuum manifold (Sigma-Aldrich) and dropwise flow rates were 
maintained for the extraction process. After extraction, the cartridges were washed with 5 mL H2O 
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to remove residual inorganic impurities. Five mL of acetone was then used to elute the sorbed 
antibiotics and organic products. The SPE eluates were then divided into two portions and dried 
under a gentle stream of air. One portion was reconstituted in phosphate buffer and analyzed for 
residual antibiotic concentration by HPLC-PDA. The other portion was reconstituted in deionized 
water and used to quantify antibacterial potency. SPE recoveries of the parent antibiotics were 
determined by comparing antibiotic concentrations in the eluates with the concentration in the 
corresponding SPE feed solutions (>76% recovery in all samples). The SPE recoveries of all 
individual oxidation products were not quantified, but HPLC data for several of the products show 
similar recoveries as the parent antibiotics. In addition, we expect similar SPE recoveries for many 
of products because the structures are similar to the parent antibiotics and the 
hydrophilic-lipophilic balance (HLB) SPE cartridges are optimized for extraction of both polar 
and non-polar compounds. 
Antibacterial activity bioassays were adapted from methods described previously [39]. 
Growth of Escherichia coli (E. coli) reference strain DH5α was measured in triplicate in untreated 
and Mn(VII)-treated solutions of each target antibiotic and compared against antibiotic-free blanks 
to quantify the relative potency of solutions. E. coli were maintained on sterile Luria-Bertani (LB) 
solid medium. Tests show that the DH5α strain responds well to all three antibiotics. Cells were 
grown overnight on Iso-Sensitest broth (ISB), and media was autoclaved to sterilize. The working 
concentration range of each target antibiotic was first determined by measuring E. coli growth in 
solutions containing varying antibiotic concentrations. One mL antibiotic solutions of varying 
concentration were mixed with 100 µL of E. coli and 9 mL of ISB in a series of test tubes. Tubes 
were then incubated at 37°C and gently shaken. Bacterial growth after 6 hours was then quantified 
by measuring the change in optical density at λ = 600 nm (∆OD600 = 6 hour OD600 - initial OD600) 
using a Varian Cary 300 Bio UV-Visible Spectrophotometer. Large ∆OD600 values correspond to 
strong growth and minimal growth inhibition from analytes in solution. The relative ability of 
Mn(VII) reaction products to inhibit bacterial growth was then tested by the same method, using 1 
mL of SPE extracts (CPR and TMP) or solution filtrate (LCM) collected from reaction mixtures. 
4.5.2 Identification of Antibiotic Oxidation Products 
A large number of products are detected for Mn(VII) oxidation of the three antibiotics as 
summarized in Table  4.1−Table  4.3. Figure  4.6−Figure  4.8 show the relative distribution of 
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LC-MS peak areas for different Mn(VII) reaction products of each parent antibiotic, providing a 
rough qualitative measure of the distribution of reaction products. However, it should be noted that 
the peak areas are from the mass spectrometry peaks and do not quantitatively correlate their 
absolute concentration since reference standards of the individual analytes are not available. 
Although a large number of reaction products were detected for each antibiotic using LC-MS/MS, 
it is likely that additional products were also formed but not detected, either because of their low 
concentration or the low sensitivity of the method for these analytes (e.g., due to poor electrospray 
ionization). 
In general, structures of reaction products are proposed based on the mass of the 
pseudo-molecular ion (MH+) observed in MS, the MS/MS fragmentation pattern (mass spectra of 
the parent compounds and reaction products are provided in Table A.2−Table A.4 in Appendix A), 
and the chromatographic retention times (R.T.), along with previously reported information on 
common reactive sites in each antibiotic and general oxidation pathways for these reactive groups. 
The MS/MS fragmentation pathways of the parent antibiotics (Table  4.5−Table  4.7) are also 
proposed and serve as a basis for the elucidation of the structures of their products. 
4.5.2.1 Ciprofloxacin (CPR) 
Twelve products were detected by LC-MS/MS for CPR reactions with Mn(VII). The mass 
of MH+, MS/MS fragment ions, R.T., and the proposed structures for the 12 products are 
summarized in Table  4.1. 
The interpretation of the MS/MS spectra of CPR is shown in Table  4.5. The fragment ions 
showed loss of the carboxylic group, the cyclopropyl ring, the fluorine atom, and partial loss of the 
piperazine ring, with the core quinolone group remaining intact. The MS/MS fragmentation 
patterns of CPR and its products do not provide decisive information that can aid the elucidation of 
product structures. Therefore, proposed structures were primarily based on the observed molecular 
weights and expected reaction sites with Mn(VII). In addition, the “nitrogen rule” that a compound 
contains odd numbers of nitrogen atoms will have an odd molecular weight is also applied in 
determining the molecular formula of several compounds. As discussed in earlier work [35], there 
are three possible reactive sites in CPR: the aromatic tertiary amine group in the piperazine ring, 
the aliphatic secondary amine group in the piperazine ring and the cyclopropyl group. Therefore, 
proposed structures of products considered oxidative structural changes to these three sites. 
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Oxidation of amines by Mn(VII) was proposed to produce hydroxylated and acetylated products 
[48]. Proposed structures for products all conform with the observed MS/MS fragmentation patterns 
(Table  4.5). Several of the observed products (I, II, IV, V, VII, and X) were also detected with 
similar MS/MS fragmentation patterns in oxidation of CPR using other oxidation systems: O3 [25], 
HOCl [22], ClO2 [18], MnO2(s) [44], alkaline permanganate (pH>12) [45], photolysis [46], and 
photocatalysis [29], and same structures of these products were proposed. 
The HPLC retention times of the products were used to supplement identification of 
products and exclude implausible structures. Because the core fluoroquinolone group remains 
intact in all products, the relative HPLC retention times of the oxidation products are heavily 
influenced by the basicity of the piperazine ring, especially considering that the mobile phases 
used for LC-MS/MS analysis contains 0.1% formic acid. Products with strong basicity will likely 
have shorter retention times because they will be present as charged species in the eluent matrix. 
The aliphatic secondary amine in CPR is responsible for the basicity of CPR since arylamines, 
amides, and nitrogen in aromatic heterocyclic rings have much weaker basicity [61]. Therefore, 
products that exhibit relatively short retention times are expected to retain the aliphatic amine 
group, whereas structural changes to the aliphatic secondary amine group is expected in products 
that exhibit much longer retention times than CPR. As shown in Table  4.1, products IV and VII 
have relatively short retention times and the aliphatic amine group in their structures is retained. 
Specifically, product VII and VIII have the same molecular weight and similar MS/MS 
fragmentation pattern, but their HPLC retention times differ dramatically. The longer retention 
time of VIII is proposed to result from the conversion the aliphatic tertiary amine to a less basic 
amide group that remains deprotonated and uncharged in the eluent matrix. 
4.5.2.2 Lincomycin (LCM) 
Seven products from Mn(VII) oxidation of LCM are detected by LC-MS/MS (Table  4.2). 
In comparison to CPR, the MS/MS fragmentation patterns observed for LCM oxidation products 
provide more valuable information for elucidating structural changes in oxidation products. 
The MS/MS fragmentation pathway for LCM (m/z: 407) is proposed in Figure  4.7Table 
 4.6. The two characteristic fragmentation pathways used to identify structural changes in LCM 
oxidation products are: (a) the formation of an (MH-48) fragment ion (m/z: 359) from the loss of a 
methyl thioether [-SCH4 (48)] group, and (b) the formation of the pyrrolidine fragment ion (m/z: 
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126) that is directly cleaved from the parent molecular ion. These two fragment ions are also the 
two most abundant fragment ions in the MS/MS spectra. The structures of the products are then 
proposed based on the two characteristic fragmentation pathways of LCM in combination with 
their molecular weights and chromatographic retention times as shown in Table  4.2 and Table  4.6. 
For product I, II, III and IV, the presence of a most abundant (MH-48) fragment ion and the 
absence of the pyrrolidine fragment ion suggest the intactness of the thioether group and structural 
modifications to the pyrrolidine ring. Products I, II, and IV were proposed to be demethylation, 
dehydrogenation, and carbonylation products of LCM, respectively, based on their molecular 
weight differences from LCM. In place of the pyrrolidine fragment ion, the fragment ions with m/z 
values of 112, 124, and 140 also support the proposed structural changes to the pyrrolidine ring of 
products I, II, and IV, respectively (note: the m/z 140 fragment ion of product IV was not directly 
observed but was seen in the MS/MS spectra of fragment ion 373 from product IV). For product III, 
the odd molecular weight of its neutral molecule suggests an odd number of nitrogen atoms in the 
molecule and thus the loss of one nitrogen atom from LCM. A lactone structure in place of the 
pyrrolidine ring was proposed for product III based on its molecular weight difference with LCM. 
For product V, the most abundant fragment ion is an (MH-66) ion and the second most 
abundant ion is an (MH-48) ion. We propose product V to be a hydroxylated LCM with the 
hydroxyl group attached to either of the two alpha positions of the pyrroline amine. The (MH-66) 
fragment ion is thus from the loss of the thioether group and the hydroxyl group on the pyrrolidine 
ring. A minor pyrrolidine fragment ion is also seen, which is probably formed by the loss of 
hydroxyl group from the hydroxylated pyrrolidine ring. 
For product VI, the most abundant ion is an (MH-80) fragment ion and the second most 
abundant ion is the pyrrolidine fragment ion. Thus oxidation of the thioether group to a sulfone 
group is proposed. The most abundant fragment ion (MH-80) is then from the loss of the sulfone 
group [-SO2CH4 (80)]. A minor (MH-48) fragment ion is also seen, which is proposed to forme by 
the loss of a SO group from the sulfone group. 
For product VII, neither the (MH-48) fragment ion nor the pyrrolidine fragment ion is 
present and the most abundant fragment ion is an (MH-80) ion. Thus, structural changes are 
proposed to occur on both moieties. We propose product VII to be a LCM sulfone with the 
pyrrolidine amine group converted to an amide. Similar to product VI, the (MH-80) fragment ion 
is from the loss of the sulfone group [-SO2CH4 (80)]. Similar to product IV, the presence of a 
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fragment ion with an m/z of 140 is also supportive of the proposed structural change to the 
pyrrolidine ring. 
The HPLC retention times of oxidation products can also be used to check whether a 
proposed structure also agree with its chromatographic behavior. Products I, II, and VI all have 
retention times either close to or shorter than that of LCM, indicating the presence of the 
pyrrolidine amine. The short retention time of product II might be due to its iminium ion form. In 
contrast, products III, IV, V and VII all have much longer retention times than LCM, resulting from 
the conversion of the pyrrolidine aliphatic amine to a less basic amide group, loss of the aliphatic 
amine group entirely, or addition of a hydroxyl group adjacent to the amine group. 
4.5.2.3 Trimethoprim (TMP) 
Seven products from Mn(VII)-oxidation of TMP are detected by LC-MS/MS (Table  4.3). 
After examining the MS/MS spectra of all products and the proposed fragmentation pathway of 
TMP, a common fragment ion is observed for TMP and several of the products (I, V, VI, and VII), 
which possesses m/z of 181 and corresponds to the trimethoxytoluene cation. For product II, a 
fragment ion with m/z of 183 is present instead of m/z of 181, and this fragment ion is proposed to 
be a pseudo-molecular ion of trimethoxytoluene. Therefore, the presence of a fragment ion with 
m/z of 181 or 183 indicates the intactness of the trimethoxytoluene moiety, and no structural 
changes were proposed to the trimethoxytoluene moiety for products I, II, V, VI, and VII. 
According to Freeman and co-workers [56], the Mn(VII) oxidation site of uracil 
(2,4-dihydroxylpyrimidine, structure similar to the 2,4-diaminopyrimidine moiety in TMP) is the 
C4=C5 double bond. Oxidation of TMP is also expected to occur at this site as well as the C5=C6 
double bond (resonance structures exist for TMP, Figure  4.4). Thus, proposed structures for 
product I, II, V, VI, and VII include hydroxylated TMP and complicated amide, ketone, carboxylic 
acid-containing compounds resulting from cleavage of the pyrimidine ring upon oxidation of 
either the C4=C5 or C5=C6 double bonds. 
For product III and IV, the absence of the fragment ion with m/z of 181 indicates a 
structural modification to the trimethoxytoluene moiety. Because the methoxy groups and the 
benzene ring are relatively inert towards Mn(VII) oxidation, the site of structural modification is 
proposed to be on the methylene group that bridges between the aromatic and pyrimidine rings. 
This group has also been proposed as the site of photolytic attack in TMP [55]. Therefore, 
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corresponding to their pseudo-molecular ion molecular weights, a hydroxylated TMP is proposed 
for product IV, and a ketone form of TMP is proposed for product III. In addition, the fragment 
ions of product III correspond well with those of TMP in that the parent compound and almost all 
fragment ions differ by a mass of 14, indicating relatively small structural changes occur in 
product III, as demonstrated by the proposed structure. 
Finally, comparing the retention times between TMP and its products, we can see that only 
product III and VI have longer retention time than that of TMP, while the rest of the products have 
similar or shorter retention time. For product I, II, and V, the disruption of pyrimidine ring in TMP 
may increase hydrophilicity by destruction of the ring group, and addition of hydroxyl groups in 
IV and VII can also be expected to increase hydrophilicity. For product III and VI, the extended 
retention time may result from decreased basicity of N-1 in the pyrimidine ring upon formation of 
the electron-withdrawing carbonyl group adjacent to this site. 
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4.7 Figures and Tables 
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Figure  4.1. Measured dissolved organic carbon (DOC) concentration of the target 
antibiotics after treatment with different doses of Mn(VII). Reaction conditions: [ATB]0 = 
100 µM, varying [Mn(VII)], 25 mM phosphate buffer, pH 7, room temperature. 
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Figure  4.2. Proposed pathways for CPR reaction with Mn(VII).  
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Figure  4.3. Proposed pathways for LCM reaction with Mn(VII).  
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Figure  4.4. Proposed pathways for TMP reaction with Mn(VII).  
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Figure  4.5. Antibacterial concentration-growth inhibition curves for untreated and 
Mn(VII)-treated antibiotics: (A) ciprofloxacin; (B) lincomycin; (C) trimethoprim. 
Uncertainties represent 95% confidence levels. 
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Figure  4.6. Integrated LC-MS peak areas of products from CPR reactions with Mn(VII): 
[CPR]0 = 160 µM, pH 7 (25 mM ammonium acetate), 25 oC. 
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Figure  4.7. Integrated LC-MS peak areas of products from LCM reactions with Mn(VII): 
[LCM]0 = 400 µM, pH 7 (25 mM ammonium acetate), 25 oC. 
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Figure  4.8. Integrated LC-MS peak areas of products from TMP reactions with Mn(VII): 
[TMP]0 = 200 µM, pH 7 (25 mM ammonium acetate), 25 oC. 
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Table  4.1. Products of CPR-Mn(VII) reactions 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b  
(min) 
MS/MS  
(m/z) 
Molecular  
formulac 
Difference  
from CPR 
Proposed  
structure 
CPRd 332 3.2 
314e, 288, 
 268, 245f, 
 231, 205 
C17H18FN3O3 --- 
NN
HN
O
COOHF
 
Id 263 7.1 
245e, 217, 
 204f, 189, 
 177 
C13H11FN2O3 -(4C 7H N) 
NH2N
O
COOHF
 
IId 291 7.2 
273e, 245f, 
 217, 205 
C14H11FN2O4 -(3C 7H N) +O 
NN
H
H
O
COOHF
O
 
III 293 10.2 275e C13H9FN2O5 -(4C 9H N) +2O 
NN
H
O
COOHF
O
H O H  
IVd 306 2.1 
288e, 268f, 
 245, 227, 
 203 
C15H16FN3O3 -(2C 2H) 
NN
HNH2
O
COOHF
 
Vd 334 7.4 
316e, 245f, 
 230, 217 
C16H16FN3O4 -(C 2H) +O NNH
NH
O
COOHF
O
H
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Table  4.1. (cont.) 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b  
(min) 
MS/MS  
(m/z) 
Molecular  
formulac 
Difference  
from CPR 
Proposed  
structure 
VI 335 3.7 291e C15H11FN2O6 
-(2C 7H N ) 
+3O 
NN
H
O
COOHF
OH
O
O H  
VII 346 1.6 328f, 318e C17H16FN3O4 -2H +O 
NN
HN
O
COOHF
O  
VIII 346 9.7 328e C17H16FN3O4 -2H +O NN
HN
O
COOHF
O  
IXd 360 9.2 
 342e, 332, 
 324, 314, 
 302f 
C17H14FN3O5 -4H +2O NN
HN
O
COOHF
O
O  
X 362 5.1 344e, 318f C17H16FN3O5 -2H +2O NN
NH
O
COOHF
O
O
H H
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Table  4.1. (cont.) 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b  
(min) 
MS/MS  
(m/z) 
Molecular  
formulac 
Difference  
from CPR 
Proposed  
structure 
XId 362 5.7 
344e, 316, 
 273, 259f, 
 245 
C17H16FN3O5 -2H +2O 
 
NN
HN
O
COOHF
O
OH  
XII 380 6.9 
362e, 334f, 
 316 
C17H18FN3O6 +3O 
 
NN
HN
O
COOHF
OH
HO
OH
(a) 
or 
NN
HN
O
COOHF
HO
OH
OH (b) 
a The numbers indicate the mass of the protonated molecular ion, equal to the molecular weight of the analyte plus 1 (M.W. +1).  
b R.T. represents retention time of each product peak in the LC-MS/MS chromatogram.  
c Molecular formula of the neutral molecule.  
d MS/MS spectra of these products are obtained in the Q-TOF instrument.  
e Most abundant fragment ion.  
f Second most abundant fragment ion. 
 
 
 107 
Table  4.2. Products of LCM-Mn(VII) reactions 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b  
(min) 
MS/MS  
(m/z) 
Molecular  
formulac 
Difference  
from LCM 
Proposed  
structure 
LCM 407 2.7 
389, 359d, 
 341, 299, 
 172, 126e 
C18H34N2O6S  
O S
OH
OH
HO
HO
N
H
O
N
 
I 393 3.3 
375e, 345d, 
 327, 285, 
 264, 216, 
 170, 112 
C17H32N2O6S -C 2H 
O S
OH
OH
HO
HO
N
H
OH
N
 
IIf 405 1.9 
387, 357d, 
 297, 216, 
 198, 170, 
 124e 
C18H33N2O6S -H 
O S
OH
OH
HO
HO
N
H
O
N+
 (a) 
or 
O S
OH
OH
HO
HO
N
H
O
N
 (b) 
III 408 6.8 
390, 360d, 
 342e 
C17H29NO8S 
-(C N 5H ) 
+2O 
O S
OH
OH
HO
HO
N
H
O
O
O
 
IV 421 8.4 
403, 373d, 
 355e, 323 
C18H32N2O7S -2H +O 
O S
OH
OH
HO
HO
N
H
O
NO
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Table  4.2. (cont.) 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b  
(min) 
MS/MS  
(m/z) 
Molecular  
formulac 
Difference  
from LCM 
Proposed  
structure 
V 423 6.0 
405, 375e, 
 357d, 317, 
299, 281, 126
C18H34N2O7S +O 
 
O S
OH
OH
HO
HO
N
H
O
NHO
(a) 
O S
OH
OH
HO
HO
N
H
O
N
OH
(b) 
VI 439 2.0 
421, 391, 
 359d, 341, 
 126e 
C18H34N2O8S +2O 
 
O S
OH
OH
HO
HO
N
H
O
N
O
O
 
VII 453 4.9 
435, 373d, 
 355e, 140 
C18H32N2O9S -2H +3O 
 
O S
OH
OH
HO
HO
N
H
O
N
O
O
O
 
a The numbers indicate the mass of the protonated molecular ion, equal to the molecular weight of the analyte plus 1 (M.W. +1).  
b R.T. represents retention time of each product peak in the LC-MS/MS chromatogram.  
c Molecular formula of the neutral molecule.  
d Most abundant fragment ion.  
e Second most abundant fragment ion.  
f This product exists as an iminium ion form, thus the molecular formula is for the ionic species instead of the neutral species. 
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Table  4.3. Products of TMP-Mn(VII) reactions 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b  
(min) 
MS/MS  
(m/z) 
Molecular  
formulac 
Difference  
from TMP 
Proposed  
structure 
TMP 291 2.6 
276, 261, 
 230d, 181, 
 123e, 110 
C14H18N4O3  
 
O
O
O
N
N
NH2H2N
 
I 280 1.8 237e, 181d C13H17N3O4 -(C H N) +O 
 
O
O
O
O
HN
N
NH2
 
II 295 1.7 
278d, 253, 
 236e, 183, 
 113 
C13H18N4O4 -C +O 
 
O
O
O
N
NH
NH2H2N
O
 
III 305 6.1 
290, 275, 
 244e, 195, 
 137d 
C14H16N4O4 -2H +O 
 
O
O
O
N
N
NH2H2N
O
 
IV 307 1.7 
289d, 274e, 
 243 
C14H18N4O4 +O 
 
O
O
O
N
N
NH2H2N
OH
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Table  4.3. (cont.) 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b  
(min) 
MS/MS  
(m/z) 
Molecular  
formulac 
Difference  
from TMP 
Proposed  
structure 
V 323 1.7 181 C14H18N4O5 +2O 
 
O
O
O
N
N
NH2
H2N O
O
 (a) 
or 
O
O
O
N
N
NH2H2N
O
H
O
 (b) 
VI 324 4.2 
307d, 281, 264, 
236, 181e 
C14H17N3O6 -(N H) +3O 
 
O
O
O
N
N
NH2
HO O
O
 
VII 325 2.0 
280, 255, 221, 
181d, 143e 
C14H20N4O5 +2H 2O 
 
O
O
O
N
N
NH2H2N
OHOH
 
a The numbers indicate the mass of the protonated molecular ion, equal to the molecular weight of the analyte plus 1 (M.W. +1).  
b R.T. represents retention time of each product peak in the LC-MS/MS chromatogram.  
c Molecular formula of the neutral molecule.  
d Most abundant fragment ion.  
e Second most abundant fragment ion. 
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Table  4.4. Gradient methods used for analysis of products 
CPR TMP LCM 
Time (min) B%a Time (min) B% a Time (min) B% a 
0 0 0 0 0 0 
3 15 12 40 10 15 
6 30 16 60 15 20 
15 70 17 90 16 50 
17 0 18 0 17 0 
19 0 20 0 19 0 
a Mobile phase A = 95% H2O + 5% acetonitrile + 0.1% formic acid. Mobile phase B = 95% acetonitrile + 5% H2O + 0.1% formic 
acid 
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Table  4.5. Proposed fragmentation pathways for products from CPR oxidation 
Product Fragmentation Pathways 
CPR 
CPR m/z: 332
NN
HN
O
COOHF
NN
+H2N
O
F
NN
HN
O
F
O
NN
+H2N
O
m/z: 288m/z: 314
m/z: 268
-H2O(18) -CO2(44)
-HF(20)
N
H
HN
O
F
O
m/z: 231
N
H
H2N
O
F
O
m/z: 205
-C4H7N(69) -C2H5N(43)
-C3H4(40)
-C2H2(26)
NH2N
O
F
O
m/z: 245
-C3H4(40)
 
I 
 
N+H3N
O
COOHF
-H2O(18)
NH2N
O
F
O
Product I m/z: 263
m/z: 245
NH2N
O
F
m/z: 217
H+
N
O
F
N
H
H2N
F
O
m/z: 177m/z: 204 m/z: 189
-CO(28)
-C3H4(40)-CON(42) +H(1)
NH2N
F
-CO(28)
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Table  4.5. (cont.) 
Product Fragmentation Pathways 
II 
NN
H2+
H
O
COOHF
O
O
m/z: 273Product II m/z: 291
NN
H
H
O
F
O
NH2N
O
F
O
m/z: 245
NH2N
O
F
m/z: 217
N
H
H2N
O
F
O
m/z: 205
N
H
H2N
F
O
m/z: 177
-H2O(18)
-CO(28) -C3H4(40)
-C3H4(40) -CO(28)
 
III 
 
NN
H2+
O
COOHF
O
H O H
m/z: 275
NN
H
O
F
O
H O H
Product III m/z: 293
O
-H2O(18)
 
IV 
 
NN
HNH3+
O
COOHF
NN
HNH2
O
F
O
Product IV m/z: 306 m/z: 288
-H2O(18)
NN
HNH2
O
O
m/z: 268
NH2N
O
F
O
m/z: 245
m/z: 203
NN
H
F
NH2N
O
O
m/z: 227
-HF(20)
-C2H5N(43)
-F(19) +H(1)-2CO(56)
-CH3N(29)
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Table  4.5. (cont.) 
Product Fragmentation Pathways 
V 
NN
H2+
NH
O
COOHF
O
H
NN
H
NH
O
F
O
H
O
Product V m/z: 334 m/z: 316
NH2N
O
F
O
m/z: 245
NH2N
O
F
m/z: 217
N
O
F
O
m/z: 230
-C3H5NO(71)
-NH(15) -CO(28)
-H2O(18)
 
VI 
 
NN
H2+
O
COOHF
OH
O
O H
NN
H2+
O
F
OH
O
O H
-CO2(44)
Product VI m/z: 335
m/z: 291
NN
H2+
O
F
O Hm/z: 291
COOH
-CO2(44)
 
VII 
 
NN
+H2N
O
COOHF
O
Product VII m/z: 346
-CO(28)
m/z: 318
NN
HN
O
F
O
O
NN
+H2N
O
COOHF
m/z: 328
-H2O(18)
 
VIII 
 
N
H+
N
HN
O
COOHF
Product VIII m/z: 346
NN
HN
O
F
O
-H2O
O O m/z: 328  
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Table  4.5. (cont.) 
Product Fragmentation Pathways 
IX 
H+
NN
HN
O
COOHF
O
NN
HN
O
F
O
O
Product IX m/z: 360 m/z: 342
-CO(28)
O O
H+
NN
HN
O
COOHF
O
m/z: 332
NN
HN
O
F
O
O
m/z: 314
NN
HN
O
O
O
m/z: 324
O
NN
HNH2
O
F
O
O
m/z: 302
-H2O (18)
-H2O (18)
-CO(28)
-C2O(40)
 
X 
 
H+
NN
NH
O
COOHF
O
O
-CO2(44)
Product X m/z: 362 m/z: 344
H H
m/z: 318
H+
NN
NH
O
F
O
O
H H
NN
NH
O
F
O
O
H H
O
-H2O (18)
 
XI 
 
H+
NN
HN
O
COOHFO
m/z: 344Product XI m/z: 362
OH
NN
HN
O
FO
OH
-H2O(18)
O
m/z: 316
NN
HN
O
FO
OH
-CO(28)
m/z: 273
NN
O
FO
m/z: 259
NN
H
O
FO
m/z: 245
NN
H
O
FO
m/z: 245
NH2N
O
F
O
-CHNO(43)
-CH2(14)-CH2(14)
-C4H5NO2(99)
H
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Table  4.5. (cont.) 
Product Fragmentation Pathways 
XII 
H+
NN
HN
O
COOHF
OH
HO
OH
Product XIIa m/z: 380
-H2O(18)
NN
HN
O
F
OH
HO
OH
O
m/z: 362
NN
HN
O
F
OH
HO
OH
m/z: 334
NN
HN
O
F
OH
O
m/z: 316
-CO(28)
-H2O(18)
 
(Fragmentation of XIIa shown as an example, fragmentation of XIIb is analogous) 
 
 117 
Table  4.6. Proposed fragmentation pathways for products from LCM oxidation 
Product Fragmentation Pathways 
LCM 
O S
OH
OH
HO
HO
N
H
O
NH+ O
OH
OH
HO
HO
N
H
O
N
O S
OH
HO
N
H
O
N
LCM m/z: 407 m/z: 359
m/z: 389
m/z: 126
N
m/z: 341 m/z: 299
OH
O
OH
HO
N
H
O
N
OH
OH
HO
N
H
O
N
O
H
O
HO
N
H
O
O
H
m/z: 172
-SCH4(48)
-C2H2O(42)
-H2O(18)
-SCH4(48)
 
I 
 
O S
OH
OH
HO
HO
N
H
OH2+
N O
OH
OH
HO
HO
N
H
OH
N-SCH4(48)
O S
OH
HO
N
H
OH
N
-H2O(18)
Product I m/z: 393 m/z: 345
m/z: 112
H
N
m/z: 327 m/z: 285
OH
O
OH
HO
N
H
OH
N
OH
OH
HO
N
H
OH
N
O
H
m/z: 216
O S
OH
HO
N
H
O
m/z: 264 OH
H
O
OH
HO
N
H
O
OH
H
m/z: 170
O
OH
N
H
O
OH
H
-C2H6O(46)
m/z: 375-SCH4(48)
-SCH4(48)
-C2H2O(42)
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Table  4.6. (cont.) 
Product Fragmentation Pathways 
II 
O S
OH
OH
HO
HO
N
H
O
N O
OH
OH
HO
HO
N
H
O
N
O S
OH
HO
N
H
O
N+
Product IIa m/z: 405 m/z: 357
m/z: 387
m/z: 297
OH
O
HO
N
H
O
N+
O
H
m/z: 216
O
OH
HO
N
H
O
OH
H
m/z: 124
N
m/z: 170
O
OH
N
H
O
OH
H
m/z: 198
O
HO
N
H
O
O
H
-H2O(18)
-SCH4(48)
-C2H6O(46)
-H2O(18)
-C2H2O(42)-SCH4(48)
 
(Fragmentation of IIa shown as an example, fragmentation of IIb is analogous) 
III 
 
Product III m/z: 408 m/z: 360
m/z: 390 m/z: 342
O S
OH
OH
HO
HO
N
H2+
O
O
O O
OH
OH
HO
HO
N
H
O
O
O
O S
OH
OH
HO
N
H
O
O
O
O
OH
OH
HO
N
H
O
O
O
-H2O(18)
-SCH4(48)
-SCH4(48)
 
IV 
O S
OH
OH
HO
HO
N
H
O
NH+ O
OH
OH
HO
HO
N
H
O
N
O S
OH
HO
N
H
O
NH+
Product IV m/z: 421 m/z: 373
m/z: 403m/z: 355 OH
O
OH
HO
N
H
O
N
OH
O O
OO O
HO
N
H
O
N
O
O
m/z: 323
-H2O(18)
-SCH4(48)
-SCH4(48) -SCH4(48)
-CH4O(32)
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Table  4.6. (cont.) 
Product Fragmentation Pathways 
V 
O
OH
OH
HO
HO
N
H
O
NH+
-SCH4(48)
-H2O(18)
Product Va m/z: 423 m/z: 375
m/z: 405m/z: 126
N
-SCH4(48)
m/z: 357
m/z: 317
OH
HO
N
H
O
N
HO m/z: 299
m/z: 281
-C2O(40)
-H2O(18)
-H2O(18)
O S
OH
OH
HO
HO
N
H
O
NH+HO
O S
OH
OH
HO
HO
N
H
O
N
O
OH
OH
HO
HO
N
H
O
N
HO
HO
OH
HO
N
H
O
N
O
N
H
O
N
O
HO
 
(Fragmentation of Va shown as an example, fragmentation of Vb is analogous) 
VI 
O S
OH
OH
HO
HO
N
H
O
NH+
O
OH
OH
HO
HO
N
H
O
N
-SO2CH4(80)
O S
O
OH
HO
N
H
O
N
-H2O(18)
Product VI m/z: 439
m/z: 359m/z: 421
m/z: 126
N
m/z: 341
OH
O
OH
HO
N
H
O
N
OH
O
O
O
OH
OH
OH
HO
HO
N
H
O
NH+
m/z: 391
O
-SO2CH4(80)
-SO(48)
 
VII 
O S
OH
OH
HO
HO
N
H
O
NH+ O
OH
OH
HO
HO
N
H
O
N
-SO2CH4(80)
O S
O
OH
HO
N
H
O
N
-H2O(18)
m/z: 453 m/z: 373
m/z: 435
m/z: 140
N
m/z: 355 OH
O
OH
HO
N
H
O
N
OH
O
O
OO
O
O O
O -SO2CH4(80)
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Table  4.7. Proposed fragmentation pathways for products from TMP oxidation 
Product Fragmentation Pathways 
TMP 
O
O
O
N
NH+
NH2H2N
TMP m/z: 291
N
N
NH2H2N
O
O
O
O
O
O
N
NH+
H2NO
O
N
NH+
H2N
O
O
N
NH+
NH2H2N
N
NH+
H2N
m/z:181
m/z: 261
m/z: 123
m/z: 276
m/z: 110
m/z: 230
-NH(15)-CH4(16)
-OCH2(30)
-NH(15)
-C2H4O(46)
-N(14)+H(1)
 
I 
 
O
O
O
O
HN
NH+
NH2
Product I m/z: 280
O
O
O
m/z: 181
O
O
O
HN
NH+
m/z: 237
-CO(28)
-NH(15)
 
II 
 
O
O
O
N
NH2+
NH2H2N
Product II m/z: 295
O
O
O
O
N
NH
H2N
m/z: 278
O
O
O
O
NH2+H2N
m/z: 253
O
O
O
O
NH
m/z: 236
O
O
O
+HO
N
NH
NH2H2N
m/z: 113
O
m/z: 183
-CNH2(26)
-NH3(17) -NH3(17)
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Table  4.7. (cont.) 
Product Fragmentation Pathways 
III 
O
O
O
N
NH+
NH2H2N
Product IV m/z: 305
N
N
NH2H2N
O
O
O
O
O
O
N
NH+
H2NO
O
N
NH+
H2N
O
O
N
NH+
NH2H2N
m/z:195
m/z: 275
m/z: 137
m/z: 290m/z: 244
-NH(15)-CH4(16)
-OCH2(30)
O O
O
O
O
O
-NH(15)
-OCH2(30)
-CH4(16)
 
IV 
 
O
O
O
N
NH+
NH2H2N
Product IV m/z: 307
OH
O
O
O
N
N
NH2H2N
m/z: 289 O
O
O
N
N
H2N
m/z: 274
O
O
N
N
NH2H2N
m/z: 243
-H2O(18)
-NH(15)-C2H6O(46)
 
V 
 
O
O
O
N
H+
N
NH2H2N
Product Vb m/z: 323
O
H
O
O
O
O
N
NH+
NH2
H2N O
O
Product Va m/z: 323
O
O
O
m/z: 181  
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Table  4.7. (cont.) 
Product Fragmentation Pathways 
VI 
O
O
O
N
NH+
NH2
HO O
O
Product VI m/z: 324
O
O
O
N
N
HO O
O
m/z: 307
m/z: 264O
O
O
O
NH+
NH2
O
m/z: 281
O
O
O
O
N
O
O
O
O
N
HO
m/z: 236
O
O
O
m/z: 181
-CONH(43)
-NH3(17) -CO(28)
-NH3(17)
 
VII 
 
O
O
O
N
NH+
NH2H2N
Product VII m/z: 325
OHOH
N
N
NH2H2N
HO
OH
m/z: 280
O
O
O
m/z: 181
m/z: 143O
O
O
m/z: 221 m/z: 255
O
O
O
NH3+
NH2
O
O
O
N NH2H2N
-NO2(46)
+H(1)
-CH5N3(59) -CN2O2(72)+2H(2)
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CHAPTER 5  
OXIDATIVE REMOVAL OF 17α-ETHINYLESTRADIOL BY POTASSIUM 
PERMANGANATE: REACTION KINETICS AND PRODUCTS 
5.1 Abstract 
The presence of endocrine disrupting compounds (EDCs) in aquatic environments has 
been reported to cause fish feminization and affect fish reproduction. There are also serious 
concerns about EDCs’ potential adverse effects on human health. This study examined the 
oxidative transformation of the synthetic steroid hormone 17α-ethinylestradiol (EE2), a potent 
EDC, by potassium permanganate [KMnO4; Mn(VII)]. Reaction kinetics can be described by a 
second-order rate law with an apparent second-order rate constant (k2) of 1.27(±0.02)×102 M-1 s-1 
at pH 7 and 25 oC, and an activation energy (Ea) value of 37(±2) kJ mol-1. Solution pH was found to 
significantly affect reaction kinetics, with k2 increasing from 2.0×101 M -1 s-1 to 5.9×103 M-1 s-1 
when pH increases from 4 to 9. The pH dependence can be quantitatively described by considering 
parallel reactions between MnO4- and two acid-base species of EE2. Predictions of EE2 oxidation 
from a kinetic model that included temperature, applied KMnO4 dose, pH, and source water 
oxidant demand as input parameters agreed reasonably well with measurements conducted in four 
drinking water utility source waters. Nine reaction products, with structural changes indicating 
phenolic ring and ethynyl group oxidation, were identified by liquid chromatography-mass 
spectroscopy methods. Overall, results indicate that Mn(VII) treatment processes have good 
potential for treatment of EE2 and structurally related EDCs in contaminated source waters. 
5.2 Introduction 
Endocrine disrupting compounds (EDCs) are chemicals that interfere with functions of 
natural hormones and affect health, growth and reproduction of humans and animals [1]. EDCs 
have been widely detected in wastewater effluents and drinking water sources [2-5], raising serious 
concerns about potential adverse effects on human health and aquatic ecology, especially effects 
on aquatic organisms living in wastewater effluent-impacted habitats. Although there remains 
considerable debate about the potential risk of many classes of trace micropollutants, reports 
demonstrate that steroidal EDCs impact aquatic organisms at levels commonly detected in aquatic 
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environments receiving effluent from wastewater treatment facilities [4, 6-10]. Orn et al. [10] reported 
that zebrafish showed significant changes in sex ratios in favor of females after a partial life-cycle 
exposure to 1 ng/L of 17α-ethinylestradiol (EE2, Table  5.1), a synthetic steroid hormone that is a 
common active ingredient in oral contraceptive pills. Parrott et al. [6] reported egg fertilization 
success reduction and feminization of fathead minnows after a life-cycle exposure to <1 ng/L of 
EE2. Although EDCs are among the relatively susceptible group of compounds being effectively 
removed by conventional wastewater treatment processes [11], reported environmental levels of 
EDCs are often higher than the lowest concentration that can induce reproductive disturbance (sub 
µg/L). For example, a U.S. Geological Survey national reconnaissance detected EE2 in 15.7% of 
139 surveyed U.S. streams with median and maximum concentrations of 73 ng/L and 831 ng/L, 
respectively [2]. 
A number of studies have explored the potential of drinking water oxidants for the 
treatment of steroid hormones like EE2 and elimination of estrogenic activity, including ozone [1, 
12-14], free chlorine [15], combined chlorine [14], chlorine dioxide [16], ferrrate [17], manganese oxide 
[18], and UV/TiO2 [19]. However, there is currently no comprehensive study addressing the potential 
use of potassium permanganate [KMnO4; Mn(VII)], a widely used drinking water oxidant [20], for 
treatment of steroidal EDCs in water. Mn(VII) is used in water treatment plants to treat taste and 
odor problems, remove color, oxidize soluble iron(II) and manganese(II), control biological 
growth, and pre-oxidize disinfection byproduct precursor compounds [21]. Mn(VII) has also been 
reported to oxidize a wide range of organic contaminants [22] and is employed for in-situ 
remediation of contaminated groundwater [23, 24]. Recent studies have shown Mn(VII) is effective 
in oxidizing some pharmaceutically active micropollutants, including carbamazepine [25], three 
common antibiotics [26], triclosan [27], and bisphenol A [28]. Because of the shared highly reactive 
phenolic group among triclosan, bisphenol A, and EE2, Mn(VII) is also expected to be an effective 
oxidant for EE2 in water treatment. 
The objective of this study was to characterize the reaction between Mn(VII) and EE2 
under natural water conditions and evaluate the potential of applying Mn(VII) for oxidative 
treatment of steroidal EDCs in contaminated source waters. Results from detailed kinetics 
experiments are presented, including examination of the effects of Mn(VII) concentration, 
temperature, and pH on reaction kinetics. A kinetic model considering changing acid-base 
speciation of the phenolic/phenolate group in EE2 was used to quantitatively interpret the effects 
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of pH. A predictive kinetic model using results from experiments conducted in well-characterized 
laboratory solutions was also applied to predict Mn(VII) treatment in four drinking water utility 
source waters. Because tests showed no significant mineralization of EE2 during reactions with 
Mn(VII), liquid chromatography-mass spectrometry (LC-MS) methods were used to identify 
organic transformation products. 
5.3 Materials and Methods 
5.3.1 Reagents and Materials 
All chemicals were of high purity and were used as received from Sigma-Aldrich-Fluka 
(USA). Solutions were prepared in reagent-grade deionized water (>17.3 MΩ·cm; Barnstead 
nanopure system). Glassware and plasticware was washed by soaking in a 1 M HCl or HNO3 acid 
bath for over 24 h followed with repeatedly rinsing with deionized water. EE2 stock solutions (25 
µM) were prepared in nanopure water with pH adjusted to ~10.6.  
5.3.2 Batch Kinetics Experiments 
Batch reaction experiments were conducted in 150-mL glass beakers immersed in a 
temperature-controlled circulating water bath. Reactions were initiated by spiking excess 
concentration of Mn(VII) into pre-equilibrated and pH-adjusted solutions containing 1 µM EE2 
and 25 mM NaCl electrolyte. No pH buffers were used in kinetics experiments because previous 
reports [27, 28] and our preliminary tests for this study showed that phosphate buffer accelerates 
Mn(VII) oxidation of phenolic compounds under some pH condisions. Instead, pH was held 
constant during reactions by continuous monitoring and manual addition of HCl and NaOH as 
needed. After reaction initiation, aliquots were periodically collected for analysis and immediately 
quenched with excess hydroxylamine [25, 26], rapidly reducing residual Mn(VII) and MnO2(s) to 
dissolved Mn2+. EE2 concentrations were then quantified by high perfomance liquid 
chromatography with photodiode array (HPLC-PDA) detection to monitor reaction progress. 
5.3.3 Utility Source Water Experiments 
Experiments were also conducted to measure Mn(VII) oxidation of EE2 in four drinking 
water utility source waters. For these experiments, a much lower initial EE2 concentration (500 
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ng/L) was used to better mimic environmental levels (ng/L - µg/L). Multiple reactors were 
prepared with 150-mL unfiltered source water amended with EE2 and reactions were initiated by 
spiking different doses of Mn(VII) and mixing rapidly. For each Mn(VII) dose, duplicate 
experiments were conducted. After the desired reaction time, excess hydroxylamine was added to 
quench any further reaction and then 500 ng/L E1 was added as an internal standard to account for 
varying solid phase extraction (SPE) efficiency. Water samples were then filtered (0.45 µm glass 
fiber) and concentrated using SPE cartridges (Waters, Oasis HLB, 500 mg, 60 µm) before 
analyzing with HPLC-PDA. Details of the SPE procedure are provided in the Section  5.5.1.2. 
5.3.4 Reaction Intermediates and Products 
To identify reaction products resulting from Mn(VII) oxidation of EE2, a series of 20 mL 
EE2 solutions (pH 7, 25 mM ammonium acetate) were treated with varying doses of Mn(VII) and 
analyzed by LC-MS methods. Ammonium acetate was used to both maintain pH and aid ionization 
in the mass spectrometer. Tests (data not shown) showed that the presence of ammonium acetate 
did not affect the reaction kinetics at pH 7. Elevated initial EE2 (100 µM in 5% (v/v) acetone) and 
Mn(VII) concentrations (40-500 µM) were used to facilitate detection of minor products. After 
allowing sufficient time for reactions to reach completion, samples were then filtered (PTFE, 0.45 
µm) and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and liquid 
chromatography high resolution mass spectrometry (LC-HRMS). A similar series of 
Mn(VII)-reacted EE2 solutions (minus ammonium acetate) were also prepared and analyzed for 
changes in total dissolved organic carbon (DOC). 
5.3.5 Analytical Methods 
Details of analytical methods, including HPLC-PDA, DOC, LC-MS, are provided in 
Section  5.5.1. 
5.4 Results and Discussion 
5.4.1 Reaction Kinetics 
Results from batch experiments (Figure  5.1) showed that EE2 was rapidly degraded by 
Mn(VII) under neutral pH conditions (e.g., t1/2 = 9 min when [Mn(VII)]0 = 10 µM, pH 7, 25 oC). 
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The kinetics of EE2 decay could be described by a pseudo-first-order rate law when initial Mn(VII) 
concentration was in excess, and measured pseudo-first-order rate constants (kobs, s-1) for all batch 
kinetics experiments are listed in Table  5.2. Results in Figure  5.2A show that kobs varied linearly 
with changing initial Mn(VII) concentration, indicating the reaction was also first-order with 
respect to Mn(VII) concentration, and confirming that overall reaction kinetics could be described 
by a generalized second-order rate law: 
 tottot2tot [Mn(VII)][EE2]dt
d[EE2]
k−=   ( 5.1) 
where [EE2]tot and [Mn(VII)]tot represent the total EE2 and Mn(VII) concentration, repectively, 
and k2 is the apparent second-order rate constant (M-1 s-1) valid at the solution conditions in 
question. At pH 7 and 25 oC, k2 was determined to be 1.27(±0.02)×102 M-1 s-1. Second-order rate 
constants for aqueous Mn(VII) reactions with a variety of organic compounds (e.g., chlorinated 
and aromatic hydrocarbons, ethers, amines, nitro explosives and substituted phenols) have been 
reported previously at similar solution conditions [22, 25-28], ranging from 7×10-6 M-1 s-1 to 3×102 
M-1 s-1, indicating that EE2 is among the more highly Mn(VII)-reactive compounds reported to 
date under natural water conditions. The EE2 structure contains phenolic and ethynyl functional 
groups, both of which have been reported to react with Mn(VII) [27-30]. Shao et al. [31] recently 
studied the oxidation of E1, a structurally related compound of EE2 but lacking the ethynyl group, 
with Mn(VII) and reported a k2 of ~9.5×101 M-1 s-1 at pH 7 and 25 oC, only slightly slower than that 
of EE2 observe here. 
Previous studies showed that EE2 is susceptible to oxidation by several other drinking 
water-related oxidants, including O3, HOCl, NH2Cl, ClO2, UV/H2O2 (·OH), and Fe(VI) [15-17, 32]. 
The k2 values for EE2 reacting with different oxidants at pH 7 and ambient temperature are listed 
in Table  5.1. The reactivity of EE2 with Mn(VII) is lower than O3 and ClO2, but comparable with 
HOCl and Fe(VI) and significantly higher than NH2Cl. With the exception of ClO2 and NH2Cl, the 
relative reactivity of EE2 with different oxidants follows the same general trend with the standard 
reduction potential of the oxidants at pH 7 (EopH 7, Table  5.3). Although ·OH and O3 exhibit the 
highest reactivity with EE2, EE2 treatment efficiency in organic-rich natural water matrices may 
be offset by lower stability and more rapid scavenging of these oxidants by non-target water 
constituents [33]. In addition, free chlorine will be rapidly converted to less reactive chloramine 
species in waters rich in ammonia and organic amines [20], whereas Mn(VII) is relatively 
unreactive with ammonia and will persist for longer times in such matrices [25]. 
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Figure  5.2B shows that the dependence of k2 on temperature (T) followed a trend 
consistent with the Arrhenius equation: 
 )ln(1)ln( a2 ATR
E
k +⋅−=   ( 5.2) 
where Ea is the apparent activation energy, R is the universal gas constant, and A is the 
pre-exponential constant. At pH 7, Ea for Mn(VII)-EE2 reactions was determined to be 37(±2) kJ 
mol-1, corresponding to a doubling of reaction rates for every 14 oC increase in temperature. The k2 
values for EE2 oxidation by Mn(VII) at other temperatures can thus be calculated using the 
determined Ea value and Equation ( 5.2). Shao et al. [31] reported an Ea of 43 kJ mol-1 for 
Mn(VII)-E1 reactions, similar to the value measured here.   
Solution pH was also found to have significant effects on the rate constants of reaction 
between EE2 and Mn(VII) (Figure  5.3). For the pH range of 6 to 9, raising solution pH greatly 
enhanced the reaction rates, with k2 increasing by ~300 fold when pH increased from 6 to 9, 
whereas little change was observed between pH 4 and 6. The pH dependent trend in the higher pH 
range is similar to that reported for EE2 oxidation by ClO2 [16], and O3 [13], both of which do not 
have acid-base speciation, and can be attributed to the deprotonated phenolate species (EE2-, 
Table  5.1) having a higher electron density on the target reaction site and thus being more reactive 
with oxidants than the protonated conjugate acid species. The overall pH dependent trends for 
oxidation of EE2 by Fe(VI) [17] and HOCl [15] are different from the trend observed here due to the 
changing speciation of the oxidants themselves with changing pH. The slight increase of reaction 
rate constants at pH<5 was also reported with Mn(VII) oxidation of E1 and was attributed to the 
higher reduction potential of Mn(VII) at lower pH [31]. It could also be explained by the added 
Mn(VII) reactivity from the acid-catalyzed pathway at lower pH as reported in Mn(VII) oxidation 
of paracetamol [34]. 
The effects of pH on Mn(VII) reaction kinetics could be quantitatively described with a 
previously reported kinetic model [26] that considers parallel reactions between the anionic 
permanganate species (MnO4-, β2), which predominates at natural water pH conditions, and 
individual species of target organic compounds with different protonation levels. 
 222212212 αα ββ kkk +=   ( 5.3) 
For the pH range studied (β2 = 1), Equation ( 5.3) is then simplified to: 
 2221212 αα kkk +=   ( 5.4) 
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where k21 and k22 are the species-specific second-order rate constants for MnO4- (second 
protonation level of Mn(VII)) reacting with neutral and deprotonated EE2 species, respectively; α1 
and α2 represent the equilibrium fraction of neutral and deprotonated EE2 species, respectively, 
both of which vary with changing pH condition. Figure  5.3 shows the results of least-square fitting 
of the kinetic data with Equation ( 5.4) and the predicted contributions of individual EE2 species to 
the apparent second-order rate constants at different pH conditions. The model fits agreed closely 
with measured data and the fit-derived species-specific rate constants are listed in Table  5.1 and 
Figure  5.3. The value of k22 is ~4 orders-of-magnitude larger than k21, indicating that 
deprotonation of the phenolic group greatly enhances EE2 reactivity with Mn(VII). Comparison of 
the species-specific rate constants for EE2 with different common oxidants is provided in Table 
 5.1. Similar to Mn(VII), EE2 deprotonation significantly increased reactivity with HOCl, ClO2, 
Fe(VI), and O3, suggesting the deprotonated phenolate group is the major target functional group 
for all oxidants at circumneutral pH conditions. 
5.4.2 EE2 Removal by Mn(VII) in Utility Source Waters 
Oxidative removal of EE2 by Mn(VII) was measured in four drinking water utility source 
waters, the properties of which are summarized in Section  5.5.1.1 (TOC = 1.3-4.3 mg/L, alkalinity 
= 70 to 144 mg/L as CaCO3, pH = 7.6-8.4). Figure  5.5 shows the measured oxidation of EE2 in the 
four utility source waters with three different KMnO4 doses (0.5, 1.0, and 2.0 mg/L). In general, 
EE2 is efficiently removed by low doses of KMnO4 and short reaction times (2-12 min), and the 
percent of EE2 removal increases with the applied KMnO4 dose. With 2 mg/L of KMnO4 and 2-12 
min of reaction time, there is >85% removal of EE2 in all source waters. 
With the kinetic parameters determined in previous sections, the EE2 removal in natural 
water can be predicted using a kinetic model previously used to describe Mn(VII) oxidation of 
antibiotics [26]: 
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where term A calculates the apparent second-order rate constant at 25 oC and the pH of interest by 
taking into account of the effects of EE2 speciation on the reactivity with Mn(VII) (Table  5.1). 
Term B corrects the rate constant to the temperature of interest using the Arrhenius equation and 
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the Ea values (Figure  5.2B). Term C, CtMn(VII), is the integrated Mn(VII) exposure during treatment 
( ∫ ⋅t dtVIIMn0 )]([ ), which is similar to the widely used Ct concept for modeling disinfection 
processes and accounts for the applied Mn(VII) dosage, treatment time, and oxidant demand of the 
source water matrix. The Mn(VII) demand of each source water was determined by measuring 
Mn(VII) decay in the absence of EE2 in separate experiments (Table  5.4) and integrating the 
Mn(VI) concentration over time using the trapezoidal method described in Chapter 3. 
The accuracy of the predictive kinetic model shown in Equation ( 5.5) was tested by 
comparing the model prediction with the measured EE2 removal in utility source waters as shown 
in Figure  5.5. Overall, the model predictions agree closely with measurements, with a few 
exceptions where measured EE2 removals were higher than predicted. Previous studies observed 
similar higher-than-expected removal rates of estrone [31] and triclosan [27] during Mn(VII) 
treatment in natural water. This underestimation of model prediction might be attributed to the 
presence of various ligands in the utility source water matrix that could enhance the Mn(VII) 
oxidation of phenolics as demonstrated by Jiang et. al [28]. Specifically, He et al. [35] reported that 
high nominal molecular weight fraction of humic acid can greatly accelerate the phenol oxidation 
rate by Mn(VII). Nevertheless, the close agreement between measured and model predicted EE2 
removal in utility source waters is notable given that the kinetic parameters used in Equation ( 5.5) 
were developed for batch reactors conducted at conditions very different from the source water 
reaction conditions used for experiments shown in Figure  5.5. (e.g., much different initial EE2 
concentrations, well vs. poorly characterized source waters, absence vs. presence of suspended 
solid). Therefore, the predictive model developed here can be used to provide a conservative 
estimate of EE2 removal to drinking water utilities that currently apply Mn(VII) treatment.  
5.4.3 Reaction Products and Pathways 
Although EE2 was effectively oxidized by Mn(VII) in both artificial water and utility 
source water, tests showed that there was no change in DOC concentration of EE2 solutions after 
Mn(VII) treatment (Figure  5.4), indicating transformation to unknown organic products. 
Therefore, identification of reaction products is important to understand the fate of EE2 during 
Mn(VII) treatment. Nine products from Mn(VII) oxidation of EE2 were detected by LC-MS/MS 
analysis. Table  5.5 lists the HRMS-determined molecular weight and molecular formula, the 
major observed MS/MS fragment ions (MS/MS spectra provided in Table A.5 in Appendix A), the 
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chromotographic retention time, and the proposed structures for each product. Because the 
MS/MS fragmentation pattern did not provide decisive information in elucidating the product 
structures, the proposed structures of each product were mainly based on the determined molecular 
formula and the preknowledge that Mn(VII) oxidation occurs predominantly on the phenolic ring 
and the ethynyl group. Most products show a dominant loss of 18 followed by 28 from the 
pseudomolecular ion [M+H]+, which is also seen in the MS/MS fragmentation pattern of the parent 
compound EE2 as illustrated in Table  5.6. The loss of 18 is proposed to be the loss of H2O from the 
hydroxyl group at the C-17 position, and the subsequent sequential loss of 28 is proposed to come 
from the loss of ethenes (C2H4) from the steroid skeleton. For five products (III, VI, VII, VIII, 
and IX), a sequential loss of two H2O molecules was observed in the MS/MS spectra, indicating 
the presence of an additional functional group that can give out a H2O molecule during 
fragmentation, either a –OH or a –COOH group. The proposed structures for these products are 
consistent with this observation. Further confirmation of the proposed product structures by NMR 
analysis or comparison with reference standards is recommended for unequivocal identification. 
A variety of oxidation products were proposed, including dehydrogenation (II), quinone 
(V), phenolic ring-hydroxylation (IV, VII, and IX), and phenolic ring-cleavage products (I, III, 
VI, and VIII), as well as products where the ethynyl group was oxidized to aldehydes and 
carboxylic acid (V and IX). In terms of LC-MS detection intensities, product IX and V are the 
two dominant products. Table  5.5 lists the products detected following treatment with different 
Mn(VII) dosages. It should be noted that no coupling products are detected in all samples, even 
when EE2 is in much excess and unreacted EE2 could potentially react with the reduction 
product of Mn(VII), MnO2(s). This is somewhat surprising because oxidation of phenol by 
permanganate have been proposed to undergo a phenoxyl radical pathway [29] and coupling 
products are expected [36]. In addtion, a previous study [37] reported oxidation of phenol to 
diphenoquinone by MnO2(s) through a phenoxyl radical pathway. The absence of coupling 
products might be due to steric hindrance posed by the substituted steroid ring structure on the 
phenolic ring.     
Hydroxylation products have been proposed and identified in several chemical oxidation 
[38, 39] and biotransformation [40-42] studies of EE2 and structurally related steroid hormones. The 
formation of hydroxylated EE2 might occur through a phenoxenium ion intermediate (shown in 
Equation ( 5.6)), which has been reported to be the intermediate of Mn(III) oxidation of phenol 
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[43].  
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The phenoxenium ion is formed by two one-electron transfer steps from deprotonated EE2 to 
Mn(VII). Nucleophilic attack of H2O molecule to the phenoxenium ion can then form a 
monohydroxylated EE2 (product IV), which can be further oxidized to its quinone form (product 
V). Different isomers of EE2 hydroxylation products are expected to form because of different 
resonance structures of the phenoxenium ion (not shown).  
The monohydroxylated EE2 shown in Equation ( 5.7) can be further hydroxylated, 
forming product VII and IX, or oxidatively cleaved by Mn(VII) to form ring-cleavage products (I, 
II, VI, and VIII). The mechnism of oxidative cleavage of monohydroxylated EE2 by Mn(VII) 
might be similar to that of Mn(VII) oxidation of olefins, during which a diol compound is first 
formed and then further oxidized to aldehydes and carboxylic acids by Mn(VII) [44]. Cleavage of 
the phenolic ring to form carboxylic acids and aldehydes has been proposed previously for 
ozonation of EE2 and E2 [12, 39]. 
The dehydrogenation product (II) was previously reported as the major product of EE2 
oxidation by Mn(III) [45], while Haaf et al. [46] also reported 9, 11-dehydrogenated estrone as one 
of the major metabolites of estrone in hamster liver. The dehydrogenation process is proposed to 
be initiated by a hydride abstraction at the C9 followed by a loss of proton at C11 to form a new 
C9=C11 double bond: 
 HO
CH3OH
Mn(VII)
HO
CH3
OH
-H+
HO
CH3
OH
9
11
  ( 5.8) 
The abstraction of hydride from the α position of an aromatic ring by Mn(VII) has been 
previously established [47]. Hydride abstraction at the C9 position is prefered over the C6 position 
because of the tertiary carbocation intermediate formed is more stable than the otherwise 
secondary carbocation [48]. In addition, the stability of the tertiary carbocation intermediate is 
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increased by multiple possible resonance structures with the phenolic ring [48]. 
Product V and IX exhibit structural modifications to the ethynyl group. Oxidation of the 
ethynyl group by Mn(VII) to produce triple bond cleaved aldehydes as seen in product V has 
been previously reported [49]. The conversion of the ethynyl group to the carboxylic acid in 
product IX is proposed to occur through oxidative hydration (Equation ( 5.9)). Metal-catalyzed 
hydration of alkynes to form aldehydes or ketones has been well-established [50-52].  
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  ( 5.9) 
Overall, results in this study show that EE2 is efficiently oxidized by Mn(VII) in both 
artificial water and utility source water. The reaction follows second-order rate law and the 
apparent second-order rate constant was measured to be 1.27(±0.02)×102 M-1 s-1 at pH 7 and 25 
oC, corresponding to a half-life of 14 min when treated with 1 mg/L of KMnO4. The reaction rate 
constants were highly dependent on solution pH and temperature, with high pH resulting in 
greatly increased reaction rate constants. The effect of pH can be well-described with a kinetic 
model considering parallel reactions between the two different EE2 species and the MnO4- ion. A 
predictive kinetic model was found to estimate the EE2 removal resonably well in utility source 
water. The model takes into account of variation of pH, temperature, Mn(VII) dosage, contact 
time, and oxidant demand in different water matrix. The phenolic ring and ethynyl group are 
found to be the two target functional group in EE2. Dehydrogenation and hydroxylation products 
along with phenolic ring-cleavage products and products with structural modification on the 
ethynyl group are tentatively identified based on LC-MS data.  
Among pharmaceutically active compounds commonly detected in drinking water 
sources, phenolic EDCs like 17α-ethinylestradiol are believed to possibly pose the greatest risk 
at environmental concentration levels (ng/L-µg/L) [6]. In agreement with other reports [27, 28], 
results in this study show that permanganate is a promising oxidant for treating phenolic EDCs in 
general. However, further research is needed to quantify the estrogenic activity of the reaction 
products and the extent of estrogenic activity removal during Mn(VII) treatment. 
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5.5 Supporting Information 
5.5.1 Analytical Procedures 
5.5.1.1 Measurement of EE2 concentration, DOC, and source water characteristics 
EE2 concentration was determined using a Shimadzu model HPLC equipped with UV-Vis 
photodiode array detection. The stationary phase was a Novapak C-18 column (3.9×150 mm, 4 µm 
particle size) and the mobile phase (1 mL/min) was an isocratic mixture of 45% acetonitrile and 
55% 10 mM phosphoric acid. The retention time was 5.6 min and the monitoring wavelength was 
200 nm. Figure  5.6 shows a representative HPLC calibration curve for EE2 at 200 nm with an 
injection volume of 400 µL. With this method, we were able to reliably quantify EE2 down to 50 
nM. Dissolved organic carbon (DOC) was measured by a total organic carbon (TOC) analyzer 
(Shimadzu TOC-VCPH) and calibrated using potassium hydrogen phthalate standards. 
Utility source water characteristics were determined using standard procedures described 
in Chapter 2. Source waters characteristics (except pH, which had drifted and was remeasured with 
new values shown in the caption of Figure  5.5) were summarized in Table  5.8. Briefly, ammonia 
concentration of source waters ranges from 0.2 to 0.6 mg/L as N; alkalinity ranges from 70 to 144 
mg/L as CaCO3; TOC ranges from 1.3 to 4.3 mg/L; total suspended solids (TSS) ranges from <1 to 
5.3 mg/L; chloride ranges from 36 to 295 mg/L; nitrate ranges from 6.2 to 12 mg/L; sulfate ranges 
from 13 to 238 mg/L. To independently quantify the matrix oxidant demand during utility source 
water experiments, Mn(VII) decay of source waters was determined spectrophotometrically (λ = 
525 nm) in 10 cm-optical-path cuvettes using a double-beam spectrophotometer (Shimadzu 
UV-2401PC). Water samples were filtered with 0.45 µM PTFE filters before analysis. 
5.5.1.2 Solid phase extraction (SPE) 
A SPE method described by Lagana et. al [53] was adapted for concentrating EE2 in utility 
source water experiments. SPE cartridges (Waters, Oasis HLB, 500 mg, 60 µm) were firstly 
preconditioned sequentially with 10 mL dichloromethane/methanol mixture (v:v, 50:50), 5 mL 
methanol, and 10 mL deionized water. A Visiprep vacuum manifold (Sigma-Aldrich) was used to 
introduce the 150 mL samples at 5 mL/min. After extraction, SPE cartridges were washed with 5 
mL water and 0.4 mL methanol before eluting with 4 mL dichloromethane/methanol mixture (v:v, 
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50:50). The eluates were then evaporated to dryness and reconstituted in 1.5 mL acetonitrile/water 
mixture (v:v, 20:80) before analyzing with HPLC-UV. The average SPE recovery of the internal 
standard E1 was 82.7±6.4 %. 
5.5.1.3 LC-MS 
EE2 oxidation products were detected and identified by both LC-MS/MS and LC-HRMS 
methods. Low resolution LC-MS/MS analysis was performed on an Agilent 1200 LC/MSD Trap 
XCT Ultra instrument to obtain molecular weight and fragmentation patterns of EE2 oxidation 
products, while high resolution LC-MS (mass accuracy: 5 ppm) was performed on a Waters 
Q-TOF ultima to obtain the elemental composition of oxidation products. The same column 
(Zorbax Eclipse XDB-C18, 2.1×50 mm, 3.5 µm) and LC gradient were used for both methods. 
Separation of reaction products was achieved with a gradient method of two mobile phases (A: 
95% H2O + 5% acetonitrile + 0.1% formic acid; B: 95% acetonitrile + 5% H2O + 0.1% formic acid) 
at 0.2 mL/min. The percentage of organic phase B was kept at 10% for the first minute and ramped 
up to 80% in the next 14 min. The percentage of B was then held at 80% for 1 minute before 
ramping down to 10% in the next 0.5 min. B% was kept at 10% for another 1.5 min to get the 
column ready for the analysis of the next sample. For MS analyses, both positive and negative 
electrospray ionization (ESI+ and ESI-) was applied over a mass-to-charge (m/z) range of 50-1000. 
Because ESI- analysis only showed a subset of products detected in ESI+, only results from ESI+ 
are presented and used for structural elucidation. For low resolution LC-MS/MS analysis, isolation 
and fragmentation of ionized target compounds were completed with an ion trap under the 
auto-MS(2) mode with a fragmentation voltage of 1.0 V. The MS/MS spectra for EE2 and its 
oxidation products are shown in Appendix A. 
5.5.2 Propagation of Uncertainty for EE2 Removal Prediction 
The EE2 removal in natural waters can be predicted using the following equation: 
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The uncertainty of EE2 removal prediction was determined according to Meyer [54]. First, term A 
is converted to the following form: 
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where α1 and α2 are the fractional concentrations of EE2 and can be calculated as: 
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Then, uncertainty of A (σA) can be expressed as: 
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where σk21, σk22, and σα2 are uncertainties of k21, k22, and α2, respectively. σk21 and σk22 are obtained 
from model fitting of Equation ( 5.4), and σα2 is derived from Equation ( 5.12) as following: 
 pH213.22 σαασα =   ( 5.14) 
where σpH represents uncertainty of pH measurements and was assumed to be ±0.2 pH units.   
Then, we let 
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and the uncertainty of D (σD) can be expressed as 
 
4
2
22
D
298
11
1
T
T
ER
T
a
Ea
⎟⎠
⎞⎜⎝
⎛ −
+⎟⎟⎠
⎞
⎜⎜⎝
⎛= σσσ   ( 5.16) 
where σEa is the uncertainty of activation energy Ea and is obtained from model fitting of Arrhenius 
equation ( 5.2), σT is uncertainty of temperature and is assumed to be ±1 oC. 
Then the uncertainty of term B (σB) an be expressed as   
 DB B σσ ⋅=   ( 5.17) 
Next, the uncertainty of term C (σC) can be expressed as 
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where
)(VIIMnCσ  is the uncertainty of Mn(VII) concentration measurement and is assumed to be ±0.1 
mg/L, σt is uncertainty of t and is assumed to be ±10 s. 
The uncertainty of EE2 removal fraction can then be calculated as: 
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5.7 Figures and Tables 
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Figure  5.1. Representative batch reaction for oxidation of EE2 by excess concentrations of 
Mn(VII) and pseudo-first-order rate law model fit. Experimental conditions: [EE2]0 = 1 
µM, [Mn(VII)]0 = 10 µM, 25 oC, pH 7, 25 mM NaCl. Uncertainty represents 1 σ. 
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Figure  5.2. Effects of (A) Mn(VII) concentration and (B) temperature on rate constants of 
EE2 reaction with Mn(VII). Experimental conditions: [EE2]0 = 1 µM, 25 mM NaCl, pH 7, 
25 oC for (A); [EE2]0 = 1 µM, [Mn(VII)]0 = 10 µM, 25 mM NaCl, pH 7 for (B). Lines 
represent linear regressions of measured data. Uncertainties represent 1 σ. 
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Figure  5.3. Effect of pH on measured and model-predicted rate constants for Mn(VII) 
reactions with EE2. [EE2]0 = 1 µM, [Mn(VII)]0 = 10 µM, 25 mM NaCl, 25 oC. Symbols 
represent measurements and lines indicate overall model predictions. Uncertainties 
represent 1 σ. 
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Figure  5.4. Measured dissolved organic carbon (DOC) concentration of EE2 solutions after 
treatment with different doses of Mn(VII). Reaction conditions: [EE2]0 = 18 µM, varying [Mn(VII)], 
pH 7, room temperature.  
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Figure  5.5. Comparison of measurements and model predictions for EE2 removal during 
treatment of utility source waters with Mn(VII). Experimental conditions: [EE2]0 = 500 
ng/L, pH = 8.4 (utility 1), 7.6 (utility 2), 8.0 (utility 3), 8.3 (utility 4), T = 16 oC (utility 1), 19 
oC (utility 2), 18 oC (utility 3 and 4). Reaction times used in experiments varied among 
utilities due to different pH conditions of the individual source waters. Uncertainties for 
measured values are duplicate-averaged 1 σ, and uncertainties for predicted values 
represent 1 σ and are obtained by error propagation of Equation ( 5.3) considering ±1 σ 
uncertainty of fit-derived k21, k22, and Ea values, and assuming ±0.2 pH and ±1 °C 
uncertainty (see Section  5.5.2).     
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Figure  5.6. Representative HPLC calibration curve for EE2 at 200 nm with an injection 
volume of 400 µL. 
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Table  5.1. EE2 reactivity with Mn(VII) and other water treatment oxidants 
 
HO
CH3
OH
4
1
2
3 5
6
8
7
9
10
11
12
13 17
14 15
16
-O
CH3
OH
pKa = 10.4
   
   17α-ethinylestradiol (EE2) 
Oxidant 
k2a  
(M-1 s-1) 
k21b  
(M-1 s-1) 
k22c 
(M-1 s-1) 
Reference 
Mn(VII) 1.27(±0.02)×102 2.5(±0.4) ×101 2.3(±0.4)×105 This study 
·OHd  9.8(±1.2)×109 --- --- Huber et al. [32] 
O3 3×106 1.83(±0.38)×105 3.65(±0.46)×109 Deborde et al. [13] 
HOCl 1.15×102 4.3(±0.5) 3.5(±0.1)×105 Deborde et al. [15] 
NH2Cle 2.5×10-1 --- --- Lee et al. [14] 
ClO2 2×105 <200 4.6(±0.8)×108 Huber et al. [16] 
Fe(VI) 7.3(±0.6)×102 9.4(±0.2)×102 5.4(±0.2)×105 Lee et al. [17] 
a Apparent second-order rate constant. pH = 7, T = 25 oC for Mn(VII) and Fe(VI); 20 oC for ·OH, O3, HOCl and ClO2. 
b Specific rate constant for neutral EE2 species. 
c Specific rate constant for deprotonated anionic EE2 species. 
d ·OH created in UV/H2O2 systems. 
e
 Rate constant estimated from Figure 1 in Lee et al [14]. 
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Table  5.2. Measured pseudo-first-order rate constants for EE2 oxidation by Mn(VII)a  
pH T (ºC) [Mn(VII)]0 (µM) kobs (10-3 s-1)b 
7 25 10 1.31(±0.01) 
7 25 15 1.93(±0.02) 
7 25 20 2.88(±0.05) 
7 25 30 3.75(±0.06) 
7 25 40 4.96(±0.07) 
7 25 50 6.3(±0.2) 
4 25 10 0.37(±0.03) 
4.5 25 10 0.27(±0.01) 
5 25 10 0.20(±0.01) 
5.5 25 10 0.14(±0.01) 
6 25 10 0.24(±0.01) 
6.5 25 10 0.74(±0.01) 
7.5 25 10 3.6(±0.1) 
8 25 10 9.9(±0.2) 
8.5 25 10 26.5(±0.4) 
9 25 10 68(±2) 
7 6.5 10 0.54(±0.02) 
7 9.5 10 0.64(±0.02) 
7 15 10 0.81(±0.01) 
7 20 10 0.99(±0.02) 
7 30 10 1.69(±0.03) 
7 34 10 2.2(±0.1) 
a Experimental conditions: [EE2]0 = 1 µM, [NaCl] = 25 mM, no pH buffer. 
b Uncertainties represent 1 σ from regression. 
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Table  5.3. Reduction potentials of common drinking water oxidants at pH 7 
Oxidant Reactiona Eo EopH 7b (V) 
Mn(VII) MnO4- + 4H+ + 3e- MnO2(s) + 2H2O 1.68 [20] 1.13 
·OH ·OH + H+ + e- H2O 2.59 [20]  2.18 
O3 O3 + 2H+ + 2e- O2 + H2O 2.08 [20] 1.67 
HOCl HOCl + H+ + 2e- Cl- + H2O 1.48 [20] 1.27 
NH2Cl NH2Cl + H2O + 2e- NH3 + Cl- + OH- 1.61 [20] 1.41 
ClO2 ClO2 + e- ClO2- 0.95 [20] 0.95 
Fe(VI)c FeO42- + 8H+ + 3e- Fe3+ + 4H2O 2.20 [55] 1.10 
a Half reactions under acidic conditions are shown.  
b Reduction potentials at pH 7 were calculated using Nernst equation and Eo values at pH 0.  
c Ferrate is an emerging oxidant and is included for comparison purposes. 
 
 
Table  5.4. Permanganate decay in utility source watersa 
Utility 1 Utility 2 Utility 3 Utility 4 
t 
(min) 
[KMnO4] 
 (mg/L) 
t 
(min) 
[KMnO4] 
 (mg/L) 
t 
(min)
[KMnO4] 
 (mg/L) 
t 
(min) 
[KMnO4] 
 (mg/L) 
0.5 0.96 0.5 1.08 0.5 1.04 0.5 1.02 
1 0.92 1 1.03 1 0.98 1 0.96 
2 0.89 2 1.02 2 0.92 2 0.92 
  5 0.95 8 0.88   
  10 0.83 12 0.79   
a Initial KMnO4 concentration is 1 mg/L.  
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Table  5.5. Products of EE2-Mn(VII) reactions detected by LC-MS/MS 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b 
(min) 
Major MS/MS
Fragmentsc 
(m/z) 
Molecular
Formula 
Theoractical 
mass for 
[M+H]+ 
Difference
from EE2d
Proposed 
Structure 
EE2 297.1854 13.6 
279, 251, 239, 
223, 185, 
159e, 147 
C20H24O2 297.1849 --- 
HO
CH3 OH
 
I 287.1648 10.7 
269e, 251, 
241, 223, 209, 
181 
C18H22O3 287.1647 
-(2C 2H) 
+O 
CH3
OH
O
O
H
H
 
II 295.1698 8.9 
277e, 249, 
235, 221, 157, 
133 
C20H22O2 294.1620 - 2H 
HO
CH3
OH
 
III 303.1613 7.5 
 
285, 267e, 
239, 221, 177, 
159 
 
C18H22O4 303.1596 
-(2C 2H) 
+2O 
CH3
OH
O
O
HO
H
CH3
OH
O
O
H
HO
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Table  5.5. (cont.) 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b 
(min) 
Major MS/MS 
Fragmentsc  
(m/z) 
Molecular 
Formula 
Theoractical  
mass for 
[M+H]+ 
Difference 
from EE2d 
Proposed 
Structure 
IV 313.1806 9.3 
295e, 267, 185, 
173, 159, 
C20H24O2 313.1804 +O 
 
HO
CH3 OH
OH
 
V 315.1599 12.5 297e, 251, 223 C19H22O4 315.1596 
-(C 2H) 
+2O 
 
O
CH3 OH
O
O
H
 
VIf 319.1542 3.4 
301, 283, 273e, 
255, 237 
C18H22O5 319.1546 
-(2C 2H) 
+3O 
 
HOOC
HOOC
CH3
OH
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Table  5.5. (cont.) 
Product 
ID 
[M+H]+ 
(m/z)a 
R.T.b 
(min) 
Major MS/MS 
Fragmentsc  
(m/z) 
Molecular
Formula 
Theoractical  
mass for 
 [M+H]+ 
Difference
from EE2d
Proposed 
Structure 
VII 329.1753 4.1 
311e, 293, 283,  
265, 237 
C20H24O4 329.1753 +2O 
 
HO
CH3 OH
OH
OH  
VIII 345.1696 8.5 
327e, 309, 285, 
267, 239, 221, 159 
C20H24O5 345.1702 +3O 
HOOC
HOOC
CH3
OH
 
IX 347.1874 4.2 
329e, 311, 293, 
283, 265 
C20H26O5 347.1859 +(2H 3O) 
HO
CH3
OH
O
OH
HO
 
a The numbers are from high resolution LC-MS analysis on Waters Q-TOF ultima., equal to the molecular weight of the analyte plus 1 (M.W. +1).  
b R.T. represents retention time of each product peak in the LC chromatogram obtained from from Agilent 1200 LC/MSD.  
c MS/MS fragmentation pattern obtained from Agilent 1200 LC/MSD.  
d Molecular formula difference from EE2. 
e Most abundant fragment ion. 
f Fragmentation pattern obtained from MS/MS of its ammonium adduct (m/z: 336). 
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Table  5.6. Proposed structures for fragment ions of EE2a 
m/z Proposed Structure m/z Proposed Structure 
297 
(EE2) 
HO
CH3
OH2+
 
185
HO  
279 
HO
CH3
 
173b
+H2O    
CH3
 
251b 
HO
CH3
 
HO
CH3
 
159b HO    
CH3
 
239 
HO  
147
+H2O  
223 
HO
CH3
 
133b
+H2O      
CH3
 
209 
HO  
107
CH3
 
197 
HO  
91 
 
a For the fragmentation pathways leading to the formation of the proposed fragment ions, a previous report [56] on mass spectra 
interpretation of steroids is referred. 
b Two plausible structures are proposed. The fragment ion could be either one of the two or could be a mixture of the two.  
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Table  5.7. Formation of EE2 reaction products under different Mn(VII) dosing 
 [EE2]0/[Mn(VII)]0 
Product ID 
1:0.4 1:1.2 1:2 1:5 
I  √ √ √ 
II √ √ √ √ 
III  √ √ √ 
IV √ √ √ √ 
V √ √ √ √ 
VI    √ 
VII √ √ √ √ 
VIII √ √ √ √ 
IX √ √ √ √ 
 
 
 
 
 
Table  5.8. Utility source water characteristics 
 Utility 1 Utility 2 Utility 3 Utility 4
Source Water Type Reservoir River River Reservoir
Ammonia (mg/L as N) 0.3 0.4 0.6 0.2 
Alkalinity (mg/L as 
CaCO3) 
144 92 70 100 
TOC (mg/L) 4.3 N/Da 1.3 N/Da 
TSS (mg/L) 5.3 1.2 20 < 1 
TDS (mg/L) 174 556 177 617 
Chloride (mg/L) 36 295 17.2 88.1 
Nitrate (mg/L) 12 14.2 6.2 8.0 
Sulfate (mg/L) 13 24.6 46.3 238 
a Below detection limit.  
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CHAPTER 6  
INACTIVATION KINETICS OF BACTERIOPHAGE MS2 WITH 
POTASSIUM FERRATE(VI)  
6.1 Abstract 
Alternative disinfectants are needed to control viral pathogens while limiting the formation 
of toxic disinfection byproducts during water and wastewater treatment. This study investigates 
the potential of an emerging oxidant, ferrate [FeO42-, Fe(VI)], as an alternative disinfectant. Batch 
kinetics experiments were conducted to quantify the inactivation kinetics of bacteriophage MS2, a 
surrogate for human enteric viruses, with potassium ferrate(VI) at 5-30 oC, pH 6-11 and Fe(VI) 
doses of 0.56 – 2.24 mg/L as Fe. The Chick-Watson model was able to describe the inactivation 
kinetics observed in individual batch experiments. The observed inactivation rate constant [kobs; 
L/(mg Fe·min)] was found to be independent of initial MS2 concentration. Fe(VI) 
autodecomposes rapidly in circumneutral pH water, but kobs was found to increase with increasing 
applied dosage of Fe(VI), possibly due to formation of a secondary disinfecting species during 
Fe(VI) decomposition. At pH 7 and 25 oC and with a Fe(VI) dose of 1.23 mg/L as Fe, the kobs value 
was measured to be 2.27(±0.05) L/(mg Fe·min), corresponding to a 4-log removal with a Ct of 4 
(mg Fe·min)/L. The temperature dependence of kobs could be described by the Arrhenius equation 
with an apparent activation energy of 39(±6) kJ mol-1. pH was found to significantly affect 
inactivation kinetics, with kobs increasing from 0.043 L/(mg Fe·min) to 2.44 L/(mg Fe·min) when 
pH decreased from 11 to 6 (applied Fe(VI) dose of 1.12 mg/L as Fe). The effect of pH can be 
modeled by considering parallel MS2 inactivation processes involving different Fe(VI) species 
(HFeO4- and FeO42-), with the protonated Fe(VI) species being 54 times more reactive with MS2 
than its conjugate base. Results from this study and previous reports on ferrate’s high reactivity 
with many water contaminants suggest that ferrate has significant potential as a drinking water 
oxidant and disinfectanting agent.  
6.2 Introduction 
Disinfection processes using free chlorine as the primary disinfectant have been applied in 
drinking water facilities to control bacteria, viruses, and other pathogenic microorganisms for over 
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a century [1]. However, the Long Term 2 Enhanced Surface Water Treatment Rule and Stage 2 
Disinfectants and Disinfection Byproducts Rule, released by the U.S. Environmental Protection 
Agency (USEPA) in 2006 in response to the need for better control of Cryptosporidium parvum 
oocysts and toxic disinfection byproducts (DBPs) [2, 3], has prompted many U.S. drinking water 
utilities to replace free chlorine as the primary disinfectant with alternative processes, most often 
UV disinfection or treatment with combined chlorine. This practice has raised serious concerns on 
the presence of viral pathogens in drinking water [4-6], especially enteric viruses, because viruses 
are much more resistant to UV light and combined chlorine than to free chlorine [1, 7]. In addition, a 
growing body of work shows that combined chlorine promotes formation of emerging classes of 
DBPs that are more toxic than regulated THM and TAA DBPs [8-10]. As a result, there remains 
strong interest in the development of alternative disinfection processes that are effective in both 
inactivating viral pathogens and producing fewer and less toxic DBPs than free chlorine [11, 12]. 
Potassium ferrate [K2FeO4, Fe(VI)] is a hypervalent form of iron that has attracted growing 
attention in recent years as an alternative oxidant and disinfectant for water and wastewater 
treatment [13-19]. Fe(VI) could be a promising alternative disinfectant for several reasons: (i) Fe(VI) 
is a strong oxidant reported to selectively oxidize amino acids and other biomolecules [20, 21]; (ii) 
past work has shown that Fe(VI) inactivates several pathogens, including coliphages f2 and Qβ, 
and E. coli [22-24]; (iii) the application of Fe(VI) is not believed to produce halogenated DBPs 
known to be mutagenic or carcinogenic [25, 26]; (iv) Fe(VI) does not oxidize bromide to bromate 
like ozone [27];  (v) the Fe(OH)3(s) byproduct of Fe(VI) reactions and autodecomposition can also 
act to promote physical removal of pathogens and secondary DBP precursors during sedimentation 
and filtration processes [15, 17], and (vi) Fe(VI) is more stable in organic-rich and ammonia-rich 
waters than O3 and free chlorine [28]. 
This study examines for the first time Fe(VI) inactivation of bacteriophage MS2. MS2 is a 
commonly studied non-pathogenic surrogate for human enteric viruses found in drinking water [29, 
30]. MS2 is a positive-sense single-stranded RNA phage that propagates in E. coli. The molecular 
structure of MS2 is well-characterized, with a small genome of 3,569 nucleotides, the full 
sequence of which has been established [31]. It possesses an icosahedral shape with a diameter of 
27-34 nm and an isoelectric point of 3.9 [32, 33]. Previous studies have examined MS2 phage 
inactivation by common water disinfectants [34-38], including free chlorine, monochloramine, 
ozone, hydrogen peroxide, and chlorine dioxide, thereby enabling comparison with Fe(VI) studies 
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presented here. Objectives of this study were to quantify the process of MS2 inactivation by 
Fe(VI), including determining the inactivation rate law and obtaining kinetic parameters as a 
function of varying initial MS2 phage concentration, applied Fe(VI) dose, temperature and 
solution pH. The resulting kinetics trends were also used to infer mechanistic insights into the 
controlling inactivation mechanisms. 
6.3 Materials and Methods 
6.3.1 Virus Propagation and Viability Assessment 
Bacteriophage MS2 (ATCC 15597-B1) and its bacterial host E. coli (ATCC 15997) were 
obtained from the American type culture collection (Manassas, VA). E. coli cells were grown and 
maintained using slants and tryptic soy broth (TSB) suspensions, and stored at 4 oC prior to use. 
MS2 stocks were grown in E. coli suspensions and purified by sequential centrifugation, 
microfiltration and ultrafiltration as reported previously [39]. The final concentrate from the 
ultrafiltration membrane was then diluted in 1 mM phosphate buffer solution (PBS) to a final MS2 
concentration of 1011 plaque forming units per mililiter (pfu/mL) and stored at 4 oC until use. 
MS2 phage concentration was determined by MS2 viability assessment with the soft agar 
overlay method [40]. In general, quenched MS2 samples from inactivation experiments underwent 
serial dilutions with TSB solutions. Each dilution was then mixed with the host bacteria E. coli 
solution in TSB and soft agar, and the mixture was spread onto pre-prepared hard agar plates. After 
solidification, the plates were inverted and incubated at 37 oC overnight. The plaques formed were 
then visually enumerated to quantify the MS2 phage concentration. 
6.3.2 Ferrate(VI) Preparation and Measurement 
K2FeO4 was prepared according to a method reported by Delaude and Laszlo [41], yielding a 
material with an iron content that is 98% Fe(VI). Fe(VI) stock solutions were prepared in 5 mM 
phosphate/1 mM borate buffer mixture (pH ~9.1), where aqueous Fe(VI) is reported to be most 
stable [20, 42]. Stock solutions were used within 30 min of preparation to minimize artifacts from 
Fe(VI) decomposition. 
A colorimetric method described by Lee et. al. [43] was used to determine Fe(VI) 
concentrations. In this method, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonate) (ABTS) is 
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rapidly oxidized by Fe(VI) to produce a stable radical cation, ABTSy+, with high molecular 
absorptivity (ε415 nm = 34,000 M-1 cm-1), which permits sensitive detection by UV-visible 
spectrophotometry.  
6.3.3 MS2 Inactivation Experiments 
Inactivation experiments were conducted in a 200 mL continuously stirred batch reactor 
immersed in a circulating constant temperature water bath. To minimize Fe(VI) 
autodecomposition, Fe(VI) stock solution was added to buffered (10 mM phosphate for pH<9, and 
10 mM phosphate/2 mM borate for pH 9-11) and pH-adjusted solutions shortly before initiating 
reactions. Reactions were initiated by spiking MS2 phage stock solution into the reactor, while 
simultaneously withdrawing an aliquot of reactor solution to quantify the initial Fe(VI) 
concentration. Due to Fe(VI) autodecomposition, the initial Fe(VI) concentration differed from the 
applied Fe(VI) dose. Aliquots were then periodically collected to monitor reaction progress. Two 
aliquots were collected at each time point, one for MS2 phage viability assessment and one for 
analysis of Fe(VI) concentration. The aliquot collected for MS2 viability assessment was 
quenched with excess sodium thiosulfate, which quickly reduces Fe(VI) to Fe(III) [44]. The 
remaining viable MS2 phage concentration was then determined by the soft agar overlay method. 
The other aliquot was mixed with excess ABTS and a buffer mixture of acetate and phosphate (pH 
4.1), which prevents the precipitation of Fe(III) and avoids interference of the optical monitoring 
from Fe(III) precipitates [45]. The remaining Fe(VI) concentration in each sample was then 
analyzed as ABTS·+ by spectrophotometry within 1 hour. 
6.4 Results and Discussion 
6.4.1 Inactivation Kinetics Model 
Experimental results show that MS2 phage can be effectively inactivated by Fe(VI). 
Figure  6.1A shows a representative inactivation data for MS2 phage in Fe(VI)-treated solution at 
pH 7.0. The individual batch inactivation kinetics is well described by the Chick-Watson model: 
 Ctkobs
0N
Nln −=⎟⎟⎠
⎞
⎜⎜⎝
⎛
  ( 6.1) 
where N0 and N are MS2 phage concentrations initially present and following a treatment time t, 
 158 
respectively; kobs [L/(mg Fe·min)] is the observed MS2 phage inactivation rate constant at the 
experimental conditions in question; and Ct ( ( )[ ]∫ t0 dttotVIFe , (mg Fe·min)/L) is the integrated exposure 
to Fe(VI) as the reaction proceeds, which accounts for Fe(VI) decay during batch experiments. 
Previous studies established that Fe(VI) decay follows second-order kinetics with respect of Fe(VI) 
concentration [46], which is also observed in our studies (Figure  6.1B). As a result, Ct values 
corresponding to different reaction times can be calculated as: 
 ( )[ ] ( )[ ]( )[ ] ( )[ ] )1VIFeln(1)dt1VIFe
VIFe
(dtVIFe 0d
t
0 0d
0t
0
+=+== ∫∫ tkktkCt d   ( 6.2) 
where kd (L/(mg Fe·min)) is the second-order rate constant of Fe(VI) autodecomposition observed 
in each batch reaction. As shown in Figure  6.1B, second-order fit-derived kd at pH 7 and 25 oC is 
0.102 L/(mg Fe·min), which is slower than two previously reported values. Cho et al. [24] measured 
a kd of 0.135 L/(mg Fe·min) at pH 7.1 and 25 oC, while the model fitting from Rush et al. [46] 
indicated a kd of 0.214 L/(mg Fe·min). The different kd values might be due to different 
experimental conditions used (e.g., buffer concentration, temperature, and presence/absence of 
pathogens) [24]. Nevertheless, the relatively slower kd value observed here indicates the Fe(VI) 
decay is predominantly from autodecomposition instead of reactions with MS2 phage or the broth 
as suggested by Schink et al [22]. The experimental conditions for each batch inactivation 
experiment and measured kobs and kd values are summarized in Table  6.1.  
As shown in Figure  6.1A, the Chick-Watson model described in Equation ( 1.1) fits well 
with the measured data and the fitted inactivation rate constant is 2.27(±0.05) L/(mg Fe·min) at pH 
7 and 25 oC, corresponding to a 4-log inactivation with a Ct of ~4 (mg Fe·min)/L. Comparing with 
Fe(VI), ozone, free chlorine, and chlorine dioxide are more effective towards MS2 phage 
inactivation, whereas monochloramine is much less effective and hydrogen peroxide does not 
inactivate MS2 phage [34-38]. Shin et al. reported that an applied ozone dose of 0.37 mg/L can 
inactivate >3-log of MS2 phage within 10 s at pH 7 and 5 oC [38]. Barbeau et al. [34, 35] reported a 
free chlorine Ct of 0.45 mg·min/L and a chlorine dioxide Ct of 1.47 mg·min/L were required to 
achieve a 4-log removal of MS2 at pH 6.5 and 7 oC, respectively. In comparison, 2 mg/L 
monochloramine yielded only 1-log inactivation after 3 hrs of contact time at pH 8 and 5 oC [37]. 
Although Fe(VI) is a weaker disinfectant for MS2 phage when compared to ozone and free 
chlorine, Fe(VI) is also less reactive with many solution matrix components [28], which may lead to 
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comparable efficient disinfection (i.e., ∆N per applied disinfectant dose) in natural waters with 
high disinfectant demand. 
The susceptibility of MS2 phage to Fe(VI) oxidation is comparable to two other phages, f2 
and Qβ, both of which are single stranded RNA coliphages and have been used as model pathogens 
for enteric viruses [22, 23]. Schink et al. [22] reported that a contact time of 5.7 min is required to 
obtain a 2-log inactivation of f2 phage with 0.28 mg/L Fe(VI) at pH 6.9 and 24 oC, while Kazama 
et al. [23] reported a contact time of 5 min is required to achieve 2-log inactivation of Qβ phage with 
0.4 mg/L Fe(VI) at pH 7 and 25 oC. However, inactivation of E. coli by Fe(VI) was reported with a 
kobs value of 0.625 L/(mg Fe·min) [24], 72% slower than the kobs measured for MS2 phage, 
suggesting much different Fe(VI) inactivating mechanisms between bacteria and viruses. 
6.4.2 Effect of Initial MS2 Concentration and Fe(VI) Concentration 
Figure  6.2 shows the effect of initial MS2 concentration on the inactivation kinetics. From 
Figure  6.2, we can see that there is no significant difference in the kinetic profiles observed for 
MS2 inactivation using different N0 values (ranging from 4.3×105 to 1.3×107) and the measured 
data from five sets of inactivation experiments can be described reasonably well by the 
Chick-Watson model with a single kobs value, suggesting that the kinetics of MS2 phage 
inactivation is not sensitive to initial phage concentration, as is commonly reported for disinfection 
processes [7, 47]. 
The effect of dosed Fe(VI) concentration on the inactivation kinetics was also investigated. 
As expected and predicted by the Chick-Watson rate law, higher inactivation rates (dN/dt) were 
observed with increased Fe(VI) doses. However, according to Equation ( 1.1), the observed 
inactivation rate constant (kobs) should be independent of the initial Fe(VI) concentration because 
the term Ct already incorporates the variation of Fe(VI) concentration. However, Figure  6.3 shows 
the MS2 inactivation profiles for batch inactivation experiments with different dosed Fe(VI) 
concentration, and it can be seen that the inactivation rate constant increased with the increases in 
the applied Fe(VI) dose. When target dosed Fe(VI) concentration increases by a factor of 4 (from 
0.56 to 2.24 mg/L), kobs increases roughly the same amount from 1.44(±0.03) L/(mg Fe·min) to 
4.5(±0.02) L/(mg Fe·min). This result is surprising because a previous study on the inactivation of 
E. coli by Fe(VI) reported that the Chick-Watson inactivation rate constant was independent of 
Fe(VI) dose [24]. In addition, it should be noted that the dosed [Fe(VI)] is different from the actual 
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measured [Fe(VI)]0 due to the Fe(VI) autodecomposition occurring during two time lapses: (1) 
between Fe(VI) stock preparation and use, and (2) between Fe(VI) stock addition to the batch 
reactions and the time when MS2 phage is added to initiate the reaction (Table  6.1 listed the 
measured [Fe(VI)]0 for each experiment). The actual measured [Fe(VI)]0 for Exp. 7 and Exp. 8 is 
only ~1.4 mg/L (applied dose ~2.2 mg/L), close to the measured [Fe(VI)]0 of Exp. 1, but kobs 
values obtained in Exp. 7 and Exp. 8 are roughly twice the value measured in Exp.1. Therefore, the 
improved inactivation efficiency at higher dosed [Fe(VI)]0 would not seem to be directly resulting 
from a higher concentration of Fe(VI) in solution, but rather some byproducts of the Fe(VI) 
decomposition process. Kazama [48] reported a similar phenomenon where solutions containing 
completely decomposed Fe(VI) still possessed inactivating capacity for coliphage Qβ, and the 
involvement of long-lived oxidative intermediate species from Fe(VI) decomposition was 
proposed. Further research is needed to identify the active species. Although kinetics experiments 
were conducted for the same target Fe(VI) dose, exact replication of Fe(VI) dose and initial Fe(VI) 
concentration was difficult due to Fe(VI)’s instability in aqueous solution (Table  6.1). 
6.4.3 Effect of Temperature 
Figure  6.4 shows effects of temperature on MS2 phage inactivation by Fe(VI). As 
expected, rates of inactivation increase with increasing temperature. When temperature increases 
from 5 oC to 30 oC, kobs increases by nearly a factor of 4 from 7.7(±0.2)×10-1 L/(mg Fe·min) to 
3.0(±0.2) L/(mg Fe·min). The Fe(VI) autodecomposition was found to be less temperature 
dependent compared to the inactivation of MS2 phage. From 5 oC to 30 oC, measured kd only 
increased by 70% from 5.8(±0.4)×10-2 L/(mg Fe·min) to 9.9(±0.9)×10-2 L/(mg Fe·min) (Table  6.1). 
The temperature dependence of MS2 phage inactivation can be described by the Arrhenius 
equation: 
 )ln(1)ln( aobs ATR
Ek +⋅−=   ( 6.3) 
where Ea is the apparent activation energy, R is the universal gas constant, and A is the 
pre-exponential constant. At pH 7, Ea for MS2 phage inactivation by Fe(VI) was determined to be 
39(±6) kJ/mol, corresponding to a doubling of inactivation rates every 13 oC increase in 
temperature. Fe(VI) autodecomposition was found to have a much weaker temperature 
dependence compared to MS2 inactivation process, with a fit-derived activation energy of 14(±2) 
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kJ/mol, corresponding to a doubling of rates every 42 oC increase in temperature. For practical 
treatment applications, it will be important to know how the temperature dependence of 
inactivation process compares to the Fe(VI) reactions with non-target water constituents that 
consume Fe(VI).  
6.4.4 Effect of pH 
Figure  6.5A shows the effect of pH on the kinetics profiles of MS2 phage inactivation. It 
can be seen that inactivation kinetics is highly dependent on pH, with higher inactivation rates 
occurring at lower pH conditions. When pH decreases from 11 to 6, a 50-fold increase in kobs was 
observed (Figure  6.5B). In general, Fe(VI) exhibits higher oxidation and disinfection activity at 
lower pH [22, 23, 49], a trend attributed to the changing acid-base speciation of Fe(VI). Under the pH 
range studied, Fe(VI) is characterized by three acid-base species related by two pKas [20]: 
 H2FeO4 = H+ + HFeO4-, pKa1 = 3.5  ( 6.4) 
 HFeO4- = H+ + FeO42-, pKa2 = 7.3  ( 6.5) 
A number of studies have shown that protonated Fe(VI) species (H2FeO4 and HFeO4-) are much 
stronger oxidants than deprotonated FeO42- [20, 49, 50]. Protonation of FeO42- reduces the 
electron-donating capacity of the coordinated oxygen ligands, thereby making the metal center a 
stronger oxidant [51]. In addition, it is possible that protonation reduces electrostatic repulsion 
between the negatively charged MS2 particulate and Fe(VI) species and thus enhances its 
reactivity. 
To quantitatively model the observed pH effect, an inactivation model considering parallel 
MS2 phage inactivation by different Fe(VI) species can be considered: 
 H2FeO4 + MS2 Æ Fe(III) + MS2inactivated  kα1  ( 6.6) 
 HFeO4- + MS2 Æ Fe(III) + MS2inactivated  kα2  ( 6.7) 
 FeO42- + MS2 Æ Fe(III) + MS2inactivated  kα3  ( 6.8) 
where kαi (i = 1, 2, 3) is the Fe(VI) species-specific inactivation rate constant. Assuming each 
inactivation process with Fe(VI) species also follows Chick-Watson law and assuming that 
equilibrium between Fe(VI) species is maintained during reaction with MS2 phage, the total 
inactivation of MS2 phage can be expressed as: 
 ( )∫++=⎟⎟⎠
⎞
⎜⎜⎝
⎛ t
tkkk
0 tot332211
0
]VI)(Fe[-
N
Nln ααα ααα   ( 6.9) 
 162 
where αi (i =1, 2, 3) is the pH-dependent fractional concentration of each Fe(VI) species, which 
can be calculated using pKa values listed in Equations ( 6.4) and ( 6.5). Combining Equations ( 1.1) 
and ( 6.9), we can get 
 332211obs ααα ααα kkkk ++=   ( 6.10) 
Thus, kαi (i = 1, 2, 3) can be determined by fitting the trend in kobs measured at different pH 
conditions. Scientist® for Windows® was used for the fitting process and results are shown in 
Figure  6.5B. Fitting results show that the kinetics model depicted by Equation ( 6.10) fits well with 
experimental data. Contribution from the fully protonated species (H2FeO4) was found to be 
negligible due to its extremely low concentration in the pH range studied. The fit-derived 
species-specific inactivation rate constants and the inactivation contribution from individual Fe(VI) 
species are shown in Figure  6.5B. As expected, the mono-protonated species (HFeO4-) was found 
to exhibit ~50 times higher reactivity with MS2 phage compared to the fully deprotonated species 
(FeO42-), with kα2 = 3.8(±0.5) L/(mg Fe·min) and kα3 = 0.07(±0.1) L/(mg Fe·min). This result is in 
line with our previous study [49] on Fe(VI) oxidation of a neutral drug carbamazepine, which 
showed the reactivity of HFeO4- being much higher than that of FeO42-. Cho et al. [24] also reported 
that the reactivity of HFeO4- on E. coli inactivation is 3 times higher than that of FeO42- while the 
fully protonated Fe(VI) species (H2FeO4) exhibits reactivity two orders of magnitude higher than 
the two deprotonated Fe(VI) species. 
6.4.5 Mechanistic Considerations 
The MS2 virus particle is composed of three parts: the genome RNA, the maturation 
protein (A-protein), and the coat protein [31, 32]. Because the viral RNA and the A-protein are 
protected in an icosahedral shell of the coat protein [32] and the active Fe(VI) oxidizing species is 
ionic, the loss of MS2 phage infectivity by Fe(VI) oxidation is likely due to oxidative structural 
alteration to the coat protein. Valegard et al. [32] established the 3-dimentional structure of MS2 
phage and revealed that the building block of the icosahedral shell has a hydrophobic surface 
containing eight amino acids, including cysteine (101), methionine (108), proline (117), two 
leucines (111 and 112), and three isoleucines (104, 118, and 119). Among them, only cysteine and 
methionine have side chains that are expected to have high reactivity with Fe(VI). Johnston and 
Read [44] reported a pH-independent second-order rate constant for HFeO4- reaction with 
methionine (analogous to kα2 in this study) to be 6.5×103 M-1 s-1, which is comparable to the 
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observed kα2 here (3.8 L/(mg Fe·min), equivalent to a bimolecular rate constant of 3.5×103 M-1 s-1). 
Reaction of Fe(VI) with cysteine was reported to be much faster than methionine with an observed 
apparent second-order rate constant of 1×105 M-1 s-1 at pH 10.17 [52], whereas the apparent MS2 
phage inactivation rate constant with Fe(VI) at pH 10 is only 7.8×101 M-1 s-1. Therefore, it seems 
methionine 108 is the more likely site of inactivation by Fe(VI). However, the reactivity of amino 
acid in its free form might be quite different from its reactivity in peptides, where there is a more 
complex environment. Thus, we can not exclude the possibility of cysteine 101 or other amino 
acids being the site of inactivation by Fe(VI). In fact, Wigginton et al. [53] identified cysteine 101 as 
the active site in MS2 phage inactivation by 1O2. To confirm the site of oxidation, further analysis 
of the virus coat protein using mass spectrometry methods as demonstrated by Wigginton et al. 
[53]could be applied. Further research is also required to probe the inactivation mechanism at a 
molecular microbiological level, to identify the MS2 phage life cycle event (e.g., attachment, cell 
entry, genome ejection, A-protein assembly) responsible for the loss of its infectivity after 
reacting with Fe(VI) [54, 55]. 
Results in this study show that Fe(VI) is a promising alternative disinfectant for water 
treatment. Fe(VI) effectively inactivates MS2 phage: a 2-log removal of MS2 phage can be 
achieved with 1 mg/L Fe(VI) dose and a contact time of 2 min at pH 7 and 25 oC. Individual 
batch inactivation experiments can be fitted with the Chick-Watson model, and the inactivation 
rate constant was found to be dependent on Fe(VI) dose, temperature and pH. The effect of pH 
was successfully modeled by considering parallel reactions of different Fe(VI) species with MS2 
phage. The methionine 101 residue on the MS2 coat protein surface was suspected to be the 
reactive site of inactivation by Fe(VI) due to comparable kinetics of the two processes. However, 
research is needed to further identify the site(s) of attack and investigate the inactivation 
mechanism in greater detail.  
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6.6 Figures and Tables 
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Figure  6.1. (A) Inactivation kinetics of MS2 phage by Fe(VI), and (B) Fe(VI) decay during 
the batch experiments (inset shows second-order rate law fit for Fe(VI) autodecomposition). 
Experimental conditions: N0 = 4.3×105 pfu/mL, [Fe(VI)]0 = 1.23 mg Fe/L, pH = 7 (10 mM 
phosphate), 25 oC. Uncertainties represent 1 σ. 
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Figure  6.2. Effect of initial MS2 phage concentration on the inactivation kinetics at pH 7 
and 25 oC. Experimental conditions are listed in Table  6.1. The line and kobs shown are from 
a single regression with the five data sets combined. Uncertainty represents 1 σ. 
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Figure  6.3. Effect of Fe(VI) dose on MS2 phage inactivation kinetics at pH 7 and 25 oC. 
Experimental conditions are listed in Table  6.1. 
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Figure  6.4. Effect of temperature on the MS2 inactivation kinetics at pH 7. (A) kinetics 
profiles; (B) Arrhenius fitting, dashed lines show 95% confidence intervals. Experimental 
conditions are listed in Table  6.1. Uncertainty in Ea represents 1 σ. 
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Figure  6.5. Effect of pH on the MS2 phage inactivation kinetics at 25 oC. (A) Inactivation 
kinetics profiles; (B) Model fitting results with Equation ( 6.10) (solid line) and contribution 
from individual Fe(VI) species: HFeO4- (dashed line), FeO42- (dotted line). Experimental 
conditions are listed in Table  6.1. Uncertainties represent 1 σ. 
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Table  6.1. Experimental conditions, measured inactivation rate constants, and second-order constants of Fe(VI) decay for each 
inactivation experiment 
Exp. ID pH T (oC) Buffera 
Measured N0 
(pfu/mL) 
Measured [Fe(VI)]0b 
(mg Fe/L) 
kobsc 
(L/(mg Fe·min))
kdd 
 (L/(mg Fe·min)) 
1 7 25 10 mM PBS 4.3×105 1.23 2.27(±0.05) 1.02(±0.04)×10-1 
2 7 25 10 mM PBS 1.3×107 1.35 2.3 (±0.2) 9.3(±0.7)×10-2 
3 7 25 10 mM PBS 6.6×105 1.23 2.37(±0.05) 1.09(±0.08)×10-1 
4 7 25 10 mM PBS 2.1×106 1.36 2.9(±0.4) 9.3(±0.1)×10-2 
5 7 25 10 mM PBS 4.0×106 1.37 2.2(±0.1) 9.6(±0.9)×10-2 
6 7 25 10 mM PBS 7.3×106 0.57e 1.44(±0.03) 1.03(±0.03)×10-1 
7 7 25 10 mM PBS 7.3×106 1.43f 4.7(±0.5) 3(±1)×10-2 
8 7 25 10 mM PBS 1.1×107 1.42f 4.5(±0.2) 3.7(±0.3)×10-2 
9 7 5 10 mM PBS 4.4×104 1.46 7.7(±0.2)×10-1 5.8(±0.4)×10-2 
10 7 10 10 mM PBS 1.3×105 1.22 9.9(±0.3)×10-1 7.3(±0.2)×10-2 
11 7 15 10 mM PBS 1.6×105 1.26 9.2(±0.3)×10-1 8.1(±0.1)×10-2 
12 7 20 10 mM PBS 3.2×105 0.95 1.49(±0.04) 8.3(±0.2)×10-2 
13 7 30 10 mM PBS 1.7×105 1.44 3.0(±0.2) 9.9(±0.9)×10-2 
14 6 25 10 mM PBS 8.8×105 1.14 2.44(±0.04) 2.3(±0.1)×10-1 
15 6.5 25 10 mM PBS 2.6×105 1.24 2.42(±0.09) 1.5(±0.1)×10-1 
16 7.5 25 10 mM PBS 1.1×106 1.52 1.66(±0.04) 8.5(±0.9)×10-3 
17 8 25 10 mM PBS 7.4×105 1.63 1.14(±0.04) <1×10-3 
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Table  6.1. (cont.) 
Exp. ID pH T (oC) Buffera 
Measured N0 
(pfu/mL) 
Measured [Fe(VI)]0b 
(mg Fe/L) 
kobsc 
(L/(mg Fe·min)) 
kdd 
 (L/(mg Fe·min)) 
18 8.5 25 10 mM PBS 1.7×106 1.54 2.8(±0.1)×10-1 <1×10-3 
19 9 25 10 mM PBS/2 mM BBS 1.7×106 1.56 1.8(±0.1)×10-1 <1×10-3 
20 9.5 25 10 mM PBS/2 mM BBS 5.9×106 1.33 1.2(±0.1)×10-1 <1×10-3 
21 10 25 10 mM PBS/2 mM BBS 7.3×106 1.36 8.4(±0.1)×10-2 <1×10-3 
22 11 25 10 mM PBS/2 mM BBS 2.7×106 1.24 4.3(±0.1)×10-2 <1×10-3 
a  PBS: phosphate buffer solutions; BBS: borate buffer solutions.  
b  Unless otherwise noted, the applied target initial Fe(VI) dose is 1.12 mg/L (20 µM). The actual measured initial Fe(VI) concentration varies because of the lapse between Fe(VI) 
stock addition and the reaction initiation (MS2 phage stock spiking). 
c  Apparent inactivation rate constant from Chick-Watson model fitting. 
d  Second-order rate constant of Fe(VI) autodecomposition. 
e  Target initial Fe(VI) concentration was 0.56 mg/L (10 µM). 
f  Target initial Fe(VI) concentration was 2.24 mg/L (40 µM). The actual measured [Fe(VI)]0 is much smaller due to faster Fe(VI) autodecomposition at higher initial concentration 
[46]. 
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CHAPTER 7  
SUMMARY AND CONCLUSIONS 
7.1 General Summary 
This study provides the first systematic assessment of the reactivity of Mn(VII) and 
Fe(VI) with widely detected classes of organic micropollutants and Fe(VI) reactions with the 
commonly studied viral surrogate, MS2 bacteriophage. Results from this study demonstrate the 
effectiveness of using Mn(VII) and Fe(VI) salts to selectively treat a number of important PhACs 
and a representative viral pathogen. Both Mn(VII) and Fe(VI) are selective oxidants that target 
compounds with specific electron-rich moieties, including olefinic, phenolic, amino, cyclopropyl, 
thioether, and alkyne groups. Table  7.1 summarizes the reactivity of surveyed PhACs with 
Mn(VII) and Fe(VI). The proposed reactive groups in each PhAC are also listed. It is likely that 
other organic contaminants with above listed functional groups will also be susceptible to 
Mn(VII) and Fe(VI) oxidation. Fe(VI) was also found to be effective towards inactivation of a 
viral pathogen, MS2 bacteriophage. 
The reaction kinetics of Mn(VII) oxidation of several representative PhACs and Fe(VI) 
oxidation of carbamazepine were carefully characterized for the first time. The effects of 
Mn(VII)/Fe(VI) concentration, PhAC concentration, temperature, and pH on reaction rates were 
investigated and corresponding kinetic parameters were determined. Oxidation of PhACs by 
Mn(VII) and Fe(VI) can be described by second-order kinetics models and temperature 
dependence of the reactions can be described using the Arrhenius equation. Solution pH was 
found to be an important factor that affects the reaction rate constants with most PhACs. The pH 
dependent trends can often be explained by the change of electron density on the target reactive 
group upon protonation/deprotonation. The pH dependences of PhAC reaction rates can also be 
quantitatively described using models that account for changing acid-base speciation of the target 
PhACs and oxidant. These models assume parallel reactions between individual PhAC species 
and individual oxidant species with characteristic rate constants. Table  7.2 summarizes the kinetic 
parameters for the representative PhACs studied in Chapters 2-5. In general, O3 exhibits higher 
reactivity than Mn(VII) with all PhACs, while NH2Cl is a weaker oxidant than Mn(VII) and an 
overall superior reactivity of HOCl and ClO2 to Mn(VII) is not seen. Notably, carbamazepine, a 
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PhAC with prevalent occurrence in U.S. stream water/source water [1], is resistant to HOCl and 
ClO2, but shows high reactivity with Mn(VII).     
The effect of non-target water constituents on the Mn(VII) oxidation kinetics was 
extensively studied with one representative PhAC, carbamazepine. Most common non-target 
water constituents were found to have negligible effects on reaction kinetics, while the effect of 
reduced species, e.g., Fe(II), Mn(II), S(-II), can be accounted for by assuming a stoichiometric 
permanganate demand of the constituents that lowers the effective concentration of permanganate 
available for reactions with the PhACs of interest. A practical kinetics model that takes into 
account the applied Mn(VII) dose, temperature, pH, and Mn(VII) demand of non-target water 
constituents was then developed to predict the extent of PhAC oxidation by Mn(VII) at relevant 
water treatment conditions. Tests in utility source waters with more environmentally-relevant 
concentrations of PhACs validated the applicability of the predictive kinetic model. 
Products from Mn(VII) and Fe(VI) oxidation reactions with representative PhACs were 
identified and corresponding reaction pathways were proposed. Product analysis results show that 
the target micropollutants are incompletely oxidized by Mn(VII) and Fe(VI) and a variety of 
products with partial structural modification to the parent compounds are produced. Oxidation 
products were identified for carbamazepine, ciprofloxacin, lincomysin, trimethoprim, and 
17α-ethinylestradiol using liquid chromatography-tandem mass spectrometry methods. Oxidation 
of olefinic, phenolic, amino, cyclopropyl, thioether, and alkyne groups lead to a variety of oxygen 
insertion products (e.g., alcohol, ketone, amide, and sulfone), dehydrogenation and dealkylation 
products, oxidative ring-cleavage products (aldehyde, amide, and carboxylic acid), as well as 
some rearrangement products from reaction intermediates. 
Since little mineralization was achieved during Mn(VII) and Fe(VI) oxidation, bioassay 
studies were also conducted to quantify the pharmaceutical potency of PhAC solutions after 
Mn(VII) treatment. For three representative antibiotics, ciprofloxacin, lincomysin, and 
trimethoprim, bioassays quantifying the antibacterial activity of ciprofloxacin and trimethoprim 
solutions before and after treatment with Mn(VII) indicate that oxidation products exhibit 
negligible antibacterial activity in comparison with the parent antibiotic compounds. The 
reduction of antibacterial activity was also related to the proposed oxidation products and 
pathways. Mn(VII) oxidation produces products that either disrupt the intactness of an essential 
molecular moiety or possess structural modifications that were reported to significantly reduce 
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the parent compound’s potency. 
Inactivation experiments with MS2 phage show that Fe(VI) is a promising alternative 
disinfectant for viral pathogens. The inactivation kinetics of individual batch experiments can be 
described by the Chick-Watson model and the reaction rates were found to be highly dependent 
on pH. Similar to PhAC reactions with Mn(VII) and Fe(VI), the pH effect can be modeled by 
considering the changing speciation of Fe(VI) and assuming parallel inactivation pathways for 
each Fe(VI) species. The kinetic parameters obtained for the MS2 phage inactivation by Fe(VI) 
are also listed in Table  7.2. In general, Fe(VI) is more effective towards MS2 phage inactivation 
than monochloramine and hydrogen peroxide, while less effective than ozone, free chlorine, and 
chlorine dioxide. The susceptibility of MS2 phage to Fe(VI) is comparable to two other phages, 
f2 and Qβ, but higher than E. coli, a bacterial pathogen. 
7.2 Applicability of Results to Water and Wastewater Treatment 
Results from this study advanced our understanding on the fate of many PhACs in 
treatment plants that currently apply Mn(VII) for the control of manganese and iron, taste and 
odor, biofouling, etc. Results suggest that PhACs containing phenolic, olefinic, amine, thioether, 
and alkyne groups will be oxidized to some degree during existing Mn(VII) treatment processes. 
Bioassay tests with several representative PhACs confirm that partial oxidation of PhACs can 
greatly reduce their pharmaceutical potency. For the representative PhACs studied, the predictive 
kinetic model developed in this work can help utilities predict the level of removal in existing 
Mn(VII) treatment processes or determine Mn(VII) dosing and reactor residence time 
requirements for achieving a desired level of removal. 
Although permanganate is not often used at wastewater treatment facilities, it may be an 
effective approach for selectively oxidizing Mn(VII)-reactive PhACs (e.g., carbamazepine, 
phenolic EDCs) in these facilities. Less selective oxidants, such as ·OH, O3, and HOCl, although 
highly reactive with many of the same PhACs, might be inefficient within such matrices because 
their lower stability and the rapid scavenging of these oxidants by the high levels of organic matter 
and/or ammonia in the water. In contrast, the more selective Mn(VII) persists for longer times 
within such matrices, possibly enabling a higher degree of PhAC oxidation for the same applied 
oxidant doses. 
Ferrate salts are not currently used in field scale drinking water or wastewater treatment 
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operations, although their use for a variety of treatment purposes is gaining increasing attention 
among water quality researchers [2-5]. Results presented in this study as well as other recent reports 
by several other groups [6-9] support the use of ferrate for oxidizing PhACs and inactivating 
pathogens during water and wastewater treatment. The primary limitations on the use of ferrate by 
the water industry are the lack of low cost bulk commercial sources for the reagent and its 
instability in water, which prevents long-term storage of stock solutions. Aqueous feedstock 
solutions of ferrate need to be prepared just prior to use. Recent reports suggest that it may be 
possible to generate ferrate on-site electrochemically [10, 11] or chemically [12] immediately prior to 
being introduced to treatment reactors. If these technologies can be made economical, practical 
applications of ferrate for water/wastewater treatment may become widely used.  
7.3 Future Research 
This study investigated the efficiency and effectiveness of using Mn(VII) and Fe(VI) to 
treat a variety of PhACs and the potential of using Fe(VI) as an alternative disinfectant. Some 
related future research topics are outlined below: 
y Flow-through reactors and pilot scale tests. The oxidation and inactivation experiments 
were conducted in batch reactors in this study. Tests in flow-through reactors and pilot 
scale tests can be done to confirm whether similar reactivity can be achieved and whether 
the obtained kinetic parameters are applicable. 
y Validation of the predictive kinetic model in wastewater-related matrices. A predictive 
kinetic model was developed in this study to estimate the extent of PhAC removal and was 
validated by tests in natural waters. It will be a good practice to test PhAC removal by 
Mn(VII) in wastewater-related matrices and compare test results with estimates from the 
predictive kinetic model. Comparsion of the efficiency between Mn(VII) and other 
drinking water oxidants (e.g., ozone, free chlorine) in oxidative removal of PhAC in 
wastewater matrix is also desired to see whether the greater stability of Mn(VII) in 
organic-rich matrices can compensate for its lower reactivity with PhACs.  
y Establishment of a quantitative structure-activity relationship (QSAR) for phenolic 
compounds. Many organic contaminants in water contain a phenolic moiety, which is 
shown to exhibit high reactivity with Mn(VII), and thus it will be helpful to establish a 
QSAR for Mn(VII) oxidation of phenolic compounds using simple substituted phenols. 
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The established QSAR can be used to predict the reactivity of different target phenolic 
contaminants with Mn(VII) during water treatment processes. Development of QSARs 
for oxidation of phenolic compounds by Fe(VI) have been reported [13]. 
y Identification of reaction products at non-neutral pH conditions. Products from 
Mn(VII)/Fe(VI) and PhAC reactions reported in this study were identified at neutral 
conditions. It is possible that different sets of products will be formed under more acidic 
or basic conditions and further research can be done to identify reaction products under 
these conditions.  
y Confirmation of proposed structures for reaction products with multiple analytical 
techniques. Although 1H-NMR analysis was applied in one instance here, LC-MS/MS 
analysis was the primary tool used to identify reaction products in this study. Therefore, 
structures postulated in this study are only the best plausible representatives with the 
information available. For the large number of products obtained in this study, it is 
difficult and time consuming to isolate each product and apply multiple analytical 
techniques to identify the structures of each product. However, interested researchers 
can take efforts to isolate major products formed during PhAC-Mn(VII) reactions and 
confirm structures proposed in this study using other analytical tools, including 1H-NMR, 
13C-NMR, FTIR, UV-Vis spectroscopy, etc. Individual isolated products can also be 
assessed for pharmaceutical potency in comparison to their parent PhACs. 
y Testing of biodegradability of reaction products. Because little mineralization was 
achieved and various organic reaction products were produced during Mn(VII)/Fe(VI) 
oxidation of PhACs, it is important to test the biodegradability of the reaction products 
compared to the parent compounds. 
y Estrogenic activity of EE2 reaction products. Among PhACs commonly detected in 
drinking water sources, phenolic EDCs like 17α-ethinylestradiol are believed to possibly 
pose the greatest risk at environmental concentration levels (ng/L-µg/L) [14]. This study 
shows that phenolic compounds in general have high reactivity with Mn(VII). However, 
further research is needed to demonstrate the estrogenic activity removal of EDC 
solutions along with the parent compound degradation during the Mn(VII) oxidation 
processes. In addition, bioassays for many types of PhACs, e.g., anticonvulsant drugs, 
are not available, and require further development. 
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y Further investigation of the effect of Fe(VI) dose on MS2 phage inactivation kinetics. This 
study shows that Fe(VI) dose rather than the initial measured Fe(VI) concentration affects 
the Chick-Watson inactivation rate constants, possibly due to a long-lived active species 
produced during Fe(VI) autodecomposition. Further research is needed to investigate the 
detailed mechanism behind this phenomenon. It will also be interesting to see how the 
non-target water constituents would affect the inactivation efficiency of MS2 phage by 
Fe(VI). 
y Inactivation mechanism of MS2 phage by Fe(VI). The inactivation mechanism of MS2 
phage by Fe(VI) is worth investigating. Mass spectrometry might be an applicable 
technique as Wigginton et al. [15] have applied the technology to correlate the MS2 virus 
inactivation by UV254 and 1O2 to chemical modifications of certain parts of the MS2 coat 
protein during the inactivation process. Molecular microbiological tools, as reported by 
Page et al. [16], can also be applied to evaluate whether genome damage occurs and 
identify the MS2 phage life cycle event (e.g., attachment, cell entry, genome ejection, 
A-protein assembly) responsible for the loss of its infectivity after reacting with Fe(VI). 
y Fe(VI) inactivation with other pathogens of concern. To further evaluate the potential of 
Fe(VI) as an alternative disinfectant, its reactivity with other pathogens of concern (e.g., 
adenovirus, coxsackie virus) should be characterized. Although Fe(VI) application in 
water does not produce chlorinated DBPs and Fe(VI) does not oxidize bromide to 
bromate, tests need to be done to evaluate whether Fe(VI) oxidation of iodide in the 
presence of many other non-target water constituents form toxic iodinated DBPs. It is 
also of interest to see whether there is any synergistic effect of sequentially applying 
Fe(VI) and other disinfectants (e.g., free chlorine, monochloramine). 
y Development of economical on-site ferrate generation technologies. As mentioned 
earlier, the high cost of ferrate and its instability in water limits its large scale application. 
Therefore, further research focusing on the development of economical on-site ferrate 
generation technologies is recommended. 
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7.5 Figures and Tables 
Table  7.1 Summary of PhACs reactivity with Mn(VII) and Fe(VI) (proposed reactive sites shown in circles) 
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a ATN and SMX showed moderate reactivity with Fe(VI), but no significant reactivity with Mn(VII). 
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Table  7.2. List of kinetic parameters for PhAC-Mn(VII) and PhAC-Fe(VI) reactions, and Fe(VI) inactivation of MS2 phage 
Contaminant 
Oxidant/ 
Disinfectant 
k2a 
(M-1 s-1) 
k21b 
(M-1 s-1) 
k22b 
(M-1 s-1) 
k23b  
(M-1 s-1) 
kα2c 
(M-1 s-1) 
kα3c 
(M-1 s-1) 
Ea 
(kJ mol-1)
carbamazepine 
(CBZ) 
Mn(VII) 3.0(±0.3)×102 --- --- --- --- --- 22(±2) 
carbamazepine 
(CBZ) 
Fe(VI) 7.0(±0.3)×101 --- --- --- 1.4(±0.5)×102 3.8(±1.9)×10-1 --- 
ciprofloxacin 
(CPR) 
Mn(VII) 6.1(±0.2)×10-1 0.52(±0.05) 0.34(±0.08) 1.2(±0.1) --- --- 54(±3) 
lincomycin 
(LCM) 
Mn(VII) 3.6(±0.1) 0.5(±0.1) 43(±6) --- --- --- 68(±4) 
trimethoprim 
(TMP) 
Mn(VII) 1.6(±0.1) --- 2.6(±0.3) 0.17(±0.05) --- --- 49(±5) 
17α-ethinylestradiol 
(EE2) 
Mn(VII) 1.27(±0.02)×102 2.5(±0.4)×101 2.3(±0.4)×105 --- --- --- 37(±2) 
MS2 phage Fe(VI) 2.27(±0.05) --- --- --- 3.8(±0.5) 0.07(±0.02) 39(±6) 
a All k2 values are for pH 7 and 25 ºC. Uncertainties represent 1 σ. 
b Species-specific rate constants for Mn(VII) reactions. 
c Species-specific rate constants for Fe(VI) reactions.  
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APPENDIX A 
MS/MS SPECTRA OF PHACS AND THEIR REACTION PRODUCTS 
Table A. 1. MS/MS spectra of carbamazepine (CBZ) and its reaction products with Mn(VII) 
and Fe(VI) 
CBZ (m/z: 237) 
60 80 100 120 140 160 180 200 220 240
m/z
0
50000000
100000000
150000000
200000000
250000000
300000000
350000000
400000000
450000000
500000000
550000000
In
te
ns
ity
194.29
220.00
237.12192.24
209.54151.74137.10
 
Product II (m/z: 224) 
60 80 100 120 140 160 180 200 220
m/z
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
8000000
9000000
10000000
11000000
12000000
13000000
In
te
ns
ity
196.30
177.03
200.80 223.19147.02125.0681.19 96.98
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Table A. 1. (cont.) 
Product III (m/z: 240) 
60 80 100 120 140 160 180 200 220 240
m/z
0
50000000
100000000
150000000
200000000
250000000
300000000
350000000
400000000
In
te
ns
ity
222.21
240.12
 
Product IV (m/z: 251) 
100 150 200 250
m/z
0
5000000
10000000
15000000
20000000
25000000
30000000
35000000
In
te
ns
ity
251.15
208.28
180.32
223.09
147.16
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Table A. 1. (cont.) 
Product V (m/z: 255) 
167.1
195.1
219.2
237.2
0
5000
10000
15000
20000
100 150 200 250 300
m/z
25000
30000
50
In
te
ns
ity
In
te
ns
ity
 
Product VI (m/z: 258) 
100 150 200 250
m/z
0
5000000
10000000
15000000
20000000
25000000
30000000
35000000
40000000
45000000
50000000
55000000
60000000
65000000
70000000
In
te
ns
ity
240.06
196.31
222.18 258.40
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Table A. 1. (cont.) 
Product VII (m/z: 267) 
100 150 200 250
m/z
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
8000000
9000000
10000000
11000000
12000000
13000000
14000000
15000000
16000000
In
te
ns
ity
224.12
268.10
250.00
196.32
239.09
210.92189.1299.33 154.58137.28
 
Product VIII (m/z: 271) 
100 150 200 250
m/z
0
2000000
4000000
6000000
8000000
10000000
12000000
14000000
16000000
18000000
20000000
22000000
24000000
26000000
28000000
30000000
32000000
In
te
ns
ity
253.11
210.15
247.35
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Table A. 1. (cont.) 
Product IX (m/z: 283) 
100 150 200 250
m/z
0
5000000
10000000
15000000
20000000
25000000
30000000
35000000
40000000
45000000
50000000
55000000
60000000
65000000
In
te
ns
ity
265.12
196.37 240.05222.14
 
Product X (m/z: 285) 
100 150 200 250 300
m/z
0
2000000
4000000
6000000
8000000
10000000
12000000
14000000
16000000
18000000
20000000
22000000
24000000
26000000
28000000
30000000
32000000
In
te
ns
ity
267.20
239.19
196.31
224.10
241.85155.21 222.11
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Table A. 1. (cont.) 
Product XI (m/z: 301) 
100 150 200 250 300
m/z
0
10000000
20000000
30000000
40000000
50000000
60000000
70000000
80000000
90000000
100000000
110000000
120000000
In
te
ns
ity
258.04
283.02
240.03
265.07196.26 302.34173.74
 
Product XII (m/z: 303) 
g ( )
100 150 200 250 300
m/z
0
2000000
4000000
6000000
8000000
10000000
12000000
14000000
16000000
18000000
20000000
22000000
24000000
26000000
28000000
30000000
32000000
34000000
In
te
ns
ity
285.14
267.15
224.18
239.14 302.45134.92
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Table A. 1. (cont.) 
Product XIII (m/z: 226) 
180.1
198.1
208.1
0
100000
200000
300000
400000
500000
120 140 160 180 200 220
m/z
600000
700000
240
In
te
ns
ity
In
te
ns
ity
 
Product XIV (m/z: 267) 
100 150 200 250
m/z
0
10000000
20000000
30000000
40000000
50000000
60000000
70000000
80000000
90000000
100000000
In
te
ns
ity
249.17
179.99 267.00197.42 221.42
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Table A. 2. MS/MS spectra of ciprofloxacin (CPR) and its reaction products with Mn(VII) 
CPR (m/z: 332)* 
 
Product I (m/z: 263)* 
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Table A. 2. (cont.) 
Product II (m/z: 291)* 
 
Product III (m/z: 293) 
 
 
274.8
292.8
+MS2(293.0), 10.2min #809
0
1
2
3
7x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
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Table A. 2. (cont.) 
Product IV (m/z: 306)* 
 
Product V (m/z: 334)* 
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Table A. 2. (cont.) 
Product VI (m/z: 335) 
 
Product VII (m/z: 346) 
 
 
317.9
345.9
+MS2(345.9), 1.6min #122
0
1
2
3
4
5
6x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
290.8
332.9
+MS2(335.0), 3.7min #285
0
1
2
3
4
5
6
6x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
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Table A. 2. (cont.) 
Product VIII (m/z: 346) 
 
Product IX (m/z: 360)* 
 
 
327.0
345.9
+MS2(345.9), 9.7min #808
0
1
2
3
4
5
6x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
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Table A. 2. (cont.) 
Product X (m/z: 362) 
 
Product XI (m/z: 362)* 
 
 
317.9
361.9
+MS2(361.6), 5.1min #423
0.0
0.5
1.0
1.5
6x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
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Table A. 2. (cont.) 
Product XII (m/z: 380) 
 
* Spectra obtained in the Q-TOF instrument 
 
 
315.9
333.9
361.9
379.9
+MS2(379.8), 6.9min #585
0.0
0.5
1.0
1.5
2.0
2.5
7x10
Intens.
100 150 200 250 300 350 400 450 500 m/z
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Table A. 3. MS/MS spectra of lincomycin (LCM) and its reaction products with Mn(VII) 
LCM (m/z: 407) 
 
Product I (m/z: 393) 
 
 
112.1
169.9
216.0 264.0
285.1
327.1
345.1
375.1
+MS2(393.2), 3.3min #236
0
2
4
6
7x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
126.1
172.0 299.1 341.2
359.1
389.1
+MS2(407.4), 2.7min #186
0.00
0.25
0.50
0.75
1.00
1.25
8x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
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Table A. 3. (cont.) 
Product II (m/z: 405) 
 
Product III (m/z: 408) 
 
 
342.1
360.1
390.0
+MS2(408.4), 6.8min #485
0.0
0.2
0.4
0.6
0.8
1.0
1.2
7x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
124.0
170.0
197.9
297.1
357.1
387.1
+MS2(405.4), 1.9min #122
0.0
0.2
0.4
0.6
0.8
1.0
7x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
  
 200 
Table A. 3. (cont.) 
Product IV (m/z: 421) 
 
Fragment ion of product IV (m/z 373) 
140.0
283.1 313.1
337.1
355.1
+MS2(373.2), 8.7min #715
0
1
2
3
7x10
Intens.
100 200 300 400 500 600 m/z
323.1
355.1
373.1
403.0
+MS2(421.4), 8.4min #605
0.0
0.2
0.4
0.6
0.8
1.0
1.2
8x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
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Table A. 3. (cont.) 
Product V (m/z: 423) 
 
Product VI (m/z: 439) 
 
 
126.1
341.1
359.1
391.1
421.1
+MS2(439.2), 2.0min #134
0.0
0.5
1.0
1.5
2.0
2.5
7x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
126.0
281.1
299.1
317.1
357.0
375.1
405.1
+MS2(422.9), 6.0min #426
0
1
2
3
4
5
6
6x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
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Table A. 3. (cont.) 
Product VII (m/z: 453) 
 
 
140.0
355.1
373.1
435.1
+MS2(453.4), 4.9min #352
0
1
2
3
4
7x10
Intens.
50 100 150 200 250 300 350 400 450 m/z
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Table A. 4. MS/MS spectra of trimethoprim (TMP) and its reaction products with Mn(VII) 
TMP (m/z: 291) 
 
Product I (m/z: 280) 
 
 
180.9
236.9
+MS2(280.1), 1.8min #116
0.0
0.5
1.0
1.5
2.0
2.5
3.0
7x10
Intens.
50 100 150 200 250 300 m/z
109.9
123.0
180.9
229.9
260.9
276.0
+MS2(291.3), 2.6min #180
0
1
2
3
7x10
Intens.
50 100 150 200 250 300 m/z
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Table A. 4. (cont.) 
Product II (m/z: 295) 
 
Product III (m/z: 305) 
 
 
95.0
136.9
194.9
230.9
244.0
275.0
290.0
305.9
+MS2(305.1), 6.1min #430
0.00
0.25
0.50
0.75
1.00
1.25
1.50
5x10
Intens.
50 100 150 200 250 300 m/z
113.0
182.9
236.0
252.9
278.0
+MS2(295.2), 1.7min #102
0
1
2
3
4
5
6x10
Intens.
50 100 150 200 250 300 m/z
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Table A. 4. (cont.) 
Product IV (m/z: 307) 
 
Product V (m/z: 323) 
 
 
180.9
+MS2(323.2), 1.7min #106
0.00
0.25
0.50
0.75
1.00
1.25
8x10
Intens.
50 100 150 200 250 300 m/z
243.0
274.0
289.0
+MS2(307.3), 1.7min #103
0.0
0.2
0.4
0.6
0.8
1.0
1.2
7x10
Intens.
50 100 150 200 250 300 m/z
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Table A. 4. (cont.) 
Product VI (m/z: 324) 
 
Product VII (m/z: 325) 
 
 
180.9
235.9
263.9
281.0
307.0
+MS2(324.2), 4.2min #302
0.0
0.5
1.0
1.5
7x10
Intens.
50 100 150 200 250 300 m/z
180.9
235.9
263.9
281.0
307.0
+MS2(324.2), 4.2min #302
0.0
0.5
1.0
1.5
7x10
Intens.
50 100 150 200 250 300 m/z
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Table A. 5. MS/MS spectra of 17α-ethinylestradiol (EE2) and its reaction products with 
Mn(VII) 
EE2 (m/z: 297) 
91.1
107.1
147.0
159.0
185.0
196.9
209.0
239.0
279.1
+MS2(296.7), 13.6min #752
0.0
0.2
0.4
0.6
0.8
6x10
Intens.
50 100 150 200 250 300 350 400 m/z
Product I (m/z: 287) 
131.1
169.0
180.9
195.0
209.0
223.0
251.0
269.1
+MS2(287.3), 10.7min #594
0.0
0.5
1.0
1.5
2.0
2.5
6x10
Intens.
50 100 150 200 250 300 350 400 m/z
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Table A. 5. (cont.) 
Product II (m/z: 295) 
91.1105.1
133.0
156.9
171.0
183.0 207.0
221.0
235.0
277.1
+MS2(295.3), 8.9min #498
0.0
0.2
0.4
0.6
0.8
1.0
6x10
Intens.
50 100 150 200 250 300 350 400 m/z
Product III (m/z: 303) 
159.0
177.0
196.9
221.0
239.0
267.0
285.0
+MS2(303.4), 7.5min #420
0.0
0.5
1.0
1.5
6x10
Intens.
50 100 150 200 250 300 350 400 m/z
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Table A. 5. (cont.) 
Product IV (m/z: 313) 
105.1
131.1
159.0
173.0
213.0 239.0
253.1
267.1
295.1
+MS2(313.3), 9.3min #520
0
1
2
3
6x10
Intens.
50 100 150 200 250 300 350 400 m/z
Product V (m/z: 315) 
223.0
251.1
297.1
+MS2(315.4), 12.5min #690
0.0
0.5
1.0
1.5
7x10
Intens.
50 100 150 200 250 300 350 400 m/z
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Table A. 5. (cont.) 
Product VI (m/z: 319) 
158.9
209.0 237.0
255.0
273.0
301.1
319.1
+MS2(336.4), 3.4min #196
0.0
0.5
1.0
1.5
2.0
6x10
Intens.
50 100 150 200 250 300 350 400 m/z
Product VII (m/z: 329) 
133.1 172.9
209.0
247.1
265.1
283.1
311.1
+MS2(329.3), 4.1min #234
0.0
0.5
1.0
1.5
7x10
Intens.
50 100 150 200 250 300 350 400 m/z
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Table A. 5. (cont.) 
Product VIII (m/z: 345) 
Product IX (m/z: 347) 
200.9 221.0 251.0
265.1
283.1
311.1
329.1
+MS2(347.4), 4.2min #244
0
2
4
6
6x10
Intens.
50 100 150 200 250 300 350 400 m/z
 
 
111.0
159.0
187.0
221.1
239.0
267.1
285.0
309.0
327.1
+MS2(345.3), 9.7min #540
0.0
0.2
0.4
0.6
0.8
1.0
1.2
7x10
Intens.
50 100 150 200 250 300 350 400 m/z
